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ABSTRACT 
This project has been directed towards the design, preparation and evaluation of 
novel polymeric vehicles that can control the release of ophthalmic drugs. 
Hydrogels based on several synthetic and naturally-derived polymeric and 
monomenc units, including poly(vinylpyrrolidone-co-[meth] acrylic acid)s, N-
isopropylacrylamide or 2-hydroxyethyl methacrylate and different types of chitosan, were 
synthesised, and the effects of hydrogels' network structure and composition upon their 
swelling properties, adhesion behaviour and drug release characteristics were examined. 
These novel materials were formulated as either ophthalmic inserts or as 
nanosuspensions, and were investigated both in vitro and in vivo for their ability to act as 
controlled release vehicles for ophthalmic drug delivery. 
Comparative in vitro studies employing a range of common ophthalmic drugs 
(chloramphenicol, atropine, norfloxacin or pilocarpine) informed the selection of drug-
specific carrier. compositions for the controlled delivery of these compounds, and indicated 
that some of these materials have a high potential for the delivery of sparingly water-
soluble actives. 
In vivo (rabbit model) experiments involving the delivery of pilocarpine showed 
that chitosan-based hybrid polymeric networks containing 2-hydroxyethyl methacrylate 
may be potentially useful carriers for the delivery of this therapeutic agent. 
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Chapter 1 - Introduction 
1.1. Challenges faced by drug delivery to the eye 
In most cases, topical drug delivery is the preferred route for the treatment of ocular 
diseases and associated infections. The ophthalmic delivery of drugs (fJ-blockers, 
cholinergic or antibacterial agents) has been adapted from existing systemic formulations, 
taking little account of the intrinsic physiology of the eye. 
The main barrier to efficient ophthalmic drug delivery is the rapid elimination of 
conventional liquid drops from the eye. Instilled eye drops are typically 30-75 JlI in 
volume, a portion of which is quickly drained, until the precorneal region contains the 
normal resident volume of around 7 Jll [1]. The turnover of lachrymal fluid (approximately 
0.16 Jll/minute) affects the concentration of the drug remaining on the surface of the eye. 
As the precorneal fluid is replaced by washing with lachrymal fluid, so the residual drug 
concentration is reduced. The concentration of drug in the precorneal area acts as a driving 
force for its transport through the cornea. If the precorneal drug concentration falls below 
that of the corneal epithelium, uptake of drug into the cornea ceases [2]. Several factors 
lead to a high rate of lacrimal drainage, paramount amongst which are: the rapid tear 
turnover and the ensuing precorneal loss, and the induction of tear flow due to irritation 
caused by chemical entities within the drug preparation and/or by the relatively large 
volume of the administered eye drops. The precorneal half-life of the active in a typical 
ocular formulation is considered to be of the order of 1-3 minutes [3]. As a consequence, 
only a very small proportion (1-3%) of the therapeutic agent penetrates the cornea and has 
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the opportunity to reach intraocular tissues [4]. Furthermore, the posterior segments of the 
eye are protected with refinement from the external environment, and this poses unique 
and fairly challenging ~bstacles for drug delivery [5]. 
In the last decades considerable research effort has been directed towards the 
improvement of ophthalmic drug delivery. The various approaches attempted in the early 
stages can be divided into two main categories: bioavailability improvement, and 
controlled-release drug delivery. The former was attempted using methods that aim to 
improve the corneal penetration of the drug molecule and to delay its elimination from the 
eye by means of viscosity enhancers, gels, nanosuspensions, emulsions, penetration 
enhancers, prodrugs, or liposomes [4-7]. Controlled release delivery was attempted by 
using various types of erodible or soluble inserts, by utilising hydrophilic or water 
insoluble inserts or by employing membrane-controlled diffusional inserts [8]. 
Although successful in prolonging the contact time between drugs and the corneal 
surface, many of these systems have been associated with problems of discomfort and 
blurring of the vision in patients, resulting in poor patient compliance. Non-mucoadhesive 
polymers are quickly cleared from the eye and may blur the vision [9]. Mucoadhesive 
polymers can lead to matted eyelids after sleep but these are reported to blur vision to a 
lesser extent than ointments [10]. In situ gelling systems often require a high polymer 
concentration and may cause irritation to the patient. Inserts are not user-friendly and 
suffer with poor patient compliance [2]. Liposomes have been shown to exhibit prolonged 
association with the external tissues of the eye but not necessarily with the cornea, and 
nanoparticles have presented problems with controlling the release rate of drugs [11]. 
Thus, there remains the need for an ophthalmic delivery system that prolongs the contact 
time between the drug of choice and the corneal epithelium, and affords controlled release 
of the drug into the precorneal area as well as comfort and ease of use to the patient. 
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To explain the context of this work, and to clarify some technical terms, the next 
sections present some details of the anatomy and physiology of the eye, common 
ophthalmic diseases and associated medications. Drug delivery to the eye is discussed then 
in more detail, and examples of current ophthalmic delivery systems, either in use or still 
under study, are given. A special attention is paid to ocular inserts and to mucoadhesivity, 
an important characteristic of the delivery formulation that can prolong the contact time 
between the active and the corneal epithelium, with a dramatic increase of the 
bioavailability of the active. Finally, brief reviews of each of the main physical methods 
used in this study are presented. 
1.2. Anatomy and physiology of the eye 
The eye is the organ of the sense of sight that is situated in the orbital cavity and it 
is supplied by the 2nd cranial nerve (optic nerve). It is almost spherical in shape and is 
about 2.5 cm in diameter. The space between the eye and the orbital cavity is occupied by 
adipose tissue. The bony walls of the orbit and the fatty layer help to protect the eye from 
injury. The two eyes are structurally separate but unlike the ear some of their activities are 
coordinated so that they can function as a pair. It is possible to see with only one eye but 
three-dimensional vision is impaired when only one eye is used, especially in relation to 
the judgement of distance. 
There are three main layers oftissue in the walls of the eye. 
• The outer fibrous layer: sclera and cornea 
• The middle vascular layer or uveal tract: choroids, ciliary body and iris 
• The inner nervous tissue layer: retina 
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Inside the eyeball there are other structures such as the lens, aqueous fluid (humour) 
and vitreous body (humour) . 
Sclera --_ _ ~.....:.. 
Vrtreoos 
Iris 
~:---- Choroid 
Comea---
Pupil 
--....;.:...:.-- Optic nerve 
Macu1a 
Lens 
Conjunctiva ~ Retina 
Fig. l.l. Structure of the eye [12]. 
Sclera and cornea 
The sclera, or white of the eyes, forms the outermost layer of tissue of the posterior 
and lateral aspects of the eyeball and is continued anteriorly with the transparent cornea. It 
consists of a firm fibrous membrane that maintains the shape of the eye and gives 
attachment to the extraocular or extrinsic muscles of the eye. 
The cornea is an optically transparent tissue that conveys images to the back of the 
eye and covers about one-sixth of the total surface areas of the eyeball. It is an avascular 
tissue to which nutrients and oxygen are supplied via bathing with lachrymal fluid and 
aqueous humour, as well as from blood vessels that line the junction between the cornea 
and sclera. The cornea is considered to be the main pathway for the permeation of drugs 
into the eye [13]. It is approximately 0.5 mm thick in the central region, increasing to 
approximately 0. 7 mm at the periphery and is composed of five layers (Fig. 1.2). 
l~ 
Fig. 1.2. Transverse section 
of corneal tissue [14]. 
i) Epithelium 
U) Bowman's 
membrane 
iii) Stroma 
(Substantia 
propria) 
iv) Descemet's 
membrane 
v) Endothelium 
Aqueous Humor 
of Anterior 
Chamber 
The epithelium consists of 5-6 layers of cells, increasing to 8-10 layers at the 
periphery and has a total thickness of around 50-100 /-lm and a turnover of about one cell 
layer per day [2]. The tight junctions and hydrophobic domains in this layer make it the 
most important barrier against foreign substances including drugs. The basal layer consists 
of columnar celis, which show extensive lateral interdigitation of plasma membranes and 
are therefore relatively permeable. The interdigitations may also help to confer mechanical 
linkage between cells whilst preserving the transparency of the cornea [\5]. On top of the 
basal layer there are two or three layers of polygonal or wing-shaped cells. The uppermost 
layer consists of non-keratinised squamous superficial cells, which possess microvilli on 
their anterior surface that may help to anchor the precorneal tear film [\6]. Tight junctions 
(zona occludens) between the superficial cells exclude all solute movement apart from that 
which occurs by partitioning through the apical and plasma membranes of the surface 
epithelial cells. The intercellular spaces between the wing cells and between the basal cells 
are wider than those between the superficial cells. This allows paracellular diffusion of 
large molecules such as horseradish peroxidase (MW 40,000) [17] . Cell divisions occur in 
the basal layer of the epithelium and cellular differentiation occurs gradually as cells move 
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towards the corneal surface. The corneal epithelium is negatively charged at physiological 
pH [18]. 
Bowman first described the membrane that bears his name in 1847 [19]. Bowman's 
membrane is an acellular homogenous sheet consisting of unoriented fibres (8-14 f.lm) 
between the basement membrane of the epithelium and the stroma. This membrane is not 
sharply differentiated from the remainder of the stroma and it may be more accurate to 
describe it as Bowman's layer; it is likely that it is a specially modified layer of the anterior 
stroma [19]. 
The stroma or substantia propria forms around 90% of the corneal thickness. It 
contains approximately 85% water, and is composed of about 200-250 collagenous 
lamellae superimposed onto one another and running parallel to the surface. These 
lamellae consist mainly of regularly arranged collagen fibrils with a uniform diameter of 
25-35 nm, with smaller amounts ofproteoglycans and corneal fibroblasts (keratocytes) that 
occupy 2-3% of the total volume of the corneal stroma [20]. These keratocytes repair 
damage caused by physical or chemical trauma via synthesis and degradation of 
extracellular matrix material in the stroma in a manner analogous to fibroblasts in the skin 
[21]. The lamellae lie at right angles to one another in alternating layers and this provides 
physical strength while permitting optical transparency. The stroma has a relatively open 
structure and will normally allow the diffusion of solutes with a molecular weight of below 
500 kDa. The stroma is easily penetrated by hydrophilic drugs but can act as a barrier 
against lipophilic drugs that may pass through the epithelium. 
Descemet's membrane, which is secreted by the endothelium, is 10-15 f.lm thick 
and lies between the stroma and the endothelium. 
The c?rneal endothelium is responsible for maintaining normal corneal hydration 
and consists of a single layer of flattened hexagonal cells 5 f.lm high and 20 f.lm wide. The 
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endothelium is in direct contact with the anterior chamber and is subject to a passive influx 
of water from the aqueous humour towards the stroma. The endothelium houses an active 
Na+/K+ cell pump that prevents swelling of the stroma by regulating corneal hydration and 
maintaining corneal thickness and thus ensuring corneal transparency. Although tight 
junctions are present in the endothelium too, it is about 200 times more permeable to water 
than the epithelium and thus represents a very weak barrier. It has been estimated that 
drugs with molecular dimensions of about 20 nm are able to diffuse across the normal 
endothelium [3, 16]. 
Choroid 
Very rich in blood vessels and deep chocolate brown in colour, the choroids line the 
posterior five-sixths of the inner surface of the sclera; when light enters the eye through the 
pupil, it stimulates the nerve endings in the retina, and is then absorbed by the choroids. 
Ciliary body 
The ciliary body is the anterior continuation of the choroids consisting of ciliary 
muscles (smooth muscle fibres) and secretory epithelial cells. It gives attachment to the 
suspensory ligament, which at its other end is attached to the capsule enclosing the lens. 
Contraction and relaxation of the ciliary muscle changes the thickness of the lens, which 
bends or refracts light rays entering the eye to focus them on the retina. The epithelial cells 
secrete aqueous fluid into the anterior segment of the eye. The ciliary body is supplied by 
parasympathetic branches of the oculomotor nerve (3rd cranial nerve). Stimulation causes 
contraction of the smooth muscle and accommodation of the eye. 
Iris 
The iris is the visible coloured part ofthe eye and extends anteriorly from the ciliary 
body, lying behind the cornea in front of the lens. It divides the anterior segment of the eye 
into ~terior and posterior chambers that contain aqueous fluid secreted by the ciliary 
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body. The iris is a circular body composed of pigmented cells and two layers of smooth 
muscle fibres, one circular and the other radiating. The centre of aperture is known as the 
pupil. The colour of the iris is genetically determined and depends on the number of 
pigment cells present. Parasympathetic and sympathetic nerves control the iris: 
parasympathetic stimulation constricts the pupil and sympathetic stimulation 'dilates it. 
Lens 
The lens is a highly elastic circular biconvex body lying immediately behind the 
pupil. It consists of fibres enclosed within a capsule and is suspended from the ciliary body 
by the suspensory ligament; its thickness is controlled by the ciliary muscle. The lens 
refracts light rays reflected by objects in front of the eye. The lens is the only structure in 
the eye that can vary its refractory power, achieved by changing its thickness. When the 
ciliary muscle contracts, it moves forward releasing its pull on the lens, therefore 
increasing its thickness. The nearer the object being viewed, the thicker the lens becomes 
in order to allow focusing. 
Retina 
The retina is the innermost layer of the wall of the eye. It is an extremely delicate 
structure and is especially adapted for stimulation by light rays. It is composed of several 
layers of nerve cell bodies and their axons, lying on a pigmented layer of epithelial cells 
that attach the retina to the choroids. The layer of sensory receptor cells (i.e. rods and 
cones) is highly sensitive to the light. The retina lines about three quarters of the eyeball 
and is thickest at the back; it thins out anteriorly to end just behind the ciliary body. Near 
the centre of its posterior part is the macula lutea, or yellow spot. In the centre of this area 
there is a little depression called the fovea centralis, consisting of cone-shaped cells only. 
Towards the anterior part of the retina there are fewer cone-shaped than rod-shaped cells. 
The rods and cones contain photosensitive pigments that convert light rays into nerve 
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impulses. About 0.5 cm to the nasal side of the macula lute a, all the nerve fibres of the 
retina converge to form the optic nerve. The small area of retina where the optic nerve 
leaves the eye is the optic disc, called also The blind spot because it has no light sensitive 
cells. 
Conjunctiva 
This is a fine transparent membrane, which lines the eyelids and the front of the 
eyeball. The area where it lines the eyelids consists of highly vascular columnar 
epithelium, while the corneal conjunctiva consists of less vascular stratified epithelium. 
Conjunctiva plays many roles including protection of ocular surface, production of tear 
film, and a conduit for drug clearance (depending ondrug properties) into the systemic 
circulation or for drug transport to the deep tissues of the eye [22]. When the eyelids are 
closed the conjunctiva becomes a closed sac, protecting the delicate cornea and the front of 
the eye. Usually eye drops are administered by placing them in the lower conjunctival sac. 
The medial and lateral angles of the eye where the upper and lower lids come together are 
called the medial canthus and the lateral canthus respectively. The conjunctival epithelium 
differs somewhat from that of the cornea in that it is thicker and posses as mucus-secreting 
. 
goblet cells. The human conjunctiva is between 2 and 30 times more permeable to drugs 
than the cornea and for this reason it has been proposed that loss by this route is a major 
path for drug clearance [23]. 
The nasolachrymal drainage system 
It consists of three parts, the secretory system, the distributive system and the 
excretory system. The secretory system consists of basic secretors (lacrimal glands that are 
stimulated by blinking and temperature change due to tear evaporation) and reflex 
secretors, which have an efferent parasympathetic nerve supply and secrete in response to 
physical or emotional stimulation. The lacrimal glands are exocrine glands situated in 
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recesses in the formal bones on the lateral aspects of each eye just behind the supraorbital 
margin. Each gland is approximately the size and shape of an almond and is composed of 
secretory epithelial cells. The glands secrete tears composed of water, mineral salts, 
antibodies and lysozyme, which is a bactericidal enzyme. 
lachrymal gland 
secretory 
ducts 
superior 
punctum 
lachrymal 
sac 
nasolachrymal 
duct 
inferior 
J--- meatus 
of nose 
Fig. 1.3 . The nasolachrymal drainage system [24]. 
The distributive system consists of eyelids and the tear meniscus around the lid 
edges of the open eye that spreads tears over the ocular surface by blinking and thus 
preventing dry areas from developing. 
The excretory part of the nasolachrymal drainage system consists of two lachrymal 
canaliculi (inferior and superior) and one lachrymal sac and one nasolachrymal duct for 
each eye. Tears leave the lachrymal gland by several small ducts and pass over the front of 
the eye under lids towards the medial canthus, where they drain into the two lachrymal 
canaliculi, the opening of each is called the punctum. The two canaliculi are situated one 
above the other, separated by a small red body, the caruncle. The tears then drain into the 
lachrymal sac, which is the upper expanded end of the nasolacrimal duct. This is a 
membranous canal approximately 2 cm long, extending from the lower part of the lacrimal 
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sac to the nasal cavity, which opens at the level of the inferior concha. Normally the rate of 
secretion of tears keeps pace with the rate of drainage, but when a foreign body or other 
irritant enters the eye the secretion of tears is greatly increased and the conjunctival blood 
vessels dilate. Secretion of tears is also increased in emotional states. It is thought that tears 
are largely adsorbed by the mucous membrance that lines the ducts and the lachrymal sac, 
and only a small amount reaches the nasal passages [23]. 
The cul-de-sac of the eye normally holds around 7-9 III of tears but can retain up to 20-30 
III if care is taken not to blink. The normal tear flow rate is 1 Ill/min and the pH is 
nonnally maintained between 6.5 and 7.6 [25]. 
The precorneal tear film is a highly specialised fluid layer that consists of tears and 
the oily secretion of tarsal glands and covers the corneal epithelium, conjunctiva and the 
walls of the conjunctival cul-de-sac. The functions of this mixture of fluids include: 
• washing away irritating material, i.e. dust, grift, 
• preventing microbial infection, 
• delaying evaporation and preventing drying of the conjunctiva, .and 
• nourishment of cornea. 
The wandering cells from the limbal vessels reach a central corneal wound via the 
precorneal tear film and these cells participate in the initial stages of wound healing [26]. 
Normal secretion of tears by the lachrymal system is also responsible for nutrition of the 
cornea, the removal of cell debris and foreign substances as well as for protection against 
bacterial infection. 
It was first suggested by Wolff et al. [27] that the tear film has three distinctive 
layers. The layer adjacent to the corneal epithelium is known as the adsorbed mucin layer, 
and is composed of glycoprotein. Mucin is secreted by the many goblet cells located on the 
conjunctival surface, the crypts of Henle, which are situated on the conjunctival surface of 
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the upper and lower tarsus, and the glands of Manz, which are positioned in a circular ring 
on the limbal conjunctiva [24]. Mucin contributes to the stability of the tear film and aids 
to its attachment of the tear fi lm to the corneal and conjunctival epithelia. The mucin acts 
as a wetting agent and serves as a bridge between the hydrophobic corneal epithelial 
surface and the aqueous layer of the tear film that lies immediately above the mucin. 
Superficial oily layer 
-sterol esters 
-wax esters 
-fatty acids 
Aqueous layer 
-electrolyes 
-proteins 
-glycoproteins 
-lipids in suspension 
-glucose 
Mucin in solution 
Mucous layer 
Corneal epithelial cells 
Fig. 1.4. Structure of the tear fiI m [31]. 
This aqueous layer represents about 98% of the tear fil m and is composed of water, 
inorganic salts, glucose and urea as well as biopolymers and various proteins and 
glycoproteins. This layer has a thickness of around 6-10 lJ.m and is secreted by the 
accessory lachrymal glands of Kraus and Wolfring, most of which are situated in the upper 
conjunctival fornix. The upper layer of the tear film is a thin layer of lipid of around 0.1 
lJ.m and contains small amounts ofmucins and proteins [28]. The lipids, in the form of wax 
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and cholesterol esters, are secreted from the Meibomian glands and the glands of Zeis 
situated at the palprebal margin of each eyelid and from the glands of Moll, which are 
situated at the root of each eyelash [24]. The presence of the lipid layer is believed to retard 
the evaporation of the middle aqueous layer by 10- and 20-fold, preventing the corneal 
surface from drying out [29]. 
Abnormalities of the tear film can lead to dysfunctions of the conjunctiva and 
eyelids as well as to loss of corneal transparency. 
1.3. Ophthalmic disorders 
There are several disorders and diseases of the eye that may be treated with the aid 
of topical ophthalmic formulations. Glaucoma, characterised by an increase in intraocular 
pressure, has been historically treated with pilocarpine or beta-blockers. Conjunctivitis, 
which can be caused by a host of environmental, bacterial, viral and fungal agents, may be 
treated with topical antibiotics, which are commonly formulated in solutions, suspensions 
or ointments. 
Dry eye disorders constitute a considerable proportion of ophthalmological 
, 
consultations and are the cause of both ocular discomfort and corneal damage in many 
patients. Such disorders are usually treated with artificial tear preparations, which may 
contain cellulose derivatives, dextran or polyvinyl alcohol. Iritis is a condition that may 
occur in association with a number of diseases and disorders and is usually treated with 
mydriatics and anti-inflammatory drugs. 
A wide variety of topical medications are used for treating the numerous diseases 
and disorders of the eye, Table 1.1. Pilocarpine and timolol are two of the most commonly 
used anti-glaucoma treatments; due to their need for frequent instillation and long-tenn 
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use, such drugs may benefit most from fOl1llulation into controlled release systems. 
Glaucoma represents a group of conditions associated with an increased intraocular 
pressure due to impaired drainage of the aqueous fluid through the scleral venous sinus 
(canal of Schlemm) located in the anterior chamber in the angle between the iris and 
cornea. Persistently raised intraocular pressure may damage the optic nerve by mechanical 
compression of the axons or by compression of the blood supply, causing ischaemia of the 
axons. The extent of damage varies from some visual impail1llent to complete blindness 
[30]. 
Chronic open angle glaucoma. There is a gradual painless rise in intraocular 
pressure with progressive loss of vision. Peripheral vision is lost first but may not be 
noticed until only central vision remains. As the condition progresses, atrophy of the optic 
disc occurs leading to irreversible blindness. It is commonly bilateral and occurs mostly in 
people over 40 years of age. 
Acute closed angle glaucoma. This is most common in people over 40 years of age, 
and usually affects one eye only. With progressing age, the lenses gradually increase in 
size pushing the iris forward. In dim light, when the pupil dilates, the lax iris bulges stilI 
further forward and may come into contact with the cornea, blocking the scleral venous 
sinus (canal of schelemm) causing a sudden rise in the intra ocular pressure. Sudden severe 
pain, photophobia, lacrimation and loss of vision accompany an acute attack. Following 
repeated attacks spontaneous recovery may be incomplete, leading to progressively 
impaired vision. 
Chronic closed angle glaucoma. The intraocular pressure rises gradually without 
symptoms. Peripheral vision deteriorates, followed by atrophy of the optic disc and 
blindness. 
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The function of anti glaucoma medication is to lower the intraocular pressure via one of the 
following three mechanisms. 
i) Increasing the aqueous humour drainage, by producing pupillary constriction 
(miosis) or directly enhancing drainage through the canal of Schlemm. When the 
iris is fully constricted, aqueous humour flows easily out of the anterior chamber 
through the canal. Constriction of the iris is achieved either by directly stimulating 
cholinergic receptors on the iris or by inhibiting the enzyme that is responsible for 
terminating the cholinergic transmitter, aetylcholinesterase. Pilocarpine is an 
example of a direct cholinergic stimulant; phyostigmine and carbachol are 
anticholinesterases. 
ii) Decreasing the amount of aqueous humour production. This may be achieved by 
using carbonic anhydrase inhibitors that compete for the active site of carbonic 
anhydrase isoenzyme II, which is found in the epithelium of the ciliary apparatus. 
This results in decreased production of bicarbonate, and consequently diminished 
\ 
secretion of sodium and bicarbonate into the posterior chamber [32]. This in tum, 
reduces the amount of aqueous humour formed in the anterior chamber. Topical 
carbonic anhydrase inhibitors consist of a free sulphonamide group linked to an 
aromatic ring, for example, acetazolamide. Alternatively, ~-blocking agents such as 
timolol, betaxolol and levobunalol may be used to reduce aqueous humour 
production. These are either non-selective (work by inhibiting both ~I- and P2- . 
adrenoceptors) or, preferentially, P I-selective (inhibit P I-adrenoceptors). 
iii) Reducing intraocular pressure by dehydrating the aqueous humour. This is 
achieved by making the plasma hypertonic in relation to the aqueous humour, 
which promotes movement of fluid from the ocular chambers to the plasma. Such 
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agents include mannitol and glycerine, which induce varying degrees of diuresis 
[33]. 
Conjunctivitis is an inflammation of the conjunctiva and is a common eye disorder; 
it may be caused by bacterial and viral infections, or by environmental factors such as 
pollen, smoke and pollutants. Symptoms include excessive tear production, discharge and 
pain, but vision remains unaffected. 
Trachoma is a chronic inflammatory condition, caused by Chlamydia trachomatis, 
in which fibrous tissue forms in the conjunctiva and cornea leading to eyelid deformity: it 
is a common cause of blindness in tropical countries. 
Blepharitis is a chronic inflammation of the eyelid margins that is usually caused by 
microbes or by allergy, e.g. staphylococcal infection or seborrhoea (excessive sebaceous 
gland secretion). Inflammation caused by a bacterial infection normally responds to 
antibiotics. Many of the topical ophthalmic antibiotics have a broad spectrum of activity 
and are used for a number of bacterial infections. 
Viral infections of the eye include herpes simplex keratitis, varicella zoster and 
adenovirus. The general treatment for viral infection requires frequent application of a 
solution or ointment; instillation on an hourly basis is common. Many of the antiviral 
agents used interfere with viral DNA synthesis. 
Dry eye syndrome encompasses a number of separate disease processes, which can 
lead to an inadequate wetting of the ocular surface. This may be secondary to a deficiency 
or abnormality of a component of the tear film, or to incomplete spreading of the tear film 
over the ocular surface. The dry eye syndromes may be divided into five categories: lipid 
abnormalities, aqueous deficiency (keratoconjunctivitis sicca), mucin deficiency, lid-
surfacing abnormalities and epitheliopathy [34]. Inadequate tear production is an important 
cause of ocular discomfort and often contributes to failure to tolerate contact lenses. The 
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dry eye condition is common in the elderly. The patient usually complains of a chronic 
gritty sensation in the eye, which may not appear to be particularly red. Systemic diseases 
such as rheumatoid arthritis are associated with dry eye. Diuretics may also exacerbate the 
symptoms of a dry eye. The treatment of dry eye often involves the use of artificial tears, 
which may be used as necessary. Ointment, which helps to give prolonged lubrication, 
especially at night when tear secretion is minimal, may be prescribed and acetyl cysteine 
drops may be used if there is clumping of mucus on the eye (filamentary keratitis) [35]. 
Although artificial tear preparations can relieve the symptoms of dry eye, the major 
drawback of these treatments is their short duration of action [36]. 
Keratoconjunctivitis sicca (KCS) is a condition particularly associated with patients 
suffering from rheumatoid arthritis. Other causes include age-related atrophy of the 
lachrymal gland, congenital disorders such as Riley-Day syndrome and congenital 
hypoplasia of the lachrymal gland, trauma and tumours affecting the lachrymal gland, local 
and systemic inflammation, and neurological and pharmacological effects. Patients 
suffering from Sjorgen's syndrome, a chronic systemic disease characterised by 
polyglandular tissue destruction and involving infiltration of lymphocytes into the 
lachrymal and salivary glands, develop KCS along with rheumatoid arthritis [37]. The 
symptoms of keratoconjunctivitis sicca include intermittent burning and tearing, which is 
exacerbated by reading, drafts, wind, smoke and fumes. Grittiness or foreign body 
sensation, itching and redness are also common. The precomeal tear film may contain a 
considerable amount of cellular debris, which is inadequately flushed from the ocular 
surface. Abnormal accumulation of mucus also occurs, leading to the formation of 
prominent strands, which tend to settle in the inferior cul-de-sac. This is thought, again, to 
be the result of poor flushing action by the aqueous layer and is usually treated with 
artificial tears, which are instilled as required by the patient. Other treatments have been 
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used in conjunction with tear replacement therapy, including inhibition of tear drainage, 
stimulation of tear production, bandage contact lenses and the use of anti-inflammatory 
agents and mucolytic agents [34]. 
Keratitis may be caused by a variety of agents and often leads to ulceration of the 
cornea. A corneal ulcer is defined as a breach of the corneal epithelium other than a 
traumatic abrasion. Causes of corneal ulceration include bacterial, viral and fungal 
infection (such as with Candida albicans), the presence of a foreign body and toxic 
reactions. Contact lenses represent the first suspect in cases of keratitis. The herpes 
simplex virus is also a common cause of keratitis; this may affect any of the corneal 
tissues, and can lead to epithelial keratitis, disciform keratitis, stromal keratitis and iritis. 
Treatment for such infections may take a variety of forms including topical trifluridine or 
orally administered acyclovir for epithelial keratitis; topical corticosteroids combined with 
an antiviral are used in cases of disciform and stromal keratitis and iritis [38]. Other forms 
of keratitis include neuroparalytic keratitis and Rosacea keratitis, which is a chronic 
disorder of the face involving reddening and inflammation of the skin. Ophthalmic 
complications associated with this condition include inflammation of the lid margins 
(blepharitis), meibomian cysts of the eyelid (chalazia), conjunctivitis and keratitis. 
Treatment is usually with low dosage oral tetracycline [25]. Neuroparalytic keratitis arises 
when there is loss of corneal sensation, which may result from a herpes zoster infection, or 
any lesion of the fifth nerve. This condition may be treated with the copious use of 
ointment at night or with 'bandage' soft contact lenses. 
Iritis also referred to as anterior uveitis, is a condition that may occur in association 
with diseases such as ankylosing spondylitis, sarcoidosis, tuberculosis and syphilis; it is 
commonly seen in patients following intraocular surgery, ocular trauma and in those 
suffering from corneal ulcers. Commonly, iritis has an acute onset, with the patient 
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suffering with pain and inflammation of the eye. Pain may be quite severe and is partly due 
to the spasm of the ciliary muscle. The vision is often blurred and there may be some 
photophobia and watering of the eye. It is not uncommon for the second eye to become 
infected a few days later. The inflamed iris becomes sticky with the pupil margin often 
becoming adhered to the lens. Initially, the points of adhesions are difficult to detect but 
these become apparent upon instillation of a mydriatic agent as the pupil dilates irregularly. 
If the entire pupillary margin is adhered to the lens, the aqueous humour is prevented from 
passing from the posterior to the anterior chamber. Aqueous humour accumulates rapidly 
behind the iris and pushes it forward; a rise in intraocular pressure follows and can lead to 
secondary glaucoma. The treatment of iritis is directed towards the control of 
inflammation, the breakdown of adhesive interactions and the relief of pain. Anti-
inflammatory drugs are used in conjunction with mydriatics to dilate the pupil, thus 
separating the iris from the lens. Pain usually subsides upon successful treatment of the 
other symptoms but analgesics may also be prescribed [14]. 
1.4. Commonly used ophthalmic drugs 
A wide variety of topical ophthalmic medications are used for treating the numerous 
diseases and disorders of the eye; these are summarised in Table 1.1. Pilocarpine and 
timolol are just two of the most commonly used anti-glaucoma treatments. Antibiotics, e.g. 
chloramphenicol and norfloxacin, are also common in use for treating various kinds of 
bacterial infections. 
29 
Table 1.1. Ophthalmic therapeutic agents [33]. 
Treatment Type 
Topical anaesthetics 
Topical mydriatics and 
mydriatics and cycloplegics 
Vasoconstrictor 
Topical antibiotics 
Antiglaucoma medications 
Topical antiviral agents 
Topical antifungal agents 
Topical corticosteroids 
Cocaine 
Proparacaine 
Tetracaine 
Drug 
Benoxinate hydrochloride 
Dibucaine hydrochloride 
Ketorolac 
combined Phenylephrine 
Atropine 
Homatropine hydrobromide 
Cyc1opentolate hydrochloride 
Scopolamine hydrobromide 
Tropicamide 
Dipirefrin hydrochloride 
Phenylephrine hydrochloride 
Bacitracin 
Chloramphenicol 
Aminoglycosides (neomycin, gentamycin, 
tobramycin) 
Penicillins and cephalosporins 
Sulphonamides 
Tetracycline 
Muscarinic agonist (Pilocarpine, 
Carbachol) 
Anticholinesterase agents (physostigmine, 
neostigmine, isofluorophate, echothiophate) 
Sympathomimetics (epinephrine) 
Beta-adrenergic-blocking agents (timolol, 
betaxolol, levobunalol) 
Carbonic anhydrase inhibitors 
(acetazolamide, dorazolamide) 
Hyperosmotic agents (mannitol, glycerine 
isosorbide) , 
Alpha-2 adrenoceptor agonist (c1onidine) 
Prostaglandin analogue (latanoprost) 
Acyclovir, Gancyclovir 
Idoxuridine 
Viadarabine 
Trifluridine 
Natamycin 
Nystatin 
Prednisolone 
Dexamethasone 
Betamethasone 
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Pilocarpine 
Pilocarpine, a derivative of the plant genus Pilocarpus, is one of several alkaloids 
that mimic the effect of acetylcholine on the autonomic effector cells that control smooth 
muscle contraction. It has been used in the treatment of glaucoma for more than a century. 
The compound, (Fig. 1.5) binds to the muscarinic class of acetylcholine receptors and 
exhibits partial agonist activity [39]. 
Fig. 1.5. Structure of Pilocarpine 
Pilocarpine solutions ranging from 0.5 to 10 % have been used in the treatment of 
glaucoma. The usual therapeutic concentration is 2 %, which is administered as one to two 
50 JlI drops for up to 4 times per day. Pilocarpine is also available as a gel preparation 
containing 4 % drug, which is applied once per day. The Ocusert® Pilo 40 system offers 
an alternative to eyedrops and gels and takes the form of an insert, which, when placed into 
the upper fornix, is able to release pilocarpine for up to one week at an average rate of 40 
micrograms per hour [40]. Pilocarpine reduces intraocular pressure by about 20 to 30 % 
[41]. 
Although pilocarpine is considered to be the safest and most effective form of anti-
glaucoma medication, it has several characteristics and side effects that can limit its use. It 
has a short duration of action (4 to 6 hours) and aqueous drops must be administered four 
times per day. Miosis decreases the amount of light that enters the eye and thus dims the 
sense of vision and prolongs dark adaptation. In younger patients, the contraction of the 
ciliary muscle by pilocarpine induces artificial shortsightedness and can also cause 
31 
uncomfortable muscle spasms. Other adverse effects include conjunctival hyperaemia, lens 
opacities and retinal detachment. Systemic effects are also observed when higher 
concentrations of pilocarpine are used; these include vomiting, nausea, diarrhoea, 
tachycardia, bronchospasm and sweating [41]. In aqueous solution, pilocarpine presents at 
least two possible pathways of degradation: hydrolysis to pilocarpic acid and 
epimerisation to isopilocarpine. Pilocarpine is relatively stable in acidic solutions but as the 
pH is increased, it progressively becomes unstable, especially at elevated temperatures. 
The addition of 0.5% methylcellulose has been shown to improve the stability of 
pilocarpine solutions [42]. 
Timolol 
Timolol is a non-selective, ~-adrenergic blocking agent that reduces intraocular 
pressure by inhibiting aqueous humour production. The'precise mode of action oftimolol 
is unclear, but it has been suggested that timolbl down-regulates the adenyl ate cyclase 
enzyme by inhibiting ~2-adrenoceptor sites at the ciliary processes. Clinical studies have 
reported 27-35 % reductions of intraocular pressure during long-term treatment [41]. 
Timolol is available in 0.1, 0.25 and 0.5% solutions and is normally applied twice daily. A 
formulation employing a gel as a vehicle (Timoptic-XE®) permits once-daily application. 
Timolol causes fewer ocular adverse effects than miotic or sympathomimetic drugs but its 
use reduces tear flow and can result in dry eye syndrome or give difficulties for contact 
lens wearers. However, ~-blockers may induce adverse systemic effects by blocking the 
~l-adrenoceptors of the heart. Timolol may cause bradycardia, arrhythmia and congestive 
heart failure. In addition, it can cause bronchospasm in patients with chronic obstructive 
pulmonary disease and asthma. Furthermore, timolol may induce anxiety, depression, 
fatigue, disorientation and hallucinations. All these systemic side effects are caused by the 
immediate uptake of timolol in the blood via the epithelium of the nasopharynx. Plasma 
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levels of timolol after instillation can be reduced by up to 70% by compression of the 
nasolachrymal punctum at the time of application, thereby minimising the unwanted 
systemic effects [41]. 
Antibiotics 
Examples include bacitracin, commercially available as an ointment, and 
chloramphenicol, manufactured as both a solution and an ointment. Bacitracin is a broad-
coverage antibiotic that inhibits bacterial cell wall synthesis and is effective against gram-
positive cocci, bacilli, Neisseria, Haemophilus and spirochaetes. Chloramphenicol inhibits 
bacterial protein synthesis by competing with binding of the 50S ribosomal unit. This 
compound is active against gram-positive, gram-negative and anaerobic organisms and 
achieves good penetration into the corneal epithelium. Acyclovir is the most commonly 
prescribed antiviral, although idoxuridine has been used against herpes simplex keratitis 
and works by replacing viral thymidine [43]. Vidarabine is effective against herpes 
simplex keratitis, varicella-zoste; however, its administration may delay corneal 
regeneration. Trifluridine is used against herpes simplex and adenovirus infections. Side 
effects may include swelling of the eyelids, photophobia, stinging upon administration and 
increased intraocular pressure [44]. 
Norjloxacin 
Fig. 1.6. Structure ofNorfloxacin. 
Norfloxacin is an oral broad-spectrum quinoline antibacterial agent used in the 
treatment of various ophthalmic disorders., The mechanism of action of norfloxacin 
involves inhibition of the A subunit of the important bacterial enzyme DNA gyrase, which 
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IS essential for DNA replication [45]. The most common adverse effects are 
gastrointestinal, neuropsychiatric and skin reactions, and include nausea, headache, 
dizziness, rash, heartburn, abdominal pain/cramps and diarrhoea. Frequent applications of 
topical norfloxacin in patients with decreased tear secretion may result in deposition of 
drug onto the cornea [46]. 
Atropine 
Atropine IS a tropane alkloid extracted from the deadly nightshade (Atropa 
belladonna) and other plants of the family Solanaceae. It is a secondary metabolite of these 
plants and serves as a drug with a wide variety of effects. 
Fig. 1.7. Structure of Atropine 
Atropine binds to the muscarinic class of acetylcholine receptors and exhibits 
antagonist activity. Topical atropine is used as a cyclopiegic, to temporarily paralyze 
accommodation, and as a mydriatic, to dilate the pupils. It degrades slowly, typically 
wearing off in 2 to 3 days, so tropicamide is generally preferred as a mydriatic. In atropine-
induced mydriasis, the mechanism of action involves blocking the contractiOIl of the 
circular pupillary sphincter muscle (which is normally stimulated by acetylcholine release), 
thereby allowing the radial pupillary dilator muscle to contract and dilate the pupil. It is 
contraindicated in patients predisposed to narrow angle glaucoma. Side effects may include 
urinary retention, dry mouth and blurred vision. The active is a racemic mixture of D-
hyoscyamine and L-hyoscyamine, with most of its physiological effects due to L-
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hyoscyamine. The most common atropine compound used in medicine is atropine sulfate 
hydrate: (C17H23N03)2. H2S04. H20, 1a-H, 5a-H-tropan-3-a-ol (±)-tropate(ester), sulfate 
monohydrate. 
1.5. Drug delivery to the eye 
The complicated removal mechanisms in the precomeal area (Section 1.1) are 
necessary for the protection of the eye from foreign substances. In order to design a drug 
delivery vehicle that could safely overcome these mechanisms, it is necessary to appreciate 
the disposition pathways of the drug molecule and its ocular 
pharmacokinetic/pharmacodynamic profile. The various types of ophthalmic drug delivery 
carriers are also described in this section. 
1.5.1. Ocular pharmacokinetics and pharmacodynamics 
Pharmacokinetics is the study of the absorption, distribution and elimination of a 
drug and describes the quantitative relationship between the administered dose, the dosing 
regimen and the observed plasma or tissue concentration. Pharmacodynamics may be 
described as the quantitative relationship between observed plasma or tissue concentration 
of the active form of the drug and the corresponding pharmacological effect. 
Pharmacokinetic analysis of drugs is often approached by dividing the body, or organ of 
interest, into a series of compartments, which mathematically represent time variations of 
levels of drug in tissue as a summation of exponentials. 
Ocular pharmacokinetic studies are generally undertaken using the rabbit eye as the 
model organ. It is not possible to carry out ocular pharmacokinetic studies in humans 
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without risking pain or injury. Although the rabbit eye is useful for predicting human 
ocular toxicities, the eyes of each species have a number of differences in anatomy and 
physiology, such that predicting human ocular pharmacokinetics from rabbit data may not 
be very precise for certain drugs (Table 1.2). 
Table 1.2. Comparative anatomical and physiological features of New Zealand 
rabbit eye vs human eye 
Pharmacokinetic Factor Rabbit Eye Human Eye 
Tear volume 7.5 III 7.0-30.0 III 
Tear turnover rate 0.6-0.8 III I min 0.5-2.2 III I min 
Spontaneous blink rate 4-5 I min 15 I min 
Nictitating membrane Present Absent 
pH of tears . 7.14-7.82 7.14-7.82 
MiIIiosmolarity of tears 305 mOsmll 305 mOsm/1 
Corneal thickness 0.40 mm 0.52mm 
Corneal diameter 15 mm 12mm 
Aqueous humour volume 310 III 310 III 
Aqueous humour turnover rate 1.53 III I min 1.53 III I min 
The single compartment model (Fig. 1.8) represents the simplest pharmacokinetic 
model for the eye. 
FD k ~I Cornea 
Fig. 1.8. Schematic of one-compartment model 
The expression that is used to describe this process in terms of drug concentration, 
C, is: 
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c = (~J( k J(e-K1 - e-kl ) Vd (k-K ) 
where D is the dose, F is the fraction of dose absorbed, k and K are the absorption and 
elimination rate constants, respectively, and Vd is the apparent volume of distribution. 
However, it may be more appropriate to consider the various tissues of the eye as 
separate compartments. Lee and Robinson [47] considered some of the pathways 
accounting for drug loss in the precorneal area by means of a four-compartment model 
(Fig. 1.9) capable of predicting pre corneal and intraocular drug movement following 
topical dosing. 
Instilled dose 
1 
Precorneal 
Area (1) 
k12 
k23 
f Cornea (2) 
Instilled solution drainage 
C I absorption onJunctlva 
~ 
Nictitating m embrane absorption 
~ Tear turnover --•• Kloss 
~ 
~ Drug protein binding 
Drug metabol Ism 
I~ Aqueous humour (3) I Anterior segment -~ Disposition (4) 
Fig. 1.9. Model depicting precorneal and intraocular drug movement [47] 
Drug penetration through the cornea and lens may be analysed in terms of a 
diffusion process. The iris-ciliary body and lens may be considered as reservoirs that bind 
drugs and release them slowly. Makoid and Robinson [48] considered a four-compartment 
model - consisting of the precorneal area, cornea, aqueous humour and reservoir tissues 
37 
(lens, iris etc.) - in which there is a two-way movement of drug between cornea and 
aqueous humour and between aqueous humour and the reservoir tissue. Excellent 
correlation between predicted and observed values was seen in multiple dosing studies. 
Furthermore, it was found that the drainage rate of pilocarpine at the precorneal area was 
one to two orders of magnitude greater than the rate of corneal absorption. 
1.5.2. Ophthalmic drug delivery vehicles 
Although there are a wide variety of ophthalmic drug delivery systems on the 
market, 70% of prescriptions for eye medication are for conventional eye drops. This is 
due to a number of issues related to the other types of vehicle that have been developed 
and tested over the past 20-30 years, namely: cost, difficulty in bulk manufacture, patient 
compliance, efficacy and stability. The various types of ocular drug delivery vehicles in 
existence are discussed in the following sections. 
1.5.2.1. Eye drop solutions and suspensions 
Eyedrops are the most commonly used of all dosage forms and account for around 
90 % of currently available ophthalmic formulations [4], because they can be administered 
in the form of solutions or suspensions and are convenient, safe, immediately active and, 
with the exception of the very young and the elderly, are well accepted by patients. 
However, these dosage forms require frequent instillations of highly concentrated solutions 
due to the rapid and extensive precorneal loss caused by nasolacrimal drainage and high 
tear turnover. Typically less than 5 % of instilled drug penetrates the cornea and reaches 
intraocular tissues, while a significant fraction of the dose is absorbed systemically [49,50]. 
Eye drops facilitate a pulse-entry of the drug, which is followed by a rapid decline in the 
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drug concentration in the tears, the kinetics of this process being of approximate first order 
[24J. 
The two major physical forms of eyedrops are aqueous solutions and suspensions. 
Most of the major ophthalmic therapeutic agents are water-soluble or can be formulated as 
water-soluble salts. The most common salt forms are the hydrochloride, sulphate, nitrate 
and phosphate; the selection of the appropriate salt being determined by solubility, 
therapeutic concentration, effect of pH, tonicity and buffer capacity. The adjustment of the 
pH of ophthalmic solutions is important as this can have implications for comfort, activity 
and stability of the product. The ideal pH is considered to be 7.4, as this is the value of 
normal physiological tear fluid and thus less likely to promote increased tear production, 
which, in tum, may result in excessive loss of drug. Nonetheless, in vivo experiments in 
rabbits have shown that an increased pH can enhance drug permeability across the cornea, 
owing to the solution containing a higher concentration of the non-ionised drug base [51J. 
Suhonen et al. [52] found that an increase in the pH of pilocarpine preparations from 5.5 to 
7.65 brings a three-fold increase in permeability across the isolated rabbit cornea. 
However, in order to achieve adequate stability and solubility for an acceptable shelf-life 
of at least two years, pilocarpine and its prodrugs must be formulated at an acidic pH 
solution, being neutralised following instillation on the ocular surface [53J. 
Ophthalmic solutions and suspensions should be sterile when dispensed, and a 
suitable preservative must be added to this. Eyedrop preparations are usually sterilised by 
autoclaving, although in some cases, due to their lack of thermo stability at physiological 
pH, bacterial filtration may be used as an alternative method e.g. for basic salts of weak 
acids such as sodium fluorescein. Suitable preservatives for eyedrops include 
benzalkonium chloride, chlorobutanol, phenylmercuric acetate and thiomersaI. These are 
topically non-irritating antibacterial agents that prevent growth of, or destroy, 
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microorganisms that may be accidentally introduced into the eyedrop container during use. 
Ophthalmic solutions and suspensions are usually packaged in glass or plastic containers 
incorporating a dropper. Such types of packaging are subject to contamination during use, 
which may be airborne or be brought about by the touching of the tip of the dropper on the 
ocular tissues. Eyedrops in multiple-application containers for domiciliary use should not 
be used for more than four weeks after first opening (unless otherwise stated). Solutions 
and suspensions for use in hospital wards are normally discarded one week after first 
opening; individual containers are provided for each patient. Eyedrops used in outpatient 
departments are usually discarded at the end of each day (British National Formulary, 
2001). The prescribed amount of ophthalmic solution or suspension is dropped quickly, but 
completely, into the eye without touching the dropper to the eye or surrounding tissue. If 
the patient is administering the preparation unaided, the dropper should be held above the 
eye with one hand, while the other is used to pull down the lower eyelid. The medicine is 
then dropped into the eye,while the patient looks upward. The patient should remain in 
place with the eye open for 30 seconds and should be instructed not to close the eyes 
tightly or blink more than is usual [53]. These recommendations for the correct 
administration of ophthalmic solutions and suspensions are given in order to obtain the 
maximum therapeutic effect from the prescribed dose. However, many patients, 
particularly the elderly and the very young, find this procedure difficult to coordinate and 
thus fail to administer the correct dose. 
1.5.2.2. Viscous vehicles 
Polymers are frequently added to ophthalmic solutions and suspensions in order to 
increase the ocular bioavailability of drugs by increasing the viscosity of the vehicle [54], 
thereby prolonging contact with the cornea. Such polymers are typically high molecular 
weight hydrophilic molecules (5000-100000 Da) that are unlikely to cross biological 
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membranes, and include synthetic polymers such as: polyvinyl alcohol; 
poly(vinylpyrrolidone); polyacrylic acid and poloxamers; animal polysaccharides (such as 
hyaluronic acid); or cellulose derivatives (methylcellulose, hydroxymethylcellulose and 
carboxymethylcellulose) [56,58]. Other polymers include microbial polysaccharides such 
as dextran, xanthan and gellan. Gellan is available as Gelrite®, a commercial preparation, _ 
which is obtained by the acetylation of native gellan [55]. Beside medicated eyedrops, 
viscous solutions for ophthalmic preparations are also used for artificial tears and contact 
lens solutions. 
The useful viscosity range of an ophthalmic solution often represents a limiting 
factor in the use of viscous vehicles. It has been reported that an increase in the corneal, 
penetration of an ophthalmic drug is maximal at a viscosity of about 15 to 150 cP [57]. 
Any further viscosity increase is reported to have little effect on the drainage rate and tear 
film thickness and may be associated with interference with vision and resistance to the 
movement ofthe eyelids [57]. 
Low viscosity Newtonian polymer solutions applied to the precomeal area effect 
little improvement in bioavailability, whereas at high viscosity such solutions do not 
increase residence contact time whilst making blinking painful [59]. Non-Newtonian 
formulations - that display pseudoplastic properties in which the viscosity decreases with 
increasing shear rate - offer significantly less resistance to blinking. Such formulations are 
accepted by patients more readily than viscous, newtonian formulations [16]. 
Chrai and Robinson [60] showed that the rate of drainage of a viscous 
methylcellulose solution containing pilocarpine decreased with increasing viscosity of the 
solution. They found a linear first order relationship between the drainage rate and both the 
miotic activity and drug concentration in the aqueous humour. Poly(vinylalcohol) is a 
synthetic, long chain polymer that has been used in ophthalmic preparations since the early 
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1960s. Poly(vinylalcohol) can lower the surface tension of water and enhance tear film 
stability. These properties have led to the widespread use of poly(vinylalcohol) as a drug 
delivery vehicle and artificial tear preparation. It has been shown that when 
poly(vinylalcohol) and methylcellulose are compared on a viscosity basis, there is no 
difference between the two vehicles in terms of their influence on ocular drug 
bioavailability in rabbit [57]. Meseuger et al. [61] found that even after 20 minutes, 
viscous solutions of xanthan gum and Gelrite®, containing a radioactive label 
( 99mTechnetium), were able to facilitate a level of radioactivity in the human eye that was 
at least equal to the level achieved with a non-viscous reference solution after 1 min. 
Poly(vinylpyrrolidone), PVP, has also been employed as a viscosity-enhancing agent in 
ophthalmic solutions. Nagarsenker et el [62] found that isoviscous solutions of PVP, 
poly(vinylalcohol), hyaluronic acid and hydroxypropylcellulose all reduced the systemic 
absorption of timolol, but to varying extents; PVP was found to be the most effective in 
enhancing timolol absorption. 
Polymers that enhance the viscosity of eyedrop preparations may be subdivided 
into: non-mucoadhesive polymers, bioadhesive-mucoadhesive polymers, in situ gelling 
systems and colloidal systems (liposomes, micro-particles and nanoparticles); these will be 
discussed in more detail in later sections. 
1.5.2.3. Colloidal systems 
Colloidal systems, encompassing liposomes as well as micro- and nano-particles, 
have been studied widely over the past 20 years as a means of increasing specificity of 
drug action, enhancing bioavailability, and protecting the active against enzyme 
inactivation [4]. Colloidal particles are subjected to the same clearance mechanisms as 
other foreign bodies that may come into contact with the ocular surface and tend to be 
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washed away by reflex tearing. Particles of larger size are more likely to be entrapped 
under the eyelids or in the inner canthus and so remain in contact with the corneal and 
conjunctival epithelia for extended periods. However, large particles in the eye are 
uncomfortable for the patient; it is generally accepted that particles intended for 
ophthalmic use should not exceed 5-10 Jlm in diameter. 
Liposomes are membrane-like vesicles, consisting of lipid bi-layers that surround 
an aqueous compartment; the lipid layers are composed mainly of phospholipids. 
Liposomes are classified according to their size and are known as either small unilamellar 
vesicles (10-100 nm), large unilamellar vesicles (100-3000 nm) or, if a number ofbi-layers 
are present, multilamellar vesicles. The charge on a liposome may be positive, negative or 
neutral depending on its components. If the external membrane is composed of 
stearylamine, the liposome carries a positive charge, if it is made of dicethylphosphate or 
phosphatidic acid, the liposome carries a negative charge and if the outer layer is 
phosphatidy1choline or dipalmitoylphosphatidylcholine, the liposome is neutral. Fitzgerald 
et al. [11] used y-scintigraphy to evaluate the precorneal drainage of 99mTechnetium 
labelled liposomes in rabbits. The liposomes were shown to have prolonged association 
with the ocular tissues but were found to be poorly retained on the corneal surface. 
However, more recent studies have confirmed that certain positively charged liposomes are 
capable of increasing precorneal retention and enhancing drug bioavailability [11, 63]. 
This behaviour has been attributed to interactions with the negatively charged corneal 
surface, which has an electrical potential of -30 mV [16]. The use of polymer-coated 
vesicles as a means of prolonging contact between liposomes and the corneal surface has 
also been investigated. Multilamellar vesicles coated with the mucoadhesive polymer 
Carbopol have been prepared by Davies et al. [64], who have reported that at pH 5 the 
polymer-coated liposomes were retained in the eye for a significantly longer period than 
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uncoated vesicles. Durrani et al. [31] found that although the in vivo use of coated 
liposomes containing pilocarpine imparted a larger area under the miotic intensity-time 
curve and a longer duration of action as compared with uncoated liposomes, showed equal 
activity to a pilocarpine reference solution. In addition, the potential of liposomes as a 
topical ophthalmic drug delivery system appears to be limited by their drug-loading 
capability and their stability. Furthermore, the large-scale manufacture of liposomes is 
expensive and technically challenging. 
Nanoparticles are solid colloidal drug carriers ranging in diameter from 10 to 1000 
nm and the drug may be entrapped within the particle or adsorbed onto its surface. 
Nanoparticles prepared for ophthalmic drug delivery have mainly been produced by 
emulsion polymerisation of synthetic monomers; particle size is controll~d by the size of 
the emulsion [65,67]. 
Microparticles are microcapsules or micro spheres that have a particle diameter 
exceeding 1 J!m. Microspheres are monolithic particles possessing a porous or solid 
polymer matrix, whereas microcapsules consist of a polymeric membrane surrounding a 
solid or liquid drug reservoir [69]. Upon topical instillation, the particles tend to reside in 
the ocular cul-de-sac, and the drug is released from the particles through diffusion or as a 
result of polymer degradation [10]. 
A large number of methods are available for the production of micro- and 
nanoparticles, with the method of choice being determined by the drug to be used [71]. 
Techniques for the manufacture of particles include denaturation or crosslinking of 
macromolecular emulsions [67, 68], interfacial polymerisation [70, 72], formation of 
emulsions followed by solvent removal [61], solution enhanced dispersion by supercritical 
fluids [74] and spray drying [75, 76]. A wide range of polymers has been used in the 
manufacture of micro- and nanoparticles for ophthalmic drug delivery. These include 
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poly(alkyl)cyanoacrylate, used to encapsulate drugs such as timolol; polylactic acid for the 
delivery of chloramphenicol, cyclosporine A and pilocarpine; and albumin, which can be 
formulated to deliver hydrocortisone and pilocarpine [73,77]. In an early study, Gurnyet 
al. [78] developed a cellulose acetate-hydrogen phthalate pseudolatex formulation for the 
delivery of pilocarpine. The same workers found that following administration of this 
formulation both the miosis tmax (time to reach the maximum miotic effect) and the area 
under the miotic intensity-time curve were increased by 50 %, compared to an aqueous 
reference solution. However, this has been disputed by Zimmer et al., who claimed that the 
observed pharmacological enhancement was due to an increase in viscosity of the vehicle, 
and was not caused by a slow release of drug from the particles [73]. Giunchedi et al. [75] 
found that the bioavailability of piroxicam, a non-steroidal anti-inflammatory drug 
(NSAID) used for the topical treatment of ocular inflammation, could be Increased three-
fold if formulated as pectin microspheres (prepared by spray drying), as compared with a 
commercial reference solution. Other studies have shown that the uses of micro- and 
nanoparticles in ocular drug delivery are capable of slowing the release profile of 
pilocarpine, and as a result prolong pharmacological responses (such as miosis) and 
reduced intraocular pressure [79]. Recent studies have shown that the use ofmucoadhesive 
polymeric nanoparticles is a promising means of achieving selective and prolonged drug 
delivery to the eye [31]. Kao et al. [80] found that pilocarpine/chitosan/carbopol 
nanoparticles may provide an excellent potential alternative ophthalmic sustained-release 
formulation of pilocarpine for clinical use. Zimmer et al. [73] investigated the influence of 
a number of viscous and bioadhesive polymers (methylcellulose, poly(vinylalcohol), 
hydroxypropylmethylcellulose, hyaluronic acid, mucin, sodium carboxymethylcellulose, 
polyacrylic acid) on the in vivo activity of pilocarpine-loaded albumin nanoparticles. 
Bioadhesive polymers are reported to have superior effects as compared to their viscous 
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counterparts, with the area under the miotic curve being seen to increase 1.35-fold 
following the addition of polyacrylic acid, and 1.64-fold when mucin was employed. One 
of the approaches recently developed involves drug incorporation into cationic 
submicronic polymeric vectors (such as chitosan), which exploit the negative charges 
present at the corneal surface for increased residence time and penetration [82]. 
1.5.2.4. Ointments and gelslhydrogels 
Ointments are semisolid preparations intended for external application. Ointments 
may be medicated or nonmedicated, the latter type being commonly referred to as ointment 
bases and used as such for their emollient or lubricating effect, or utilised as vehicles in the 
preparation of medicated ointments. Ophthalmic ointments are usually formulated using 
petrolatum, a mixture of semisolid hydrocarbons obtained from petroleum, and liquid 
petrolatum (mineral oil). These bases have a melting or softening point close to body 
temperature and should be non-irritating to the eye. Ointments are characterised as simple 
bases, where the ointment forms one continuous phase, and compound bases in which an 
emulsion of oil and water is formed. The medicinal agent is added to the base either as a 
solution or as a finely micronised powder. Upon instillation in the eye, ointments break up 
into small droplets and may remain as a depot of drug in the cul-de-sac for extended 
periods. Ointments are therefore useful for improving drug bioavailability and for 
sustaining drug release into the ocular tissues. The major use of ointments is in the delivery 
of antibiotics, sulphonamides, antifungals and anti-inflammatories. 
Sieg and Robinson [81] have demonstrated that ointments exhibit extended effect of 
steroidal drug fluorometholone in aqueous humour levels and enhance the percentage of 
drug penetrating the ocular tissues, as compared with suspensions of the same active. The 
same workers reported that partitioning of the steroid from the ointment had a greater rate-
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limiting effect on corneal penetration than the dissolution rate parameter characterising the 
aqueous suspension. Although ointments are safe, they suffer with relatively poor patient 
compliance due to refractive index problems and occasional ocular mucosal irritation [82, 
83]. For these reasons they are often used as a night-time medication. 
An alternative to ointments is the use of aqueous gels, commonly known as 
hydro gels. These consist of high molecular weight, hydrophilic crosslinked polymers or 
co-polymers that form a three-dimensional network, which can hold water or an aqueous 
solution containing a drug [85]. A gel of this type usually consists of macromolecules 
existing as twisted matted strands where the units are often bound together by van der 
Waals' forces. Hydrogels have been shown to bestow significantly longer residence times 
in the conjunctival cul-de-sac and increased drug bioavailability, thereby prolonging the 
therapeutic level in the eye [86,87,89]. Oxygen transmission requirements have been 
addressed through the use of siloxane and fluorosiloxane containing hydrogels [91]. 
Hydrogels may be prepared by polymerising water-soluble monomers in the presence of 
bi- or multifunctional crosslinking agents. Alternatively, chemical gels can be prepared by 
crosslinking water-soluble polymers, by using functional group chemistry. However. the 
crosslinking agents used are often toxic compounds, which have to be extracted from the 
gels before they can be applied. Moreover, crosslinking agents can give unwanted 
reactions with the bioactive substances present in the hydrogel matrix. Such adverse effects 
are avoided with the use of physically crosslinked gels [93]. 
Hydrogels may be classified into two groups: pre-formed and in situ forming gels. 
Pre-formed gels may be defined simply as highly viscous solutions whereas in situ gelling 
systems are usually,viscous liquids that shift to a gel phase upon exposure to physiological 
conditions [95]. Pre-form~d gels include the cellulose derivatives, polyvinyl alcohol, 
hyaluronic acid and carbomer. 
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1.5.2.5. Solid matrices and devices 
A number of solid polymeric inserts and discs have been developed as ophthalmic 
drug delivery systems. In contrast to eyedrops, inserts provide accurate dosing, reduced 
systemic absorption and, in some cases, improve patient compliance (resulting from a 
reduced frequency of administration and lower incidence of visual and systemic side-
effects) [97,99]. The performance of inserts is little affected by nasolachrymal drainage 
and tear flow, with such devices having been shown to produce reliable drug release over 
prolonged residence times in the conjunctival cul-de-sac [83]. 
Ocular inserts have been investigated for the purpose of delivering a range of 
therapeutic agents including antimicrobials, antivirals, antifungals, antiallergenics, anti-
inflammatories (steroidal and non-steroidal), anti glaucoma medications, 
immunosuppressants and growth factors [86]. A number of inserts are currently available 
on the market or are in the latter stages of development by pharmaceutical corporations, 
including Ocusert®, Soluble Ocular Drug Insert (S.O.D.I), Collagen shields, Ocufit®, 
Minidisc and the Novel Ophthalmic Delivery System (NODS®). Several workers have 
investigated Gelfoam ® - an absorbable gelatine sponge prepared from purified porcine skin 
and usually used for application to areas of bleeding as a haemostatic - as the basis of a 
topical ophthalmic insert [88,90,92,94]. Inserts have been classified, on the basis of their 
physico-chemical behaviour, as degradable or non-degradable. Degradable inserts are 
monolithic polymeric devices that undergo gradual dissolution, or erosion, while releasing 
an incorporated drug; these do not require removal. Various materials have been utilised in 
the development of degradable inserts, including polyvinyl alcohol, 
hydroxypropylcellulose, N-vinylpyrrolidone, poly(vinyl methyl ether/ maleic anhydride), 
xanthan gum, poly(1actic acid) and poly(1actic-glycolic acid) and hyaluronic acid [101]. 
Commercial examples include Soluble Ocular Drug Inserts (S.O.D.I.), collagen shields and 
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Novel Ophthalmic Delivery Systems (NODS®). Non-degradable inserts must be removed 
from the eye after use and have been shown to provide more predictable release rates than 
their soluble counterparts [83]. Such devices have been prepared from ethylene/vinyl 
alcohol copolymers, ethylene/vinyl acetate copolymers, styrene-isoprene-styrene block 
copolymer, poly(lactic acid-co-glycolic acid) and poly(2-hydroxypropyl methacrylate). 
Hydrogels have also been investigated as non-degradable matrices and they have been 
found to provide a constant drug release rate conforming to a non-Fickian diffusion 
mechanism. Commercial examples of non-degradable inserts include Ocusert®, Ocufit® 
and Minidisc. The Soluble Ocular Drug Insert (S.O.D.I.) is a small oval wafer, which was 
developed by Soviet scientists for cosmonauts who were unable to use eyedrops in 
weightless conditions; this was first described in 1976 by Maichuk [96]. The Soluble 
Ocular Drug Insert is composed of a soluble copolymer, consisting of acrylamide, N-
vinylpyrrolidone and ethyl acrylate. The inserts are thin, homogenous polymer platelets 
with dimensions 9 mm x 4.5 mm, a thickness of 0.35 mm and weighing 15-16 mg. After 
introduction into the upper conjunctival sac, the Soluble Ocular Drug Insert softens within 
10-15 seconds, conforming to the shape of the eyeball. The insert forms a polymer clot 
over the next 10-15 minutes and gradually dissolves within one hour, while releasing an 
incorporated drug. Over 20 common ophthalmic drugs and drug combinations have been 
delivered using the S.O.D.l. Maichuk and Erichev [98] showed that the daily 
administration of a S.O.D.I containing 2.7 mg pilocarpine hydrochloride effectively 
reduced the intraocular pressure in 155 glaucoma patients. 
The Novel Ophthalmic Delivery System (N.O.D.S.) is a water-soluble film patented 
by Smith and Nephew Pharmaceuticals Ltd. in 1985. It was developed in an attempt to 
give precise and controlled drug delivery to the eye. The device consists of a medicated 
polyvinyl alcohol flag (4 mm x 6 mm, 20 Ilm in thickness and weighing 0.5 g), which is 
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attached to a paper-covered handle. When applied to the eye, the flag detaches and 
gradually dissolves, releasing the drug [100]. 
Handle 
Medicated flag ) ~ ~ .. \ 
Fig.I.IO. Schematic representation of a N.O.D.S. device [100]. 
Greaves et al. [16] carried out a gamma scintigraphic study (12 healthy volunteers) 
on the precorneal residence and pharmacodynamic action of a radiolabelled Novel 
Ophthalmic Delivery System (N.O.D.S.) congener (99mTechnetium-Iabelled. 
diethylenetriaminepentaacetic acid) containing pilocarpine nitrate. Pilocarpine delivered by 
N.O.D.S. significantly decreased intraocular pressure as compared with pilocarpine 
delivered from a solution. The Novel Ophthalmic Delivery System (N.O.D.S.) also 
induced a greater decrease in pupil diameter as compared with the pilocarpine solution. 
A study by Lawrenson et al. [100], which compared the corneal anaesthesia 
induced by different concentrations of proxymetacaine loaded Novel Ophthalmic Delivery 
System (N.O.D.S.) and conventional eyedrops, concluded that the varying Novel 
Ophthalmic Delivery System doses produced longer lasting anaesthesia than 35JlI 
eyedrops containing more than three times the concentration of drug. The greater 
bioavailability achieved with this vehicle allowed the use of much lower drug 
concentrations, thus reducing the likelihood of adverse systemic reactions. However, 
although therapeutically effective, it has been shown that Novel Ophthalmic Delivery 
Systems (N.O.D.S.) are not as well tolerated by patients as conventional eyedrops [102]. 
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Collagen shields were originally developed as soluble bandage contact lenses that 
would promote corneal healing [16,103]. Collagen is a structural protein of bones, tendons, 
ligaments and skin and comprises more than 25% of the total body protein in mammals. 
The shields, with a diameter of 14.5 mm and a thickness of about 1.0 mm in the centre, are 
composed of porcine scleral collagen [96]. Exposure to ultraviolet light for different time 
periods induces varying degrees of crosslinking, which results in shields with a range of 
dissolution rates. The collagen shields currently on the market do not contain drugs, but 
there have been many studies on their use as delivery systems for ophthalmic therapeutics 
[105]. For drug delivery, the shields are typically rehydrated in an aqueous solution of the 
drug, whereby the drug is absorbed by the protein matrix and then released as the shield 
dissolves in the eye. Drugs that have been investigated for delivery using collagen shields 
include antibacterial agents, (tobramycin [104, 106] and gentamicin [107]), 
immunosuppressive agents (Cyclosporine A [108]), anti-inflammatory agents 
(dexamethasone [109]) and antiviral agents (trifluorothymidine [11 0]). O'Brien et al. 
[104], compared collagen shields with soft contact lenses in pharmacokinetic studies of the 
ocular penetration of tobramycin in rabbits. They compared three groups: animals 
receiving collagen shields rehydrated in 3 mg / ml tobramycin; animals receiving 
therapeutic soft contact lenses; and animals receiving topical tobramycin drops. Each 
group received tobramycin eyedrops (3 mg / ml) every five minutes for a total of six doses. 
Aqueous humour samples were taken 15 and 60 minutes following the last dose. At both 
times, the aqueous humour contained a significantly greater concentration of drug after 
administration with collagen shields than with either contact lenses or topical drops. 
Despite some promising experimental results, however, several disadvantages of collagen 
shields have been identified. The cornea must be anaesthetised before the shield is applied 
and, in contrast with medicated contact lenses, collagen shields often produce discomfort 
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and interfere with vision. In addition, there has yet to be a study that shows prolongation in 
ocular absorption of a drug beyond 30 minutes. As patients are unable to apply the shields 
without the aid of a physician, collagen shields are not considered to offer a significant 
advantage over other delivery devices [86]. 
Ocuserts are insoluble inserts used in the treatment of glaucoma [75, Ill]; these 
have been developed and marketed by Alza Corporation, USA, and are available in two 
forms: Pilo-20 and Pilo-40, which, respectively, are designed to release either 20 or 40 IJ.g 
/ h of pilocarpine for seven days when placed under the eyelid. The Ocusert is a thin, 
flexible elliptical device consisting of three layers, Fig. 1.11. The two outer layers are 
comprised of ethylene-co-vinylacetate and enclose an inner core of pilocarpine gelled with 
alginate; these are the rate-limiting membranes, i.e. they control the rate of drug release 
into the eye. A retaining ring of ethylene-co-vinylacetate, impregnated with titanium 
dioxide, as a marker of visibility, encloses the drug reservoir circumferentially. The 
dimensions of the Ocusert are 13.4 mm x 5.7 mm, with a thickness of 0.3 mm. The 
membranes are the same in both Pilo-20 and Pilo-40, but the reservoir of the Pi10-40 
system contains about 90 mg of di(2-ethylhexyl)phthalate as a flux enhancer [96] . 
Transparent rate-
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Fig.1 .11. The Ocusert device [96]. 
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Friedrich [112] carried out a study to evaluate Ocusert in 14 patients with ocular 
hypertension or glaucoma. It was found to be safe, well tolerated and as effective in 
lowering intraocular pressure as pilocarpine solution (2 %), lasting for at least 4 days. 
Edwards [40] investigated the suitability of Ocusert for the treatment of patients suffering 
from primary acute angle closure glaucoma. In two separate controlled studies, patients 
diagnosed with primary acute angle closure glaucoma were randomised to receive Ocusert 
Pilo-40 and either an intensive pilocarpine regimen or a low-dose pilocarpine treatment. 
All patients also received Diamox (acetazolamide) 500 mg i.v., as is usual in the treatment 
of primary acute angle closure glaucoma. Two hours after starting topical treatment, the 
study was terminated and ocular and systemic response to treatment and the outcome of 
treatment were assessed. Over the treatment period, a comparable reduction in intraocular 
pressure was observed in all three groups. The major advantages of Ocusert over other 
devices included longer duration of action, avoidance of accommodative spasms in 
younger patients and better patient compliance, particularly in those who fail to administer 
eyedrops due to inconvenience or forgetfulness, and in patients treated by another person; 
20 % of all patients treated with Ocusert lost the device without being aware of it. In a 
small number of cases, leakages from the insert were suspected and, rarely, a spontaneous 
dislocation of the device in front of the pupil occurred, with corresponding sight 
impediment [8]. Heller et el [113] investigated, as a means of delivering 5-fluorouracil, an 
anti proliferative agent used as an adjunct to glaucoma filtering surgery. Release of 5-
Fluorouracil from a crosslinked poly( orthoester) occurred predominantly by diffusion with 
little weight loss, while release of 5-Fluorouracil from a linear polymer occurred by an 
erosion-controlled process confined predominantly to the surface layers. 
The minidisc or ocular therapeutic system was developed by Bawa et al. [114]. It 
consists of a 4-5 mm diameter contoured disc having a convex front and a concave back 
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surface; it is placed in contact with the eyeball, and resides behind the lower or upper 
eyelid. The minidisc may be hydrophilic, where the major component is 
polyhydroxymethyl methacrylate, or hydrophobic, prepared from a silicone based 
prepolymer, a,ro-bis( 4-methacryloxybutyl)-polydimethylsiloxane). In vivo tests, usmg 
albino rabbits, showed that the hydrophilic minidisc released sulfisoxazole for 118 h, while 
the hydrophobic unit released gentamicin sulphate for more than 320 h [96]. Comfort 
studies were carried out in 120 human eyes to identify the optimum curvature of the 
mini disc. Handling and insertion studies were also conducted for the purpose of comparing 
the minidisc with another commercially available preparation, the Lacrisert. The Lacrisert 
is a rod-shaped device made from hydroxypropyl cellulose; introduced by Merck Sharp 
and Dohme in 1981. The device, which weighs 5 mg and measures 1.27 mm in diameter 
with a length of 3.5 mm, has been used in the treatment of dry eye syndrome as an 
alternative to artificial tears: 24 subjects, of varying ages, were asked to insert the minidisc 
and the Lacrisert, both prepared, in this instance, from hydroxypropyl cellulose. The mean 
time required for patients to insert the Lacrisert was 39.5 s as compared with 16.6 s for a 
mini disc of the same mass. The patients were allowed 3 attempts at inserting both devices 
and, while only 18 were able to insert the Lacrisert, all 24 patients managed to insert the 
minidisc [96]. 
Other groups have described similar systems: Saettone et al. [8] compressed coated 
ophthalmic mini-tab~ets for the controlled delivery of timolol maleate. Two types of tablet 
were prepared, containing 0.34 mg (type 1) and 0.68 mg (type 2) timolol maleate, 
respectively. The tablets (3.5 mm in diameter, 1.5 mm in thickness) had an average mass 
of 13.0 mg (type 1) or 16.0 mg (type 2), and were prepared from varying proportions of 
hydroxypropyl cellulose and glyceryl palmito-stearate and coated with acrylic polymers 
Eudragit®-RS and Eudragit®-RL. It was found that the type and amount of acrylic polymer 
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coating could control drug release adequately: an adjustment of 11.1 % Eudragit RSIRL 
(80:20 w/w) to 17.8 % of the total weight of the tablet increased the release time from 25 
hours to 70 hours [115]. Di Colo et al. [116] described the in vitro and in vivo release of 
ofloxacin from inserts (6 mm diameter, 20 mg) prepared from a mixture of high molecular 
weight (400 kDa) linear poly(ethylene oxide) and Eudragit LIOO. Inserts were also 
prepared using poly(ethylene oxide) and partially neutralised Eudragit. The insert erosion 
rate has been reported as being related to the strength of interpolymer interactions, and also 
to the hydrophilic-hydrophobic balance of the constituent polymers. In an in vivo study, the 
maximal concentration (Cmax), the area under the curve (AVC), and the effective time (teIT) 
of concentration above Minimum Inhibitory Concentration (MIC) were very similar for all 
commercial ofloxacin eyedrop controls, but were significantly increased by the use of plain 
poly(ethylene oxide) (PEO) inserts. This increase in bioavailability was attributed to the 
mucoadhesive properties of poly( ethylene oxide) and to increased tear fluid viscosity. In a 
later study, Di Colo et al. [116], investigated the effect on molecular weight of 
poly(ethylene oxide) on Cmax and AVC: poly(ethylene oxide) 400 and poly(ethylene oxide) 
900 showed increases in Cmax of 3.78- and 3.16-fold, respectively, and in AVC of 11.06-
and 12.37-fold, respectively, relative to commercial eyedrops. poly(ethylene oxide) 200 
induced smaller increases, whereas poly(ethylene oxide) 2000 was unsuitable due to 
excessive swe11ing. 
Alani first described an ophthalmic rod in 1978 [117]. The rod is made of an acrylic 
plastic and is 50 mm in length. Drug, which is present as a thin layer at one end of the rod, 
is loaded by dipping into drug solution. Pulling down the lower eyelid and rubbing the tip 
of the rod against the palpebral conjunctiva (2-3 seconds) achieves delivery of the drug. 
The thin dry layer of the drug is dissolved by the tears and buffered to pH 7.4. In a clinical 
study, [118], clonidine ophthalmic rods (20 Jlg) were used by 15 patients with glaucoma 
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for 12 days. A regimen of three rods per day was sufficient to keep the intraocular pressure 
under control; 14 of the patients preferred the rods to eyedrops. 
Gurtler et al. [119, 120] investigated soluble bioadhesive ophthalmic drug inserts 
containing gentamicin. Ophthalmic inserts based on mixtures of hydroxypropyl cellulose, 
ethyl cellulose, poly(acrylic acid) and 25.0% w/w gentamicin sulphate were manufactured, 
along with similar inserts prepared with cellulose acetate phthalate as an additional 
component. The inserts produced were rod shaped (2.0 mm x 5.0 mm, 22.5 mg) and 
consisted ofhydroxypropylcellulose (40.2 %), ethylcellulose (18.0 %), carbomer (1.8 %), 
cellulose acetate phthalate (15.0 %) and gentamicin sulphate (25 %). In vivo assays in 
rabbits and dogs showed that the inserts maintained therapeutic gentamicin levels over 72 
h. In a later study, Baeyens et al. [121] further modified the release properties of 
bioadhesive ophthalmic drug inserts by premixing the gentamicin sulphate in an acetonic 
medium to form a gentamicin sulphate / cellulose acetate phthalate solid dispersion and by 
coating gentamicin sulphate / ethyl cellulose granules with Cellulose Acetate Phthalate 
(CAP) to form a gentamicin sulphate / ethyl cellulose / cellulose acetate phthalate co-
precipitate. In addition hydroxypropylmethylcellulose (HPMC), a less hydrophilic polymer 
than hydroxypropylcellulose, was used as a vehicle constituent. Inserts containing 
gentamicin sulphate / cellulose acetate phthalate solid dispersion, gentamicin / ethyl 
cellulose / cellulose acetate phthalate co-precipitate and hydroxypropylmethylcellulose 
displayed improved efficacy as compared with inserts containing gentamicin sulphate that 
. had not been subjected to pretreatment. A high irritation level was observed for inserts 
containing the gentamicin / ethyl cellulose / cellulose acetate phthalate and 
hydroxypropylmethylcellulose; a relationship between !eff and irritation score was 
established, emphasising the importance of irritability scores for the evaluation of the 
potential of such systems. 
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Chetoni et al. [122] described the development and in vitro and in vivo testing of 
rod-shaped mucoadhesive ophthalmic inserts for the upper or lower conjunctival fornix. 
Cylindrical devices (0.9 mm x 6-12 mm, 3-8 mg) containing 0.8 mg oxytetracycline 
hydrochloride were prepared from appropriate mixtures of silicone elastomer, 
oxytetracycline hydrochloride, and sodium chloride as a release modifier. A stable 
polyacrylic or polymethylacrylic acid interpenetrating polymer network was grafted onto 
the surface of the insert. In vitro experiments showed that the polymethylacrylic acid-
grafted devices released oxytetracycline hydrochloride at lower rates than those grafted 
with polyacrylic acid. When tested in rabbits, some polymer-grafted inserts maintained 
oxytetracycline hydrochloride concentrations in the lachrymal fluid to levels exceeding the 
minimum inhibitory concentration (MIC) for several days. The ocular retention of 
polymer-grafted inserts was significantly higher than that of the ungrafted inserts; this has 
been attributed to the mucoadhesive properties of the former. 
There have been a number of studies in recent years on the use of Gelfoam® in 
ophthalmic drug delivery. Simamora et al. [123] evaluated one such ocular device, for the 
controlled delivery of pilocarpine in albino rabbits. The device was prepared by 
impregnating a section (2.5 mm x 2.5 mm x 1.0 mm) of Gelfoam® with a mixture of 
pilocarpine hydrochloride and cetyl ester wax in chloroform solution. In a crossover study, 
the efficacy of the device was compared with that of pilocarpine eyedrops and pilocarpine 
gel. The in vivo results showed that the Gelfoam® device was more effective than the two 
conventional pilocarpine dosage forms in prolonging the duration of the pilocarpine 
activity. Later, Lee and Yallowsky [92] investigated enhancer-free ocular devices based on 
Gelfoam ® for the controlled systemic delivery of insulin; it is generally believed that 
ophthalmic solutions or devices for the systemic delivery of insulin require the addition of 
an absorption enhancer, usually a surfactant or chelating agent [90]. In this study, 
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Gelfoam® ocular devices containing 0.2 mg of sodium insulin were prepared in either 
water or 10 % acetic acid and were evaluated in rabbits. Results showed that blood glucose 
levels were significantly lowered after treatment with the acidified insulin-Gelfoam ® 
device, but not with the water-treated device. The results suggested that a change in the 
Gelfoam ® upon treatment with acid is responsible for the efficient systemic absorption of 
insulin from these enhancer-free devices. A recent study by Negvesky et al. [124] has 
investigated Gelfoam® discs as an alternative topical ophthalmic drug delivery system for 
effecting pupillary dilation in humans. Discs (4.0 mm x 0.5 mm) cut from sterile Gelfoam® 
using a hole punch were impregnated with a mixture of tropicamide and I-phenylephrine 
hydrochloride. After drying, a disc was placed in the inferior fornix of a randomly selected 
eye and the fellow eye was treated with a drop each of phenylephrine hydrochloride 
solution and tropicamide solution. The Gelfoam ® treated eyes showed a median change in 
dilation diameter that was approximately 25 % greater than that for the topically treated 
fellow eyes. 
Diestelhorst et ai. [102] described a preservative-free ophthalmic delivery system 
known as "Dry Drops". The active ingredient is incorporated in a drop of hydrophilic 
polymer solution that is freeze-dried on the tip of a soft hydrophobic carrier strip. On 
contact with the tear film or conjunctiva, the lyophilisate immediately rehydrates and 
detaches from the carrier. Dry Drops containing hydroxypropylmethylcellulose as the 
active ingredient and a preservative-free tear substitute were applied to the eyes of 32 
healthy volunteers, and tolerability and safety were quantified using slit-lamp 
biomicroscopy, questionnaire and visual analogue scales. Although there were no 
statistical differences between Dry Drops and the conventional formulation, the initial 
sensation was slightly less uncomfortable than that of the solution control. The authors 
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claim that other advantages of this system include improved chemical stability, exact 
dosing and reduced risk of lesions to the eye surface. 
1.5.2.6. Prodrugs 
Prodrugs are phannacologically inactive derivatives that are chemically or 
enzymatically converted to their active parent compound after administration [125]. The 
principle of ocular prodrugs is to enhance corneal drug permeability by modifying the 
lipophilicity or hydrophilicity of a drug. Most ophthalmic drugs contain functional groups 
such as alcohol, carboxylic acid and phenol, which lend themselves to simple 
derivatisation. Prodrug derivatisation of drug molecules that target various nutrient 
transporters (which include peptide, amino acid, folate, monocarboxylic acid transporters 
and so on, that have been reported to be expressed on the retina and blood-retinal barrier) 
could result in enhanced ocular bioavailability [126]. An ideal prodrug for ophthalmic 
delivery should be stable and soluble in aqueous solutions, be sufficiently lipophilic in 
order to penetrate through the cornea and be capable of releasing the parent drug in the eye 
at a rate that satisfies the therapeutic requirement. Bodor et el [129] suggested that real 
breakthrough in the area of ophthalmic therapeutics can be achieved only by specifically 
designing new prodrugs for ophthalmic applications to incorporate the possibility of eye 
targeting into their chemical structure. 
Pilocarpine, that is widely used to treat patients with glaucoma, has a poor ocular 
bioavailability if administered topically [127]. Suhonen et al. [128] produced a series of 
prodrugs of pilocarpine esters that were hydrolysed by esterases after instillation to yield 
pilocarpine on the endothelial side of the cornea. These prodrugs showed a 2-7 x higher 
permeability than pilocarpine despite their large molecular weights. Pilocarpic acid esters 
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are reported to be of particular interest as they combine enhanced bioavailability and 
prolonged duration of activity with high stability in eyedrop formulations [83]. 
Sasaki et al. [130] prepared lipophilic, acetylated prodrugs of the P-blocker tilisolol 
and investigated their in vitro ocular permeability and in vivo absorption in rabbits. All the 
derivatives considered showed increased lipophilicity, due to the introduction of a 
lipophilic group, and rapid enzymatic conversion to tilisolol in ocular tissue homogenates. 
Corneal penetration of lipophilic derivatives was found to be 3-6 x higher than that of 
tilisolol. It was concluded that the use of prodrugs in the delivery of P-blockers might help 
to overcome some of the problems associated with their systemic absorption when applied 
topically. Nonetheless, the usefulness of P-blockers in the treatment of glaucoma has been 
limited by the relatively high incidence of cardiovascular and respiratory side effects [131]. 
Although prodrugs have been proven to be of value, they are considered particularly 
demanding in terms of the extensive pharmacokinetic and pharmacological information 
required for their commercial development [10]. 
1.5.2.7. Ion pairs 
Some anions and cations are able to form complexes (ion pairs) by intermolecular 
electrical interaction. Lipophilic ion pair formation has been proposed as an approach for 
the enhancement of the corneal penetration of drugs: the drug is paired with a counterion, 
which imparts appropriate properties of lipophilicity, physiological compatibility and 
stability. Wilson et al. [132] reported ion pair formation between sodium cromoglycate and 
dodecylbenzyldimethylammonium chloride. The extent and rate of corneal penetration of 
both constituent ions was altered upon their co-administration. In particular, a marked 
increase in the concentration of both ions in the aqueous humour was observed after 
instillation of the ion pair formulation. 
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1.5.2.8. Iontophoresis 
Iontophoresis is a non-invasive process for the delivery of ionic drugs, in which a 
direct current (1-2 rnA) is used to drive the ions into cells or tissues. The technique was 
first introduced in the early 1900s for the transcutaneous administration of strychnine to 
rabbits, and has since been employed in ophthalmology for the treatment of corneal ulcers, 
keratitis and episc1eritis [9]. An iontophoresis unit consists of a battery-operated variable 
power supply (0.2- rnA, DC) and two electrodes. The drug is applied with an electrode 
carrying the same charge as the drug, while the ground electrode, which is of opposite 
charge, is placed elsewhere on the body to complete the circuit. The salt form of a drug is 
usually used as the dissociated salt is highly soluble in water and has a high charge density. 
The probe features an eyecup that is held in place by the partial vacuum obtained by 
withdrawing the plunger of the syringe. Transcorneal and transsc1eral iontophoresis have 
been shown to be effective. Transcorneal iontophoresis can deliver and sustain high 
concentrations of drugs into the anterior segment of the eye, particularly into the cornea 
and aqueous humour [133,135]. Hughes and Maurice [134] have found that transcorneal 
iontophoresis of gentamicin in the rabbit eye increased permeability to the antibiotic more 
than 100 x, as compared to topical exposure in the absence of current. Transscleral 
iontophoresis has been used successfully to deliver gancyc1ovir, gentamicin and 
vancomycin into the vitreous body in sufficient doses for the treatment of such posterior 
segment diseases as cytomegalovirus retinitis and endophthalmitis [9]. Barza et al. [136, 
13 7] reported the transsc1eral iontophoresis delivery of therapeutic concentrations of three 
antibiotics (cefazolin, ticarcillin and gentamicin) to the vitreous humour of uninfected 
rabbit eyes. This study showed that high concentrations of antibiotics could be delivered to 
the vitreous humour by a method that does not involve subconjunctival injection [137]. 
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The advantages of iontophoresis over other drug delivery techniques include the 
minimisation of systemic exposure to the drug, delivery of the drug directly to the target 
tissue and improved consistency of drug penetration [134]. Maurice and Barza et al. [138] 
performed transscleral iontophoresis by placing the iontophoretic probe over the pars 
plana and were able to deliver high concentrations of drugs to the vitreous humor. 
However, although iontophoresis is an effective method of delivering ophthalmic drugs _ 
including antibacterials, antivirals and antifungals - to the cornea, aqueous humour and 
vitreous body, it has not become popular since it requires the use of inconvenient 
equipment and has specific electrical requirements. Furthermore it has been shown that 
iontophoresis can cause damage to the ocular tissues, although this may be minimised by 
using the lowest current densities and shortest duration of treatment required for ensuring 
adequate penetration of the drug [139]. 
1.5.2.9. Cyclodextrins 
Cyclodextrins are compounds used to complex drugs that have problems associated 
with issues such as poor solubility, instability, irritation to the target organ or area and 
difficulty in formulation. Complexing of some drugs with cyclodextrins can result in 
improved dissolution, wettability, stability, solubility and reduced side effects [140,141]. 
Cyclodextrins are a group of cyclic oligosaccharides with a hydrophilic outer surface 
consisting of six, seven or eight glucose units - n, ~ and y-cyclodextrin, respectively - and 
although soluble in water, have a lipophilic cavity in the centre. Cyclodextrin molecules 
are relatively large, having molecular weights of between 1000 and 1500 and, under 
normal conditions, will only penetrate biological membranes with considerable difficulty 
[142, 143]. The central lipophilic cavity enables fat-soluble drugs to be taken up inside the 
cyclodextrin and so increases the solubility of such drugs. The cyclodextrins act as 
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penetration enhancers by ensuring a constant high concentration of dissolved drug at the 
membrane surface. Studies on the earliest cyc10dextrins showed that they possessed 
nephrotoxicity and haemolytic activity; this limited their use in ocular drug delivery [144]. 
Since then, new cyc10dextrin derivatives such as 2-hydroxypropyl-p-cyc1odextrin have 
been developed for use in ophthalmic drug delivery systems. Fridriksdottir et al. [145] 
investigated the effect of 2-hydroxypropyl-p-cyc1odextrin solutions, mixed with the 
carbonic anhydrase inhibitor methazolamide, on the lowering of intraocular pressure in 
rabbits. Methazolamide, which has a limited aqueo~s solubility, is usually administered 
orally to treat glaucoma. The results of this study indicated that, in reducing intraocular 
pressure, methazolamide formulated in aqueous 2-hydroxypropyl-,B-cyc1odextrin solutions, 
was almost as effective as a 0.5 % w/v solution oftimolol. Reer et al. [146] demonstrated 
that a formulation containing 2-hydroxypropyl-p-cyc1odextrin, buffered in the range pH 
6.5-7.0, increased the in vitro permeability of dic10fenac sodium through the pig cornea. 
On the basis of this work it was suggested that such a formulation would be suitable for the 
dissolution, stabilisation and ocular administration of dic10fenac eye drops. Nonetheless, 
although cyclodextrins seem to be beneficial for poorly water-soluble drugs, they do not 
seem to afford a real improvement for hydrophilic drugs, except in eliminating ocular 
irritation in c~ses where this has proved to be a problem. 
1.5.2.10. Mucoadhesive polymers and in situ gelling systems 
Bioadhesive / mucoadhesive vehicles 
There has been much interest in the use of mucoadhesive polymers as a means of 
prolonging contact between the drug instilled and the corneal epithelium. A suitable 
mucoadhesive polymer for use in the eye is one that will attach to corneal mucin, via non-
covalent bonds, and remain in contact with precorneal tissues until mucin turnover causes 
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elimination of the polymer. 
Bioadhesion (see section 1.6 for more details) may be described as the attachment 
of synthetic or natural polymers to a biological substrate. The term mucoadhesion is used if 
the substrate is mucous or a mucous membrane. Mucoadhesives are usually polymers with 
numerous hydrophilic functional groups that are capable of forming hydrogen bonds, for 
example carboxyl, hydroxyl, amide and sulphate groups. Hydrogen bonding appears to 
playa significant role in mucoadhesion, as does the presence of water [147]. 
Mucoadhesive polymers used in ocular drug delivery are placed in the front of the 
eye and attach themselves through non-covalent interactions to the mucin that covers the 
conjunctiva and cornea. Water-soluble mucoadhesive polymers dissolve slowly and are 
removed by tears while water-insoluble ones remain attached until the mucin replaces itself 
or until they are dislodged by blinking [82]. The use of mucoadhesive polymers in 
ophthalmic drug delivery may help to prolong contact between drugs incorporated into the 
formulation and the corneal and conjunctival epithelia and, hence, may facilitate improved 
delivery of the drug into the ocular tissues [148,149,150]. Examples of mucoadhesive 
polymers include hyaluronic acid, polyacrylic acid hydro gels and chitosan. 
Hyaluronic acid is a glycosaminoglycan that is present in some bacterial capsules, 
the intercellular matrix of the connective tissue of most vertebrates, and also in the vitreous 
and aqueous humours of the eye. The molecule is a linear polydisaccharide of the form _ 
(G-N)n-, in which G is glucuronic acid and N is N-acetylglucosamine. Sodium hyaluronate 
products are already widely used in intraocular surgery. Investigations into the use of 
sodium hyaluronate as an ophthalmic drug delivery system have shown that sodium 
hyaluronate can increase the precorneal residence time of certain drugs in humans, and that 
low concentrations of the polymer « 0.1 %) are particularly effective [59,151]. Saettone et 
al. [152] investigated the mucoadhesive properties and in vivo activity of ophthalmic 
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vehicles based on hyaluronic acid. The hyaluronic acid preparations were found to have 
good mucoadhesive properties; when tropicamide was incorporated into the hyaluronic 
acid formulations, these were capable of increasing the area under the mydriasis curve by 
up to 4 x compared with polyacrylic acid formulations. 
Polyacrylic acids are available in a range of molecular weights and may be 
branched, linear or crosslinked: Carbopol934P is appropriate for use in the pharmaceutical 
industry: it is lightly crosslinked through co-polymerisation with allyl sucrose or allyl 
pentaerythritol, has a molecular weight of ca. 3.0 MDa and is soluble in aqueous media. 
Carbopol 934P has several advantages over other vehicles in that it is generally more 
comfortable than inserts and is instilled like an ointment without significant blurring of 
vision. Smart et al. [153] investigated the adhesiveness of various materials to mucus and 
found polyacrylic acid to possess good mucoadhesive properties. Hui and Robinson [154] 
investigated the ocular delivery of progesterone using polyacrylic acid. Acrylic acid 
crosslinked with divinyl glycol and 2,5-dimethyl-l,5-hexadiene showed excellent 
bioadhesion to conjunctival mucin, as determined by visual inspection and an in vitro 
method using the force required to separate a polymer specimen from a freshly excised 
rabbit conjunctival membrane. Davies et al. [64] evaluated the potential of Carbopol 934P 
as an ophthalmic vehicle in the rabbit and found that precomeal clearance of Carbopol was 
significantly lov,ter than for polyvinyl alcohol. Thermes et al. [155] compared the effect of 
poly(acrylic acid) on the ocular bioavaiIabiIity of timolol using 0.5% aqueous Timoptol or 
isoviscous solutions of polyvinyl alcohol as controls. Polyacrylic acid formulations 
extended the concentration versus time profiles of timolol and gave the highest timolol 
concentrations in the iris and ciliary body. 
Chitosan has been evaluated by a number of workers for both its mucoadhesive 
properties and its suitability as a drug delivery vehicle [156,158,160,161]. Chitosan is a 
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natural polyaminosaccharide and is composed of deacylated chitin, a cellulose-like 
biopolymer consisting predominantly of unbranched chains of f3-(l ~4)-2-acetamido-2-
deoxy-D-glucose. It is obtained from the exoskeleton of marine invertebrates and 
arthropods and isolated industrially by hydrolysing the aminoacetyl groups of chitin from 
crabs or shrimps in aqueous alkaline solutions. Lehr et al. [157] and Henriksen et al. [159] 
have reported that chitosan possessess fairly good mucoadhesive properties. Park and 
Robinson [161] and Lehr et al. [157] suggest that, in neutral or slightly alkaline conditions 
as would be desirable for adhesion in the eye, cationic polymers (such as chitosan) are 
likely to be superior mucoadhesives. Felt et al. [162] evaluated the ocular tolerance and 
precorneal retention of chitosan. An ocular irritation test, using confocal laser scanning 
ophthalmoscopy combined with corneal fluorescein staining, showed excellent tolerance of 
chitosan in rabbits. In parallel, gamma scintigraphic data showed that the clearance of 
99mTc-diethylenetriaminepentaacetic acid was significantly delayed in formulations 
incorporating chitosan; at least a three-fold increase of the corneal residence time was 
achieved in the presence of chitosan as compared with Tobrex® formulations. 
In situ gelling systems 
In situ gelling systems have been developed in an attempt to overcome some of the 
problems associated with the delivery of ophthalmic drugs. These systems are more 
acceptable to patients since they are conveniently dropped into the eye, typically as a 
solution, after which they undergo transition into a gel [163]. Studies have shown that the 
precorneal residence times of some in situ gelling systems last for several hours [61, 154]. 
The change in viscosity that characterises these systems can be due to a change in pH, 
temperature or ionic strength and leads to an increase in drug bioavailability by slowing 
nasolacrimal drainage [10,164]. The sol-to-gel phase transition results from a competitive 
balance between a repulsive force that expands the polymer network and an attractive force 
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that contracts the network. The most effective repUlsive force that can be imposed upon a 
phase-transition polymer is the electrostatic interaction between the polymer charges· 
caused by introducing ionisation into the network. The osmotic pressure created by the 
counterion adds to the expanding pressure. The attractive forces can be van der Waals, 
hydrophobic interaction, ion-ion electrostatic interaction and/or hydrogen bonding [165]. 
Polymers that are pH-sensitive possess charges or ionisable groups that are 
covalently attached to a macromolecular backbone; thes0 are either polymeric acids, such 
as those containing carboxylic acid, or bases such as those containing primary amines. 
Such polymers ionise reversibly over an inherent pH range. The resultant charge facilitates 
the swelling of the polymer network and renders the matrix permeable to water-soluble 
solutes [165]. Typical polymers used as pH-sensitive systems are lightly crosslinked 
acrylic acid polymers, which have an extensive capacity to attract and hold water. 
Examples of in situ gelling systems include cellulose acetate phthalate latex, 
crosslinked polyacrylic acid and derivatives, such as polycarbophil and carbomers, which 
all undergo a phase change when pH varies. Poloxamers, methy1cellulose and Smart 
HydrogeFM, a graft co-polymer of poloxamer and polyacrylic acid, all exhibit a phase 
change due to a change in temperature. Gelrite and alginate are polymers that undergo a 
phase change due to a change in ionic strength. Kumar et al. [166] investigated the 
rheological characteristics of an in situ gelling system consisting of a combination of 
Carbopol and methylcellulose. The study showed that a solution containing 1.5 % 
methy1cellulose and 0.3 % Carbopol at pH 4.0 and 25°C formed a strong gel at pH 7.4 
under simulated physiological conditions. 
Paulsson et al. [167] investigated the effect of temperature and that of various ions 
on gel formation characteristics of gellan gum in vitro; gellan is an anionic polysaccharide 
composed of tetrasaccharide repeating units. The influence of the various ions present in 
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tear fluid (Na+~ K+ and Ca2+) were considered in tenns of their effects on gel strength and 
the consequences of dilution due to reflex tearing were considered. Na + was reported to be 
the most important gel-promoting ion in vivo. 
Gurney et al. [151] conducted a comparative study of the miotic response induced 
by a pH-sensitive dispersion, a temperature setting gel and hyaluronic acid all fonnulated 
with pilocarpine. This group of workers reported that fonnulations containing hyaluronic 
acid induced the highest miotic response in man whereas the in situ gelling systems are 
washed off the corneal surface as miotic activity could be measured for only ten minutes 
following administration. 
Rozier et al. [168] investigated the ocular absorption of timolol administered in 
Gelrite, or in an equiviscous solution of hydroxyethylcellulose; the albino rabbit model 
was employed for both sets of experiments. In both cases, Timolol was detected in the 
cornea for up to two hours, but a significantly higher corneal content of timolol is reported 
for all the Gelrite fonnulation at all time points. 
Although certain gelling systems have been shown to improve precorneal retention 
and the bioavailability of ocular drugs, the benefits are of limited value as once- or twice-a-
day dosing is the typical expectation from these systems. 
1.6. Bioadhesion and mucoadhesion 
The concept of mucosal adhesives was first introduced in the early 1980s. 
Mucoadhesives are synthetic or natural polymers that interact with the mucus layer 
covering a mucosal epithelial surface. The concept of mucoadhesion has alerted many 
investigators to the possibility that such polymers may be used to overcome the 
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physiological barriers in sustained drug delivery and to facilitate prolonged contact 
between a drug and its target tissue. 
Bioadhesion may be defined as the regime at which two materials, at least one of 
which is of biological origin, are held together for extended periods of time [169]. In the 
context of drug delivery, the term 'bioadhesion' refers to the adhesion of synthetic or 
biological macromolecules to biological tissue. The biological substrate may be epithelial 
tissue, or it can be the mucus that is coating the surface of a tissue. If adhesive attachment 
is to a mucous coating, the phenomenon is referred to as mucoadhesion [147]. 
Mucoadhesive drug delivery systems utilise hydrophilic polymers that become bioadhesive 
on mild hydration; such systems may be used for targeting drugs to mucosal regions of the 
body. 
1.6.1. Mechanisms ofmucoadhesion 
Mucus is a naturally occurring bioadhesive, which is present as either a gel layer 
adherent to the mucosal surface or in a luminal, soluble, or suspended form, depending on 
its location in the body. Mucus binds to the surface of cells and exhibits adhesive 
properties toward a variety of substrates. The attachment of mucin to the cell surface is the 
result of a non-covalent interaction between a macromolecule and mucin. In many 
descriptions of the interactions between mucoadhesive materials and a mucous membrane, 
two discrete steps are identified: the contact stage, during which intimate contact is 
established between the mucoadhesive and mucous membrane, is followed by the 
consolidation stage, at which various physicochemical interactions operate synergistically 
to consolidate and strengthen the adhesive joint [169]. 
Mortazavi and Smart [170] have reported that, on application of a constant tensile 
stress to compacts of mucoadhesive polymers, a cohesive failure of the swelling polymer 
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occurs for all but the weakest adhesives. Various theories have been put forward to account 
for the cohesive mechanism operating between the mucin and mucoadhesive material. 
1.6.2. Theories ofmucoadhesion 
Amongst the number of theories have been proposed to explain the fundamental 
mechanisms of adhesion [171, 172], five have been adapted to the study of bioadhesion. 
Some of these theories consider the formation of mechanical bonds whereas others focus 
on chemical interactions, they will be briefly described below [173]. 
1.6.2.1. Electronic theory 
The hypothesis of the electronic theory relies on the assumption that the 
bioadhesive material and the target biological substrate have different electronic structures. 
Electron transfer occurs when the two materials come into contact, resulting in a double 
layer of electrical charge at the bioadhesive-biological substrate interface. The bioadhesive 
interaction is believed to be due to the attractive forces across this double electrical layer. 
1.6.2.2. Adsorption theory 
According to the adsorption theory, the bioadhesive bond formed between an 
adhesive substrate and tissue or mucosal is due to van der Waals' interactions, hydrogen 
bonds and electrostatic forces. Although these forces are individually weak, the large 
number of interactions is able to produce intense adhesive strength. The adsorption theory 
is the most widely accepted of the five theories of adhesion. 
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1.6.2.3. Wetting theory 
The wetting theory is predominantly applicable to liquid bioadhesive systems and 
uses interfacial tensions to predict spreading over a biological substrate and, in tum, 
adhesion. The contact angle (B) between a liquid and a biological substrate should be close 
to zero for proper spreading. It is related to interfacial tensions (n through Young's 
equation. The expression for bioadhesive gel spreading over soft tissue in the gut, may be 
written as: 
Ytg = Ybt + Ybg cos e 
where the subscripts t, g, and b stand for tissue, gastrointestinal contents and bioadhesive 
polymer, respectively. For spontaneous wetting, the contact angle must be equal to zero, 
i.e.: 
Ytg ~ Ybt + Ybg 
The work of adhesion (Wa) is an important parameter that may indicate the strength 
of an adhesive bond. It is expressed in terms of surface and interfacial tension (Y), and is 
defined as the energy per unit area that is released when an interface is formed. The work 
of adhesion is given by: 
Wa = Y A + Y B - Y AB 
where the SUbscripts, A and B, refer to the biological membrane and the bioadhesive 
formulation respectively. 
1.6.2.4. Diffusion theory 
The diffusion theory supports the concept that the interpenetration and 
entanglement of bioadhesive polymer chains and mucus molecules produces semi-
permanent adhesive bonds. It is thought that bond strength increases with the degree of 
penetration of the polymer chains into the mucus layer. The depth to which the polymer 
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chains penetrate the mucus depends on the diffusion coefficients and concentration 
gradients of the materials and the time of contact between them. The diffusion coefficient, 
in tum, depends on the degree of crosslinking of the polymer. The macromolecular 
penetration effect, where the mucoadhesive molecules interpenetrate and bond by 
secondary interactions with mucus glycoproteins, is a theory that has received considerable 
support. labbari et al. [174] have found that when a mucin solution is placed into contact 
with a thin crosslinked film of polyacrylic acid formed on an attenuated total reflectance 
crystal, the attenuated total reflectance (ATR-FTIR) spectra reveal a peak at 1550 cm-1, 
which is attributed to mucin dimeric carboxylic C=O stretching. It was proposed that this 
indicated the presence of interpenetrating mucin molecules within the polyacrylic acid 
film. 
1.6.2.5. Fracture theory 
The fracture theory analyses the forces required to separate two adhered surfaces 
after adhesion. The maximum tensile stress (sm) associated with detachment can be 
determined by dividing the maximum force of detachment Fm by the total surface area (Ao) 
involved in the adhesive interaction: 
sm=Fml Ao 
The fracture strength (1, equivalent to the bioadhesive bond strength, may be calculated 
from: 
where E is Young's modulus of elasticity, c is the fracture energy and L is the critical crack 
length upon separation of the two surfaces [172]. Thus, the stiffuess (elastic modulus) of 
the material can be used as a measure ofbioadhesion. 
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1.6.3. Factors affecting mucoadhes"ion 
The bioadhesive strength of a polymer may be affected by several factors, as 
discussed below. 
1.6.3.1. Nature a/the polymer 
Studies have shown that there is a critical polymer molecular weight at which 
bioadhesion is at a maximum. According to Gumy et al. [175] the bioadhesive force 
increases with average molecular weight of the polymer up to around 0.1 MDa but beyond 
this value there is no further influence on the bioadhesive effect. Smart et al. [176] have 
found that the average molecular weight of sodium carboxymethylcellulose must exceed 
78.6 kDa if this material is to exhibit significant bioadhesion. In contrast to the findings by 
Gumy et al. [175], studies by Duchene and Ponchel [177] and also by Mortazavi and 
Smart [176] have revealed that polyacrylic acid with an average molecular weight of 0.75 
MDa is the most bioadhesive amongst this class of materials. Polyethylene oxide, a 
polymer containing molecules of highly linear configuration, exhibits an increase in 
adhesive strength up to an average molecular weight of 4.0 MDa. By contrast, dextrans 
with an average molecular weight of 19.5 MDa have been found to possess similar 
bioadhesive strength as those with a molecular weight of 0.2 MDa [172]. The flexibility of 
polymer chains is important in facilitating interpenetration and entanglement. The higher 
the chain mobility, the greater the interdiffusion and the more efficient the penetration of 
the polymer into the mucus network [177,178]. Park and Robinson [179] found that on 
lowering the concentration of the crosslinking agent, the mucoadhesive strength of 
polyacrylic acid increased. Increased crosslinking density also resulted in a decrease in 
swelling ofthe polymer; attributed to a reduction in chain mobility [180]. 
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1.6.3.2. Swelling and hydration 
Bioadhesive polymers in aqueous media hydrate and swell to form a gel. The 
strength of adhesion of such polymers has been shown to reach a maximum at an optimum 
degree of hydration [181]. The type and number of hydrophilic groups within the polymer 
structure influences the extent and rate of hydration of the polymer; these commonly 
include carboxyl, hydroxyl, amide and sulphate groups, all of which are capable of 
participating in hydrogen bond formation. The presence of water leads to partial hydration 
of the polymer and increased availability of the adhesive sites for secondary bond 
formation. However, large volumes of water can lead to the formation of a slippery, non-
adhesive mucilage at the bioadhesive interface as a result of the incorporation of excessive 
amounts of water within the hydrogen-bonded network [182]. 
1.6.3.3. Effect o/the pH o/surrounding medium 
Studies have shown that the bioadhesive properties of some polymers are affected 
by the pH of the surrounding media. Ch'ng et al. [183] observed that the pH of the medium 
is critical in determining the degree of hydration of highly crosslinked poly( acrylic acid)s: 
hydration was seen to increase with increasing pH, up to pH 7. This was attributed to 
differences in charge density at different pH levels and suggests that mucoadhesion is 
favoured when the carboxylate groups are in the unionised form; at pH of about 4, around 
80% of the carboxylate ions of the polyacrylic acid are in the unionised form. Park and 
Robinson [179] investigated the mucoadhesive strength of polycarbophil at various pH 
values. This polymer showed maximum adhesive strength at pH 3 with a gradual decrease 
in adhesive strength as the pH increased to 5; the material failed to exhibit any 
mucoadhesive property above pH 5. This study showed that it is the protonated, rather than 
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ionised carboxyl groups, that interact with mucin molecules to promote mucoadhesive 
bonding. 
1.6.3.4. Contact time andforces applied 
Park and Robinson [179] showed that the strength of adhesion of poly( acrylic acid-
co-divinylbenzene) and poly(hydroxyethyl methacrylate) to a mucin substrate can increase 
with the force applied or with the duration of application. In parallel, Leung and Robinson 
[147] postulated that mucoadhesion is a time dependent process. The same workers 
showed the importance of openness of the interacting networks with regard to 
mucoadhesion, and as a result suggested that interdiffusion is a process of paramount 
importance. According to these workers, an increase in the openness of the network can 
lead to an increase in interpenetration between the substrate and the mucoadhesive. This, in 
tum, results in an increase in contact surface area and mechanical entanglement with a 
consequent increase in mucoadhesive strength. If interdiffusion is important in 
mucoadhesion, the mean diffusional path (s) will be related to the diffusion coefficient (D) 
and time (I), according to: 
s =.J2DI 
However, experimental evidence showed that the mucin-mucin and polymer-mucin 
tensile strengths are both time dependent [184]. Furthermore, the effect of additional 
factors needs to be considered. These include: mucin turnover [180], temperature [184], 
formulation [155, 185], metal ions [186] and concentration of polymer [172, 180]. 
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1.7. Techniques used for physical characterisation 
1.7.1. Swelling measurements 
The swelling experiments described in this thesis examine the swelling 
characteristics of a number of mucoadhesive and non-mucoadhesive polymers in order to 
identify and select those materials which display limited but rapid swelling for further 
investigation. It is deemed important that in order to prolong retention and minimise 
discomfort and disruption of vision, the polymers chosen for further study must swell 
quickly but to a limited degree. 
Swelling controlled release systems may be capable of delivering drugs at constant 
rates over an extended period of time. In such systems, the rate of drug delivery is 
controlled by drug (solute) diffusion across a concentration gradient, by polymer relaxation 
(occurring as the crosslinked polymer takes up water), and by osmotic pressure variations 
during the swelling process. Swelling controlled release systems are valuable due to the 
possibility of achieving zero-order release [187]. 
In swelling-controlled polymeric systems the drug is usually dissolved or dispersed 
in the polymer. The solvent is then removed to give a solvent-free glassy polymeric matrix 
that contains the dispersed drug. In a drug release experiment, there is no drug diffusion 
through the unhydrated solid phase. As the dissolution medium (usually water, saline or 
biological fluid) penetrates the matrix, the polymer begins to swell. If the thennodynamic 
compatibility of the dissolution medium with the polymer is favourable, the glass transition 
temperature (Tg) of the polymer becomes lowered. Under these conditions, the swollen 
polymer converts to the rubbery state and the dispersed drug is able to diffuse outward. 
Two interfaces, or fronts, are characteristic of this type of swelling behaviour: a 
front separating the glassy from the rubbery state (swelling interface), which moves toward 
76 
the glassy state with velocity v; and a front separating the rubbery polymer from the pure 
dissolution medium (polymer interface), which moves outward (see Fig.1.12). 
Fig. 1.12. Moving fronts during 
dynamic swelling of a glassy 
polymer. A, glassy state; B, 
rubbery state; C, dissolution 
medium; S, swelling interface; P, 
polymer interface [188]. 
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If no physical or molecular restrictions to swelling are present, the polymer will 
eventually dissolve. It is possible to formulate matrices that do not dissolve, by employing 
semi-crystalline or amorphous polymers that are slightly crosslinked. Such systems are 
known as swellable, non-erodible release systems. In other systems, dissolution of the 
polymer may occur due to chemical degradation, such as hydrolysis; such materials are 
known as swellable, erodible release systems. Controlled release matrices that are 
susceptible to enzymatic biodegradation are known as swellable, bioerodible release 
systems. 
There have been a number of experimental and theoretical investigations of solvent 
and solute transport in polymeric' systems, with several mathematical models developed to 
describe transport behaviour. Fickian or non-Fickian drug diffusion mechanisms may be 
observed depending on the dynamics of polymer swelling, the relative mobility of the drug 
and the dissolution medium. Transport phenomena conforming to the Fickian mechanism 
77 
(also known as Case I diffusion) represent simple diffusion of solute down a concentration 
gradient. Fick's first law relates the flow of material through a concentration gradient: 
J = -D( dc/dx) 
Where J is the flux of a component across a plane of unit area and D is the diffusion 
coefficient, c is the concentration and x is the distance travelled. The negative sign 
indicates that the flux is in the direction of decreasing concentration. J is in mol m'2 S'l, C is 
in mol m,3 and x is in m and the units of Dare m2 S'l. [189] 
It is known that the diffusion of the solvent is linked to the physical properties of the 
polymer network and the interactions between the polymer and the solvent. The amount of 
solvent absorbed per unit area of polymer at time t, Mit is represented by 
U=kt 
where k is a constant and n a parameter (the value of which lies between ~ and 1) related 
to the diffusion mechanism. This equation can be used to describe solvent diffusional 
behaviour for any polymer-solvent system whatever the temperature and solvent activity. 
Fickian diffusion is often observed in polymer networks at temperatures well above 
the glass transition temperature of the polymer. If the polymer is in the rubbery state, the 
polymer chains have a high mobility that allows the solvent to penetrate the bulk material 
. 
more easily. Thus, Fickian diffusion is characterised by a solvent diffusion rate that is 
slower than the polymer relaxation rate. The solvent c~ncentration profile shows an 
exponential decrease from the completely swollen region to the core of the polymer. The 
diffusion distance is proportional to the square root of time: 
M, = k..[i 
where Mt is the amount of drug released at time t and k is a constant. 
Non-Fickian diffusion processes are mainly observed in glassy polymers, below Tg• 
At a specific temperature below Tg , the polymer chains are not sufficiently mobile to 
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permit immediate penetration of the solvent into the polymer core [190]. Two types of 
non-Fickian diffusion have been defined: Case II diffusion, and anomalous diffusion. The 
main difference between the two types concerns the solvent diffusion rate. In Case II 
diffusion, the solvent diffusion rate is faster than the polymer relaxation process, whereas 
in anomalous diffusion the solvent diffusion rate and the polymer relaxation are of about 
the same order of magnitude [191]. • 
Case II diffusion may involve a number of alternative scenarios. There may be a 
rapid increase in solvent concentration at the swollen region, which in tum leads to a sharp 
solvent penetration front between the swollen region and the inner polymer core. 
Alternatively, solvent concentration may be fairly constant in the swollen region behind 
the solvent penetration front or the solvent penetration front may be sharp and advancing at 
a constant rate. In the latter case, diffusion distance is directly proportional to time: 
Mt=kt 
Finally, there may be an induction time to Fickian diffusion, which precedes the 
solvent penetration front into the glassy core [192]. Fickian and Case II diffusion processes 
are considered as limiting types of transport whereas anomalous diffusion lies in between 
and is characterised by the equation 
and 
Y2<n<1. 
Brazel and Peppas [187] investigated solvent and solute transport in swellable 
hydrophilic glassy polymers using two dimensionless parameters, the Deborah number, 
(De), and the swelling interface number, (Sw). The diffusional Deborah number relates net 
solvent motion to the rate of polymer relaxation, and is defined as: 
A De=-() 
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where A is the characteristic relaxation time for the polymer when subjected to 
r sG(s)ds 
swelling stresses: A = -=-----r G(s)ds 
and e is the characteristic penetrant diffucion time into a swelling sample, as is 
defined as the square of the diffusional distance divided by the diffusion coefficient of 
water in the polymer: 
G(s) is the shear relaxation modulus, 15 is the thickness of the sample, and Ds is the 
dissolution medium coefficient. Fickian diffusion is observed for De » 1 or for De « 1. 
Anomalous diffusive behaviour occurs when the Deborah number is of the order of 1. Case 
II transport is observed when the glassy/rubbery front moves at a constant velocity. Sw 
defines the relationship between the mobility of the diffusing solute (drug) and the 
penetrating dissolution medium and is given by: 
where v is the velocity of the swelling interface, Dj is the concentration-independent 
diffusion coefficient of the drug and 8(t) is the time-dependent thickness of the rubbery, 
gel-like layer. 
When the rate of solute transport through the solvated region is faster than the rate at 
which the glassy/rubbery front advances, the swelling interface number Sw is much smaller 
than 1, and zero-order release kinetics of the drug is observed. If the swelling front 
advances faster than the release of the drug, the value of Sw is much greater than 1 and 
Fickian release is observed. For values of Sw :::::; 1, non-Fickian, non-zero order release is 
observed. 
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1.7.2. Tensile testing 
Several methods have been developed to measure the bond-strength of 
mucoadhesive materials. Various techniques that measure the tensile force required to 
break the adhesive bond between a model membrane and a test polymer have been 
reported [183,193]. Smart et al. [153] investigated the force required to detach a test 
polymer from a mucus or mucus glycoprotein gel. 
A variety of model mucosal surfaces have been utilised, such as Rat intestine [170], 
rabbit gastric mucosa [183], bovine conjunctiva [155], porcine cornea[159], ovine intestine 
[194], mucin-covered filter paper disks [152], cellulose dialysis tubing [159], cellulose 
paper impregnated with porcine gastric mucin [155]. 
There are number of methods for determining the force applied to the mucoadhesive 
joint. Smart et al. [153] developed a method for the measurement ofbioadhesiveness that 
is similar to the Wilhelmy plate method. The apparatus consisted of a glass plate 
suspended from a microbalance. A' 5 ml glass vial containing a mucus sample was placed 
in a water-bath at 20oe, and the water-bath positioned on a moveable platform. The 
platform was raised until the glass plate penetrated the mucus and was then left in contact 
with the mucus for a predetermined period of time before the platform was lowered at a 
rate of 1 mm/min. The maximum force recorded by the microbalance and displayed on a 
recorder when the plate became detached was noted. Bioadhesive polymers may be studied 
using this apparatus by coating the glass plate with a solution of the test material and oven 
drying to a constant weight. 
Gurny et al. [175] developed a tensile method using an Instron tester equipped with 
a special cell for the determination of the adhesive bond strength. The cell was constructed 
using two 10 cm diameter Plexiglass discs connected through the centres by metal bars, 
which were attached to a tensile tester. Two cylindrical chambers enclosed the discs. The 
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bioadhesive material under tested was placed between the discs and held at an initial 
distance of 2 mm. The discs were pulled apart at an extension rate of 0.1 mmlmin and the 
stress/strain curves were recorded. 
Smart [170] assessed the mucoadhesiveness of a number of polymers using a tensile 
apparatus which consisted of a top pan balance beneath which was suspended a 1.5 g 
hooked weight. The polymer test disc was attached to the weight using a cyanoacrylate 
adhesive. A section of rat intestinal mucosa was mounted on a platform in isotonic 
phosphate buffer at 37°C to expose a 1.1 cm diameter circle of tissue. The test disc was 
lowered onto the mucosal surface and left for 1-2 minutes after which the platform was 
lowered at a rate of 1 mm/min until the disc was pulled clear of the membrane. The force 
at which the adhesive bond failed, the maximum detachment force, was recorded. 
1.7.3. Infrared spectroscopy 
Although a number of physical methods have been used to establish the 
compatibility of polymer blends, including thermal analysis and NMR spectroscopy, none 
of these techniques is conducive to rapid analysis of the kinetics of the interactions within 
the blends. FT -IR spectroscopy can be used to establish the nature and level of molecular 
interactions of blends and the changes in these interactions with aging [195]. In terms of 
IR, the compatibility of a blend may be defined by the presence of an interaction spectrum 
that arises when the spectrum of the blend is compared with the spectra of the two 
homopolymers. If the homopolymers are compatible, an interaction spectrum with 
frequency shifts and intensity modifications that are intrinsic to the system will be 
observed. 
The energy range of the infrared region corresponds to that required to cause 
vibrational excitation of bonds within a molecule. The types of bond excitation that can 
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occur are stretching (higher energy) and bending (lower energy) vibrations. Absorption of 
certain wavelengths of infrared radiation can often be correlated with the bending and 
stretching of specific types of bond within a molecule. However, any single vibrational 
excitation cannot be considered in isolation from other parts of the molecule. Infrared 
spectra of organic molecules are usually complicated by bond oscillations within the whole 
molecule affecting absorption of the incident radiation and giving rise to overtones and 
harmonics. Thus, in addition to observing absorption due to individual bond vibrational 
excitations, absorption due to molecular vibrational excitations is also observed. Spectra 
recorded in solution may also show further complexity due to hydrogen bonding with 
solvents or the presence of dimeric or polymeric associated species. 
Vibrational frequencies can be calculated using the 'ball and spring' model and 
applying Hooke's Law to correlate frequency with bond strength and atomic mass: 
v = k bond strength 
mass 
where v is the frequency of vibration and k is the force constant of the bond, 
that becomes 
1 k 
V=-
2:r 
where m/ and m2 are the masses of the two constituent atoms and [m/m21(m/+m2)] is the 
reduced mass ofthe system (P). 
Since numerical values of v in S·I are inconvenient, absorptions are usually given in 
'wavenumbers' : 
where c is the speed oflight (2.98 x lO IO cm S·I). 
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It is not usually necessary to carry out calculations using these formulae, as it is 
us.ually sufficient to use the guideline that the vibrational frequency of a bond should 
increase as the bond strength increases and when the reduced mass of the system 
decreases. Bond stretching requires more energy than bond bending, and so bond 
stretching absorptions require shorter wavelength (higher frequency) radiation than bond 
bending absorptions. Systems containing double and triple bonds require progressively 
higher energies for vibrational excitation. 
Stretching vibration 
Bending 
Fig. 1.13. 'Ball and spring' 
schematic diagram showing 
two types of vibrational 
motion in molecules 
Molecules have characteristic bending and stretching modes. A molecule of the 
form XY 2 (eg CH2, NH2) may have a symmetric or asymmetric stretching mode. A number 
of bending modes are also possible and these are termed scissoring, rocking, twisting and 
wagging (see Fig.l.14). 
Stretching Modes 
,~// ,~//. 
SymmetrIc V VAsymmetrlc 
Bending 
Modes 
Vv\ 
Twisting Wagging 
V 
Scissoring 
Fig. 1.14. Vibrational modes of an XY 2 molecule 
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Some of these modes of stretching and bending, in particular symmetric stretching 
and scissoring, give rise to only weak IR absorption [196]. In addition, not all frequencies 
will give rise to absorption as they may have frequencies outside the normal infrared 
region or may by masked by absorption due to other, stronger frequencies. 
Infrared spectra are usually recorded over the range 4000-400 cm- I . The radiation 
source is an electrically heated Nemst filament (mixed Zr, Th and Ce oxides) or a Globar 
filament (silicon carbide). The interferogram produced is submitted to Fourier transform 
and converted into a plot of absorption against wavenumber. 
FT-IR spectroscopy has been used by a number of groups to investigate the 
formation ofintermacromolecular complexes between various polymers. Ozeki et al. [197] 
produced interpolymer complexes of poly(ethylene oxide) and Carbopol and subjected 
them to FT-IR. The spectra showed that the amount of the complex formed by hydrogen 
bonding changed depending on the grade of Carbopol used. Lee et al. [139] prepared 
interpenetrating polymer network hydro gels of poly( ethylene glycol) and chitosan by W 
irradiation. The use of FT-IR and Raman spectroscopy confirmed the presence of 
interactions between the two polymers. 
1.7.4. UV-Visible spectroscopy 
Organic molecules absorb radiation in discrete packets known as quanta of energy: 
he M=hv=-
A 
where M is the energy difference between the ground state and the excited state of a 
molecule, which is overcome by the incident radiation of frequency v, h is Planck's 
constant, e is the speed of light and A is the wavelength at which the species absorbs. The 
absorbed energy causes electronic transitions in the molecule, a process known as 
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excitation. This motion is quantized and absorption occurs only when radiation supplying 
exactly the right quantum of energy impinges on the compound under investigation. A 
molecule can undergo many different types of excitation, each of which requires its own 
distinctive energy till. Ultraviolet (UV) and visible light are capable of moving valence 
shell electrons, typically from a filled bonding molecular orbital to an unfilled anti-bonding 
one. 
The W spectrometer has an appropriate source of electromagnetic radiation with a 
wavelength in the W region (usually 200 to 800 nm). The radiation is frequently split into 
an incident beam and a reference beam of equal intensity. The incident beam travels 
through a sample tube while the latter is unperturbed. A detector at the end of the 
spectrometer measures the intensity of both beams and records any difference between the 
two. Radiation of a specific frequency, within the range of the source, passes through the 
sample. Wherever the sample absorbs incident light, the resulting intensity difference, 
relative to the reference beam, is measured by the detector and electronically relayed to the 
recorder to give a peak, the height of which is directly proportional to the concentration of 
the absorbing species. 
W spectroscopy is used to obtain the position of absorption of the species of 
interest, (Amax nm) which gives information on the energy till of the electronic excitation 
and on the chromophore responsible for the absorption. W spectroscopy is also used to 
determine the molar absorptivity, also known as the molar extinction coefficient (c). This 
parameter, which is a constant for a given molecule at a specific wavelength, is a measure 
of the ease of the transition caused by the absorption of the radiation. If a particular 
electronic transition can take place readily, then the light will be absorbed strongly and c 
will have a high value. If the transition does not occur readily, the c value will be low. 
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Substituents, which increase the extinction coefficient of the basic chromophore, are said 
to have a hyperchromic effect whereas those that decrease & have a hypochromic effect. 
Due to the effects of superimposed vibrational and rotational transitions, absorption 
bands are, broad; usually the maximum value of & is measured at the corresponding 
wavelength. For dilute mixtures of non-interacting components, absorbances are additive. 
Comparison between & values for differe~t compounds is only valid if the analyses 
are run with solutions at the same molarity. The relationship between the molar 
absorptivity, &, and the concentration of the chromophore (mol L-I ) is expressed by the 
Beer-Lambert Law: 
lOs( ~ )=~l 
where 10 is the intensity of incident light, 1 is the intensity of transmitted light, & is the 
molar absorptivity (units: L mOrl cm-I; or, in SI, m2 mOrl), c is the concentration in mol L-
I, and I is the pathlength of the absorbing solution in cm. 
The equation is often stated as: 
&=Alcl 
where A is the absorbance, log (loll) 
UV -visible spectrometers record absorbance directly and the standard cuvette is 
designed to give a pathlength of 1 cm. Thus determination of c may be obtained by a 
simple calculation as the equation becomes: 
c=Alc 
The derivation of this relationship assumes that all molecules present contribute to 
the absorption of the incident beam and that no absorbing molecule is in the shadow of 
another. For the dilute solutions usually used in UV-visible spectroscopy, this is a valid 
assumption [196]. 
87 
1.7.5. Gel permeation chromatography 
Gel penneation chromatography (GPC) has been employed in this work for the 
detennination ofthe molecular weight distribution of the synthesised polymers. 
Number average molecular weight (Mn) is the sum of the products of the molar 
mass of each fraction multiplied by its mole fraction. 
where Xi is the mole fraction of molecules of molecular mass M; - given by the ratio of the 
number of molecules Ni with mass Mi to the total number of molecules. 
- "N.M. M -~ I I 
n - IN; 
Mn can be detennined from the colligative properties of the polymer, e.g. osmotic 
pressure (an affect large enough to be measurable for, in molar tenns, dilute solutions). 
The weight average molecular weight (M w ) is defined as the sum of the products of 
the molar mass of each fraction multiplied by its weight fraction and can be detennined by 
light scattering or sedimentation measurements. [154] 
The polydispersity index (heterogeneity index) is the ratio of M wand provides a 
Mn 
measure of the breath of the molar mass distribution (for synthetic polymers PDI increases 
as the molecular weight range increases). For a mono-disperse polymer, e.g. an enzyme 
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molecule, M w = 1.00, but typical values range between 1.5 and 2.0 (larger and smaller 
Mn 
values can also be obtained). 
Gel permeation chromatography (GPC), also known as SIze exclusion 
chromatography (SEC), involves a non-interactive mode of separation. The column 
packing is made of porous particles that contain pores of various sizes. The hydrodynamic 
molecular volume (size and shape) of the compounds under analysis determines the extent 
of their interaction with the pores. As the sample passes through the column, the molecules 
of larger hydrodynamic volume are unable to enter most of the pores and' are eluted 
relatively quickly. Smaller hydrodynamic volume molecules are able to enter more pores 
and as a result are retained for longer [199]. 
The column packing is usually made of crosslinked polymers, such as styrene that is 
crosslinked with divinylbenzene, or 2-hydroxyethyl methacrylate that is crosslinked with 
ethylene dimethacrylate (pore sizes 10 - 105 nm); porous glasses and silicas can also be 
used (pore sizes 12.5 - 100 nm). The particle sizes of the packing materials range from 5 
to 10 Jlm [200]. 
1.7.6. Drug release studies 
The drug release process is influenced by the physico-chemical properties of the 
drug and its vehicle, as well as the physiological and physical chemical properties of the 
biological system in which it is placed. Factors that must be considered when designing a 
slow release dosage form include drug concentration, aqueous solubility, molecular size, 
crystal form, protein binding and pKa. If a drug compound is homogeneously distributed 
throughout the matrix of an erodible tablet, the drug is said to dissolve into the polymer 
matrix. As the drug is released, the distance for diffusion becomes inc~easingly greater and 
89 
the boundary between the drug and the empty matrix recedes into the bulk matrix as the 
drug is eluted. 
The release of a drug from a granular matrix involves the simultaneous penetration 
of the surrounding liquid, and the dissolution and leaching out of the drug through 
interstitial pores. A granule is defined as a porous matrix rather than a homogeneous one. 
Higuchi [201] developed an equation for the release of a drug from an ointment base, 
which he later applied to the diffusion of solid drug, dispersed in homogenous and granular 
matrix dosage forms: 
where Q is the amount of drug depleted per unit area, D is the diffusion coefficient of the 
drug, A is the total concentration of drug in the homogenous matrix, Cs is the solubility of 
the drug in the polymer matrix and t is the time at which the solution of the equation is 
true. 
In a porous matrix, a second form of the Higuchi equation is used, which takes into 
account the volume and length ofthe opening in the matrix: 
where porosity, c, is the fraction of the matrix that exists as pores into which the 
surrounding fluid can penetrate and tortuosity, T, accounts for the increase in the path 
length of diffusion due to branching and bending of the pores. Tortuosity tends to reduce 
the amount of drug released in a given time. A straight channel has a tortuosity of one, 
while the tortuosity of a channel going through a bead bed of uniformly sized beads lies 
between 2 and 3. 
The results obtained from in vitro drug release experiments may be fitted to a 
number of mathematical models to determine the release characteristics. These 
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characteristics can then be used to assess the usefulness of the formulation as a controlled 
release system. 
Typically, zero-order drug release systems consist of a drug reservoir, containing a 
homogeneously suspended drug and enclosed by a rate-limiting barrier. Such systems 
maintain a constant surface area and activity gradient. 
In cases of first-order release, the drug activity within the reservoir declines 
exponentially and the rate of drug release is proportional to the residual activity. The 
reservoir typically contains only dissolved drug and a plot of the logarithm of residual drug 
against time is linear with the slope being equal to the rate constant: 
where M/M<XJ is the fractional drug release at time t (Mt is the amount of drug released at 
time t, and M<XJ is the initial amount of drug in a tablet) , k is a constant incorporating the 
properties of the macromolecular polymeric systems and of the drug. 
Cumulative 
release 
(%) 
I~--------------------------x 
Time (t) 
Fig. 1.15. Zero-order and first-order drug release from polymer matrices 
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The Hixson and Crowell cube-root equation 
Hixson and Crowell [202] developed a model to describe drug release from systems 
that showed dissolution-rate limitation. This model may be applied to any such system that 
does not change in shape as drug release proceeds. The following equation is used to 
describe this process: 
(1-M/Moo)'h = -kt 
where M/M 00 is the fractional drug release at time t (Aft is the amount of drug released at 
time t, and Moo is the initial amount of drug in ~ tablet) , k is a constant incorporating the 
properties of the macromolecular polymeric systems and of the drug. 
Higuchi square root of time model 
Higuchi [203] showed that drug release into a sink system consisting of drug 
dispersed within a diffusion rate-limiting planar matrix could be modelled, at steady state, 
using the following equation: 
where M/M 00 is the fractional drug release at time t (Mt is the amount of drug released at 
time t, and Moo is the initial amount of drug in a tablet), k is a constant incorporating the 
properties of the polymeric system and of the drug. 
Roseman and Higuchi equation for cylindrical matrices 
Roseman and Higuchi [204] showed that the drug release profile for a cylindrical 
matrix containing a suspended drug, may be modelled by the following equation: 
4CsD M/Moo + [1 - M/Moo] In [1 - Aft/Moo] = --t Aao,2 
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where M/Moo is the fractional drug release at time t (Mt is the amount of drug released at 
time t, and Moo is the initial amount of drug in a tablet), ao is the radius of the cylindrical 
matrix, A is the drug loading, Cs is the drug solubility in the polymer, and D is the drug 
diffusivity in the polymer phase. According to Roseman and Higuchi's assumptions, this 
equation is more applicable to cylindrical matrix systems when the drug loading is much 
higher than solubility of the drug in the polymer. 
The correlation between in vitro and in vivo drug release is usually determined 
experimentally. In vitro release profiles of pharmaceutical preparations and subsequent 
fitting of the resulting data to mathematical models are useful, particularly if the 
preparations appear to be identical but are suspected to behave differently from one 
another in vivo. 
1.8. Project Aims 
Efficient drug delivery to the eye still represents a major challenge, despite the 
considerable research effort dedicated to it in the last decade. Previous studies have 
attempted either to increase the bioavailability of ophthalmic drugs by making use of 
methods that aim either, to improve the corneal penetration of the active and to delay its 
elimination from the eye, or, to to achieve controlled release of the drug by using various 
types of ophthalmic inserts. 
This project is directed towards the preparation and evaluation of novel polymeric 
vehicles that can effect the sustained (controlled) release of ocular drugs. It aims to 
combine recent advances in mucoadhesion and polymer-based drug delivery for the 
purpose of designing a new generation of aqueous ophthalmic vehicles. Previous work at 
the University of Portsmouth has established the great promise of polycarbophil and 
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chitosan as materials that can adsorb from solution onto unfixed human buccal epithelial 
cells [182], and it is envisaged that, based on these types of polymeric materials, ocular 
wafers or a 'nanoparticulate' formul~tion can be developed. Within the programme of 
work, several objectives are outlined: 
i) Synthesis and characterisation of ~ovel mucoadhesive hydro gels that are based on 
synthetic monomers and naturally-derived polymeric units, such as N-
vinylpyrrolidone, (meth)acrylic acid, N-isopropylacrylamide or 2-hydroxyethyl 
methacrylate, and chitosan with different ~olecular weights; 
ii) Formulation of these hydrogels either as ophthalmic inserts or as nanosuspensions; 
iii) Evaluation of their swelling properties, adhesion behaviour and in vitro drug release 
characteristics, using a range of common ophthalmic drugs; and 
iv) In vivo evaluation of the most promising formulations. 
Polymers that are known to hydrate at a rapid rate, but to a limited extent, will be 
selected for mucoadhesion testing; rapid gelation is required for patient comfort and to 
allow adhesion and drug release to commence quickly, whereas limited swelling is 
required to prevent break-up and dissolution of the gel and to provide prolonged retention 
and long-lasting drug delivery. Formulations will be based mainly on polymers with 
regulatory approval, such as polysaccharides (chitosan), polyacrylates (acrylic acid, 
methacrylic acid) and poly(vinylpyrrolidone)s. 
Model therapeutic agents including pilocarpine, chloramphenicol, atropine, and 
norfloxacin will be incorporated within the polymer matrix; aqueous nanoparticulate 
suspension wil be prepared and tested both in vitro and in vivo. 
An in vitro model, which utilises a radio labelled marker, could be also employed in 
order to simulate the penetration of the particulate formulations through the corneal tissue. 
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Chapter 2 - Poly(vinylpyrrolidone-co-
[meth] acrylic acid) inserts for ocular drug delivery 
2.1. Introduction 
The efficient ophthalmic delivery of drugs (fJ-blockers, cholinergic or antibacterial 
agents) continues to be challenged by the intrinsic physiology of the eye. The removal 
mechanisms that operate at the site of action (rapid tear turnover, blinking) and the low 
corneal permeability act co-operatively to suppress the effectiveness of ophthalmic 
formulations and to limit drug bioavailability to less than 5% [1]. Pulsed drug entry 
following topical administration and a very low efficiency for drug delivery to the 
posterior segment of ocular tissue, represent further therapeutic deficiencies [2,3]. 
Undesirable side effects, induced by systemic exposure through drainage via the 
nasolachrymal duct, are also an important issue of concern. 
Attempts have been made to improve the corneal penetration of drug molecules and 
delay their elimination from the eye. These include the use of gels, viscosity-enhancing 
agents, ointments, penetration enhancers, phase transition systems, cyclodextrins, vesicular 
systems, prodrugs, micro emulsions or nanosized cationic gels and devices (e.g. inserts, 
collagen shields, ocular films or disposable contact lenses) [2-7]. However, only ocular 
inserts [8] and nano/~icro-partic1es [9,10] show significant promise in terms of effective, 
controlled and sustained drug release [2,4]. 
As potential drug carriers, polymers based on I-vinylpyrrolidin-2-one (VP), acrylic 
acid (AA) and methacrylic acid (MA) are well known for their biocompatibility [11-13]. 
VP-based polymers, used in contact lenses for many years, are promising drug carriers [14-
16], while crosslinked polyacrylic acid is known to have excellent mucoadhesive 
properties and to enhance ocular bioavailability [17-19]. Blends of poly(1-vinylpyrrolidin-
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2-one) (PVP) and polyacrylic acid (PAA) have been reported to exhibit low viscosity 
characteristics and a high mucoadhesion index [20], and recent interpolymer-complexation 
studies have indicated that these blends are very promising candidate materials for 
ophthalmic drug delivery systems [21]. Their advantages over homopolymers include 
prolonged association with the cornea (hence an increased bioavailability of the loaded 
drug), controlled release, transparency and comfort [22-24]. Although crosslinked 
materials based on VP and AA (or MA) copolymers have been considered as vehicles for 
drug delivery systems [25], there are no detaile~ studies of their potential as ophthalmic 
carners. 
This work describes the preparation and characterisation of ocular inserts based on 
VP/AA[MA] copolymers, and present the results of in vitro and in vivo investigations into 
their potential to act as vehicles for drug delivery to the eye. 
2.2. Materials and methods 
2.2.1 Synthesis 
VP (Sigma-Aldrich) was further purified by vacuum distillation; AA and MA were 
passed through an inhibitor removal column (HQ, Sigma-Aldrich). Solvents (Fischer), the 
polymerisation initiator 4,4'-azobis(4-cyanovaleric acid) (ACVA, Sigma-Aldrich) and the 
model drugs (Fluka) for controlled release studies were used as received. Phosphate buffer 
solutions (PBS, pH = 7.4, ionic strength 0.497 M) were prepared from sodium 
monohydrogen phosphate, sodium dihydrogen phosphate and NaCI [26]. 
A parallel synthesis kit (Biichi Syncor) was used for the preparation of the 
polymeric networks. Aqueous solutions of co-monomers (see Table 2.1 for feed ratios) 
were mixed with 4,4'-azobis(4-cyanovaleric acid) (1 %w/v) and stirred under N2 for 8 h at 
80°C). After removal of water, the polymers were freeze-dried, finely ground, purified by 
III 
Soxhlet extraction (THF, 6h), and dried (vacuum oven, 40°C; see Table 2.1 for yields). 
Infrared spectra (KBr discs, resolution 4 cm-I ) were recorded (Mattson RS-l). Wafers were 
prepared by embedding the powdered drug unifonnly in the hydrogel matrix (2 %w/w; 4 
mg of polymer in 200 mg of dry KBr) followed by compression (2 tonne, for 1 min). 
2.2.2. Swelling and adhesion measurements 
The swelling properties at physiological pH (7.4) were determined volumetrically 
with at least three measurements for each value of the equilibrium degree of swelling, DSeq 
(%): 
v -v DS = eq 0 X 100 
eq 
Vo 
where Va and Veq are respectively the initial and equilibrium sample volumes. The polymer 
sample (30 mg) and 0.5 ml of PBS buffer were added to a 1 ml micro syringe, and the 
increase in the volume of the sample was noted at preset time intervals (5 min x 6, then 30 
min to equilibrium). 
Adhesion measurements were perfonned on polymer wafers (0 8 mm; prepared 
from 30 mg of polymer, by applying 2 tonne for 1 min), in PBS (pH=7.4), using hydrated 
dialysis tubing membrane (cellulose, Visking DTV14000) as the test surface. A Stable 
Microsystem T AXT Plus Analyzer was used for this purpose; the maximum detachment 
force (MDF) and the corresponding work of 
adhesion (TWA) were detennined from the 
recorded Force-Distance curves (see Image 
for an example) using the standard TAXT 
Plus Analyzer software. 
Carbopol C971 (BF Goodrich) was 
employed as positive control. The test 
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parameters used for the adhesion test are presented below: 
Pre-test speed 30 mm/min Applied force 20 g 
Test speed 1 mm/min Return distance 8mm 
Post test speed 1 mm/min Contact time 2 min 
2.2.3. Drug release in vitro 
The controlled release experiments were performed on polymeric wafers (0 8 mm) 
prepared by compression (2 tonne, 1 min) of a physical mixture of 50 mg of polymer and: 
5, 10, or 20 mg of either pilocarpine hydrochloride or chloramphenicol. Thus, wafers with 
different drug loading were obtained (9.0 %, 16.7 %, and 28.6 %, respectively; w/w). In 
vitro release profiles under sink conditions (phosphate buffer, pH 7.4; 37 °C) were obtained 
spectrophotometrically using a dissolution apparatus (Copley DT -70, Erweka Instruments: 
500 ml; U.S.P. II apparatus; 25 rpm) connected to a spectrometer (UV-300 Spectronic 
Unicam; 215 nm and 282 nm for pilocarpine and chloramphenicol, respectively) via an 
automatic flow-through sampling system. At the beginning of each experiment, wafers 
were introduced (dropped in) at the bottom of the dissolution baths, then the drug release 
was followed spectrophotometric ally. Calibration was performed using standard solutions 
of drug (0.001 - 0.02 %w/w) in phosphate buffer. Blank experiments, using polymer-only 
tablets, confirmed that the hydrogels did not absorb significantly in the UV. 
2.2.4. Drug release in vivo 
Ocular inserts/wafers (0 6 mm) were prepared by the compression (2 tonne, 1 min) 
of a physical mixture comprising of polymer (10 mg) and pilocarpine hydrochloride (2.5 
mg or 1.25 mg); inserts with different drug loading were obtained (20 %w, and ILl %w, 
respectively). Inserts (0 6 mm) having the same drug loading (20 % weight), but 
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containing a higher dose of drug, were prepared from the polymer under study (20 mg) and 
pilocarpine hydrochloride (5 mg), using the same method. 
The induced miotic effect in male, albino New Zealand rabbits (4.0 - 4.5 kg) was 
assessed, until disappearance, by timed measurements of the pupillary diameter. 
Procedures were approved by the Ethical Review Committee at the University of 
Portsmouth, and all studies were performed in accordance with Home Office regulations 
for the care and use of laboratory animals. 
Each insert was administered into the lo~er cul-de-sac of the left eye, while 50 III 
of pilocarpine solution containing 5 mg, 2.5 mg, or 1.25 mg of pilocarpine hydrochloride 
were instilled into the lower cul-de-sac of the right eye. In separate experiments, empty 
wafers (without loaded drug) provided the blank controls. 
2.3 Results and discussion 
AA 
o==r.= He 
OHO~ 
MA OH 2.3.1 Yields and characterisation of copolymers 
VP 
For the free-radical copolymerisation of vinyl 2-pyrrolidone (VP) with acrylic acid 
(AA), or methacrylic acid (MA), weight ratios of VP:AA (or VP:MA) between 1:0 and 1: 1 
(w/w) were used (see Table' 2.1). The concentration of N,N'-methylenebisacrylamide 
(MBA), employed as a crosslinker, was varied over a very large range, namely between 0 
and 23 %w/w. Generally, better yields were obtained as the 
amount of crosslinker was increased (Table 2.1). 
The composition of the purified materials was examined using the C=O bands of 
the corresponding VP (-1650 em-I) and AA [MA] (-1720 em-I) units. The amide II band 
(1535 cm-I, N-H bending) was used to assess the MBA ratio in the network: its 
displacement, from 1548 cm-! in pure MBA, indicated that the crosslinker influences the 
extent of the hydrogen-bonded interactions that operate within the network (Fig.2.1 b). 
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Table 2.1. Monomers and crosslinker feed ratios (weight ratio), crosslinker concentration 
(%w), and polymer yields. 
Polymer code VP AA MA MBA MBA (%w) Yield (%) 
cp(VPI AA)M 1 1 1 0 0.004 0.2 66 
cp(VP/AA)M_2 1 1 0 0.04 2 93 
cp(VP/AA)M_3 1 1 0 0.2 9 100 
cp(VP/AA)M_ 4 1 1 _ 0 0.4 16 95 
cp(VP/AA)M_5 1 1 0 0.6 23 95 
cp(VP/MA)M_6 1 0 1 0.004 0.2 59 
cp(VPIMA)M_7 1 0 1 0.04 2 82 
cp(VP/MA)M 8 1 0 1 0.2 9 81 
cp(VP/MA)M_9 1 0 1 0.4 16 71 
cp(VP/MA)M_10 1 0 1 0.6 23 100 
cp(VPI AA)M 11 1 0.25 0 0.0025 0.2 64 
cp(VP/AA)M 12 1 0.25 0 0.025 2 62 
cp(VP/AA)M 13 1 0.25 0 0.125 9 62 
cp(VP/AA)M_14 1 0.25 0 0.25 16 95 
cp(VP/AA)M_15 1 0.25 0 0.375 23 88 
cp(VP/MA)M 16 1 0 0.25 0.0025 0.2 24 
cp(VP/MA)M_17 1 0 0.25 0.025 2 24 
cp(VP IMA)M _18 1 0 0.25 0.125 9 43 
cp(VP/MA)M 19 1 0 0.25 0.25 16 40 
cp(VP/MA)M 20 1 0 0.25 0.375 23 70 
cp(VP/AA)M 21 1 0.05 0 0.002 0.2 25 
cp(VP/AA)M 22 1 0.05 0 0.02 2 40 
cp(VP I AA)M _23 1 0.05 0 0.10 9 63 
cp(VP I AA)M 24 1 0.05 0 0.21 16 90 
cp(VP/AA)M 25 1 0.05 0 0.315 23 96 
cp(VP/MA)M 26 1 0 0.05 0.002 0.2 35 
cp(VP/MA)M_27 1 0 0.05 0.02 2 44 
cp(VP/MA)M_28 1 0 0.05 0.10 9 61 
cp(VP/MA)M 29 1 0 0.05 0.21 16 70 
cp(VP/MA)M __ 30 1 0 0.05 0.315 23 97 
p(VP)M 31 1 0 0 0.002 0.2 61 
p(VP)M_32 1 0 0 0.02 2 43 
p(VP)M_33 1 0 0 0.1 9 75 
p(VP)M 34 1 0 0 0.2 16 88 
p(VP)M_35 1 0 0 0.3 23 100 
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Fig. 2.l. Selected FTIR spectra: a) Poly(vinylpyrrolidone) with increasing crosslinking density (from bottom upwards: 0.2; 2; 9; 16; 23 %, feed 
content); b) Poly (vinylpyrrolidone-co-acrylic acid) copolymers with increasing AA ratio (from bottom upwards), crosslinked with MBA (23 
%, weight, feed content); c) Poly(vinylpyrrolidone-co-acrylic acid) copolymers with a weight ratio VP/AA of 110.05 and different crosslinking 
density (from bottom upwards: 0.2; 2; 9; 16; 23 % MBA, feed content). Codes as in Table 2.1. 
The spectroscopic data revealed that MA copolymers possess higher MA to VP ratios 
relative to the feed composition whereas, in most cases, the opposite effect was observed 
with AA-containing copolymers. This is explained in terms of the reactivity order, MA > VP 
> AA, and confirms the findings of Chapiro [27], who has also reported that methacrylic acid 
is more reactive than acrylic acid in its copolymerisation with vinylpyrrolidone. 
The incorporation of AA[MA] co-monomer into the VP network has a major effect 
upon the hydrogen-bonded associations (see Fig.2.1a and 2.1c), as the competitive 
COOH .... ·O=C«PVP) interactions displace sorb~d water molecules and reduce the intensity 
of the corresponding broad band (3600-3400 cm-\ while a lower wavelength band 
(characteristic of strongly associated O-H bonds) appears at around 3200 em-I. Notably, this 
effect is more pronounced at higher crosslinking densities (Fig.2.1c), possibly due to steric 
constraints that limit the presence of sorbed water molecules within the network. The strong 
absorption in the region 3600-3400 cm-I highlights the hygroscopic nature of the material; 
water is readily sorbed by the polymer even after a very short exposure to atmospheric 
conditions [38-40]. The weak shoulder at around 3200 em-I is most probably due to 
hydrogen bonded interactions involving the N-H group (Fig.2.1a). 
For the same amount of crosslinker, increasing the relati~e proportion of AA[MA] 
results in an increase in the number of free carboxylic acid groups - presumably their ability 
to interact with the carbonylic VP groups (or to self-associate as head-to-head dimers) is 
dictated by steric constraints within the network (see Fig.2.1 b). Both free and associated 
>C=O groups (respectively, 1721 cm-I and 1712 cm-I for AA[MA] units, 1655 cm-I and 1635 
cm-I for VP groups) were observed for all polymers, but the bands were too broad for 
quantitative analysis. 
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2.3.2. Swelling and adhesion 
The effects of the hydrogels' network structure and composition upon their swelling 
properties were investigated by volumetric swelling measurements, following the method 
described in section 2.2.2. 
The equilibrium and the dynamic swelling behaviour of the synthesised materials are 
highly dependent upon their chemical composition. This is consistent with literature reports 
on methacrylate polymers in which increasing the percentage of crosslinker reduces the rate 
and degree of swelling and changes the water transport mechanism from Fickian diffusion to 
anomalous transport [28]. 
Under controlled conditions (37.5 °C, pH 7.4), the synthesised materials displayed a 
broad range of swelling behaviour. The VPI AA copolymers exhibited greater degrees of 
swelling and more rapid swelling rates than their VP/MA congeners; equilibration times 
were generally longer for the VP/AA copolymers. For both classes of copolymer, the 
equilibrium degree of swelling at (DSeq) was at its maximum for materials containing 9 % 
w/w of crosslinker (Fig. 2.2). 
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Tablets prepared from highly crosslinked materials were more difficult to press, and 
had a greater tendency to disintegrate during swelling experiments. Increasing the proportion 
of ANMA gave a maximum degree of swelling at equilibrium at 10-15 %w/w (Fig 2.3) 
beyond which the degree of swelling at equilibrium decreased. This contrasts with the 
progressive increases in degree of swelling and water sorption rate (with equilibration time 
and solvent transport mechanism remaining unchanged) that normally result from increasing 
the proportion of ionic co-monomers [28]. 
The adhesion behaviour of the synthesised poly(vinylpyrrolidone-co-[meth]acrylic 
acid)s was studied using a Stable Microsystem Texture Analyzer, as described in section 
2.2.2. Our adhesion measurements on polymer wafers allowed the determination of the 
maximum detachment force (MDF) and the corresponding work of adhesion (TWA). 
Crosslinked polyacrylic acids (e.g. Carbopols) are known to exhibit excellent mucoadhesive 
properties and to enhance the bioavailability of some drugs [17]; the bioadhesive behaviour 
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of Carbopols is optimal in acidic media (PH < 5), due to H-bonding between its 
undissociated COOR groups and mucin [29-31]. 
Table 2.2. Variations in the maximum detachment force (MDF) and the total work of 
adhesion (TWA) with crosslinker density, for the copolymers studied (SD - standard 
deviation; Ilexp = 6; means tabulated). 
Crosslinker 
Copolymer (MBA) 
density MDFav SD TWAav SD 
(%w/w) (mN) (mN) (pJ) (jJJ) 
cp(VPI AA)M 1 0.2 94 49 9.0 1.6 
cp(VPI AA)M 2 2 38 10 8.3 2.2 
cp(VP/AA)M 3 9 36 22 15.5 11.5 
cp(VP/AA)M 4 16 51 19 21.7 11.1 
cp(VPI AA)M 5 23 116 14 9.8 1.9 
cp(VP/MA)M 6 0.2 135 13 7.8 0.8 
cp(VP/MA)M 7 2 15 1 1.8 0.4 
cp(VP/MA)M 8 9 13 3 10.0 3.5 
cp(VPIMA)M 9 16 53 7 6.0 1.6 
cp(VPIMA)M 10 23 63 14 25.0 2.4 
Both copolymer-network and PVP wafers exhibited maXImum adhesion at low 
crosslinking densities (Table 2.2, MBA ratio 0.2-2% w), indicating that the incorporation of 
AA[MA] moieties into the VP network suppresses its bioadhesive properties progressively as 
the degree of crosslinking in the materials is reduced (Table 2.2). This effect can probably be 
explained in terms of the relative contributions of the strong interpolymer hydrogen bonding 
[COOH"·· .. O=C«PVP)] and the much weaker polymer-substrate interactions under the 
various crosslinking regimes. The findings are consistent with Tan's observation [23] that, in 
Carbopol-PVP complexes, the adhesion properties are reflective of Carbopol content. 
Interestingly, Tan et al. [23] also found that the adhesion. strength of the copolymers was 
lower than that of corresponding physical mixtures of the constituent polymers. Also, Chun 
et al. [22] have reported that PVP/p AA complexes are more bioadhesive than pure Carbopol. 
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2.3.3. Drug release studies 
Since prolonged retention, minimal discomfort and disruption of vision are critical 
requirements for ocular inserts, only the polymers containing 0.2 and 2.0 %w/w MBA, i.e. 
those that showed at least minimal adhesive properties that were coupled with slow and 
limited swelling, were selected for further studies. Pilocarpine (cholinergic agonist, a 
common antiglaucoma drug) and chloramphenicol (a broad-spectrum antibacterial agent) 
were selected as model drugs for the in vitro stu~ies (Fig. 2.4). 
a) b) 
Fig. 2.4. Drug structures: a) pilocarpine hydrochloride; b) chloramphenicol. 
Copolymers were loaded with model drugs by physical mixing (grinding the two 
powders together) and pressing into a tablet, and the release of the active was monitored 
spectrophotometrically over time using a dissolution bath connected to a UV spectrometer 
via an automatic flow-trough sampling system, as described in section 2.2.3. In some cases 
, 
gradual tablet disintegration has been observed over the course of the experiment. 
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Fig. 2.5. Chloramphenicol (10 mg in 50 mg of copolymer) in vitro release profiles for 
materials (Table 2.1) with different VP/AA ratios, and with different crosslinking densities 
(PBS, pH = 7.4; 37°C; nexp = 6; means represented; standard errors were < 10 %). 
Overall, differences in release rates between systems that contain PVP only (i. e. 
p(VP)M_31 to 35) and copolymers with AA and MA (i. e. materials numbered _ 1 to _30, 
Table 2.1) were less pronounced with pilocarpine than with chloramphenicol. The results 
suggest that the more hydrophilic the delivery vehicle the less suitable it is for applications 
that demand the immobilisation of water-soluble, low molecular weight drugs. Nonetheless, 
highly hydrophilic gels may be useful for the release of active agents that are sparingly 
soluble in water (e.g. hydrocortisone-acetate), or for that of water-soluble macromolecules 
(enzymes, proteins, antigens) that can be immobilized in the hydrophilic matrix by physical 
entanglement [32] . 
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of polymer; PBS, pH=7.4; 37°C; nexp = 6; means represented; standard errors were < 10 %). 
The materials with intermediate crosslinking densities (2 %w/w MBA) released the 
drug more rapidly than those with 0.2 %w/w MBA (Figs. 2.5 & 2.6) . For these materials 
there appears to be an optimum AA[MA] content for slow release . Statistical treatment of the 
results (ANOV A, two-factors with replication; 5 replicates; p < 0.05) indicated that there is a 
significant difference between the materials with 2 %w/w crosslinking densities and 
materials with 0.2 %w/w crosslinking densities. 
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For both types of materials tested, the initial release of chloramphenicol was slower 
compared to that of pilocarpine (Fig. 2.7). Up to ca. 50 % of drug released, the release rate 
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was approximately constant for chloramphenicol, whereas for pilocarpine it decreased 
progressively. 
The observed differences in the release profiles of the two drugs (Fig. 2.7) can be, at 
least partially, explained in terms of their relative solubility in water; the chloramphenicol 
structure allows for stronger hydrogen-bonded interactions between the polymer matrix and 
the active (Fig. 2.4). It is worth noting that uncrosslinked copolymeric VP/AA hydrogels are 
more hydrophilic in neutral and alkaline media than in acidic environments [25]. 
To investigate the differences in release rates characterising the two actives, drug 
release exponents (n) were determined using the well-known expression, used for example 
by Korsmeyer et a/.[33]: 
where M/M ao is the fraction of drug released, t is the release time and k is a constant 
incorporating the structural and geometrical characteristics of the release device. From here, 
log(gradient) = (n -1) ·logt +const , hence 'constant rate' corresponds with "n = 1". 
The values of n were derived from the linear regression slopes of the release profiles 
(0-80 %) using the above expression. Release exponents (Table 2.3) for chloramphenicol-
based systems were significantly greater than for those incorporating pilocarpine; if values 
for the latter active were interpreted as indicative of a release mechanism that ranges from 
Fickian (n = 0.5) to anomalous diffusion, a Super Case II transport mechanism [34] would 
appear to operate for most chloramphenicol-based systems. 
However, the basis of the Korsmeyer equation takes no account of the complex 
mechanism - involving parallel swelling, diffusion and erosion - that is integral to the process 
of drug release from hydrophilic matrices [35-37]. With only a few exceptions, release rates 
were higher for pilocarpine (Table 2.3); consistent with its inability to act as an H-bond 
donor to the polymer matrix. 
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Table 2.3. Comparison of release exponents (n) and specific release rates (k) with copolymer 
composition (R2 = correlation coefficient). 
Drug chloramphenicol pjlocarpine 
'Rolymer 11 klh-n R2 11 klh-n R2 
~p(VPlAA)M 12 1.52 · 6.26 0.968 0.53 2.06 0.964 
~p(VPlAA)M 22 1.29 1.46 0.989 0.68 1.65 0.994 
'fJ(VP)M 32 0.97 0.423 0.991 0.60 1.62 0.993 
cp(VPlAA)M 11 1.29 1.73 0.950 0.48 1.18 0.984 
cp(VPIAA)M 21 1.04 0.115 0.999 0.52 0.883 0.995 
p(VP)M 31 0.90 0.885 0.993 0.67 2.46 0.991 
~p(VPlMA)M 6 0.86 0.300 0.995 0.39 0.883 0.997 
Icp(VPlMA)M 26 0.92 0.402 0.999 0.61 2.66 0.991 
~p(VPlMA)M 7 1.31 1.11 0.992 0.56 1.84 0.995 
~p(VPlMA)M 27 1.53 1.32 0.999 0.93 1.99 0.999 
The significant influences on release rates of both drug-polymer interactions and 
matrix hydrophobicity h~ve been shown: while increasing the proportion of acrylic to VP co-
monomer produces copolymers that exhibit faster release rates, its replacement by 
methacrylic acid (more hydrophobic) has the opposite effect (as indicated by values of k; 
Table 2.3). 
2.3.4. In vivo experiments 
The New Zealand albino rabbit model was employed for the in vivo studies (two 
animals; rest period between experiments 48 h). As a positive control, an aqueous solution of 
the drug was administered dropwise; drug-free wafers (blank controls) confirmed that the 
pure hydro gels had no contribution to the observed miotic effect. The variation in pupillary 
diameter was monitored over time using a standard pupillary diameter gauge. In all 
observations, a sharp initial effect was followed by a slow return towards the original level 
(Fig. 2.8). 
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The inserts induced a more pronounced miotic effect (decrease in pupillary diameter) 
than the eyedrop control, and the period of significant activity increased by up to 110 %. The 
127 
E 
.§. 
U 
CD 
II:: 
CD 
.!:! 
0 
E 
results reveal that materials with reduced hydrophilicity, which have a limited swelling 
capacity, yield more desirable activity profiles (Fig. 2.9). 
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%; nexp = 6. 
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Statistical treatment of the results (ANOVA, two-factors with replication; 6 replicates; 
p < 0.05) indicated a highly significant difference (in terms of the induced miotic effect) 
between some of the materials [cp(VPIMA)M_6; p(VP)M_32] and control solution, and a 
highly significant interaction (in terms of the induced miotic effect) between the same 
materials [cp(VPIMA)M_6; p(VP)M_32] and time. 
The concentration of methacrylic acid (more hydrophobic than acrylic acid) and the 
degree of crosslinking seem to be the key factors that control pilocarpine release. Loading 
with greater amounts of pilocarpine produced only a slight increase in the duration of the 
pilocarpine-induced miotic effect, possibly due to the limited drug loading capacity of the 
materials. 
2.4. Conclusions 
A number of hydrogel polymeric networks were prepared by the free radical 
copolymerisation of vinylpyrrolidone with methacrylic or acrylic acids, in the presence of 
N,N'-methylenebisacrylamide as a crosslinking agent. Dependent on their composition, the 
materials exhibited a broad range of swelling and adhesion properties, which could be fine-
tuned by altering the relative proportion of each constitutional repeat unit. 
In vitro drug release studies involving pilocarpine or chloramphenicol demonstrated 
that the materials under consideration may be most appropriate for the delivery of sparingly 
water-soluble actives. 
In vivo experiments revealed that the degree of swelling and hydrophobicity of the 
matrix are key factors in effecting controlled drug release. The inserts induced a more 
pronounced miotic effect than the eyedrop control, and the period of significant activity 
increased by up to 110 %. 
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Chapter 3 - Hybrid polymeric networks based on 
acrylic acid-functionalised chitosan and NIP AM or 
HEMA, as inserts for ocular drug delivery 
3.1. Introduction· 
As a biocompatible and biodegradable material that also shows good release 
characteristics, chitosan possesses many of the desired properties for safe use as a 
pharmaceutical excipient [1-4]. Consequently, much research has concentrated on the use of 
chitosan as a vehicle for the controlled and targeted release of therapeutic agents [5-9], with 
many recent publications highlighting the need for chemical functionalisation as the key to 
optimal carrier properties [10-15]. The hydroxyl moieties and the primary amino group of the 
D-glucosamine unit represent two readily accessible sites for the attachment of pendent 
functionalities [16,17]. Such structural modifications both impact upon the physicochemical 
and biological properties of the material, and allow the manipulation of its morphology [13]. 
The covalent cross linking of chitosan affords three-dimensional networks that exhibit 
desirable drug-diffusion characteristics. Examples of agents that have been used to effect 
crosslinking include: aldehydes [18-22], itaconic acid [23], naturally-occurring genipin [24], 
diisocyanates [25], diepoxides [26] and gelatin [27]; thermal crosslinking has also been 
demonstrated [28]. An alternative crosslinkin~ strategy involves the formation of direct 
covalent bonds between chitosan and other biocompatible polymers (Fig. 3.1). This approach 
offers the opportunity for further refinements to the properties of the drug carrier (e.g. 
mechanical strength; pH and temperature sensitivity), by combining the advantages of the 
chitosan molecule with those of the partner polymer. While semi- or full- interpenetrating 
polymer networks (IPN) combining chitosan with synthetic macromolecules have received 
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considerable attention as controlled release systems [29-33], little is known about the drug-
carrier capabilities of analogous hybrid polymer networks (HPN), with reports on chitosan-
based systems limited to materials incorporating gelatin [34-36], collagen[37], glyoxal [38] 
or silylating agents [39]. With the exception of an enzymatically catalysed crosslinking 
reaction involving chitosan and gelatin [40], crosslinking is normally effected using 
dialdehydes, which are toxic [41-43]. 
~ chitosan chain 
'--- synthetic polymer chain 
a) b) 
~ ~ 
Fig. 3.1. Covalently crosslinked three-dimensional networks: a) hybrid polymer networks 
(HPN; chitosan-polymer crosslinks); b) semi-interpenetrating polymer networks (semi-IPN; 
inter-chitosan crosslinks); c) full- interpenetrating polymer networks (full-IPN; inter-chitosan 
and inter-polymer crosslinks); and, d) interpolymeric complexes (no crosslinks). 
Here we report the results of our study on the synthesis and characterisation of hybrid 
polymer networks based on acrylic acid-functionalised chitosan (CSf) that is coupled with 2-
hydroxyethyl methacrylate (HEMA) [44-48] or with N-isopropylacrylamide (NIP AM) 
[30,49], and evaluate the ability of these systems to act as vehicles for ophthalmic drug 
delivery. The performance of the materials is compared with that of interpolymeric complex 
analogues (Fig. 3.1) that have been obtained by radical-induced polymerisation of HEMA or 
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NIP AM in the presence of chitosan that had not been subjected to functionalisation. The 
influences of network structure and composition upon the swelling properties, potential 
bioadhesion behaviour and drug release characteristics have also been measured, and in vivo 
experiments (rabbit model) have been performed to establish the release profile of 
pilocarpine hydrochloride that has been incorporated into these systems. 
3.2. Materials and methods 
Low molecular weight chitosan (Mw = 75,000; deacetylation degree 87.5 %) was 
used as obtained from Fluka. N-isopropyl acrylamide (Acros) was recrystallised from a 
mixture of n-hexane and toluene (40/60, v/v) , while 2-hydroxyethyl methacrylate (Sigma-
Aldrich) was purified by passing it through an inhibitor removal column (hydroquinone, 
Sigma-Aldrich). Pharmaceutical gr<l:de therapeutic agents (pilocarpine hydrochloride, Acros; 
atropine sulphate, Fluka; chloramphenicol and norfloxacin, Sigma-Aldrich) were used as 
received. Preparation of phosphate buffer solutions (PBS; pH = 7.4; ionic strength 0.497 M) 
were prepared from sodium monohydrogen phosphate, sodium dihydrogenphosphate and 
NaCI [50]. All other solvents and chemicals were obtained from Sigma-Aldrich and used as 
received. 
3.2.1. Synthesis of acrylic acid1unctionalised chitosan (CSf) 
A solution of l-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDAC; 
5.75 g; 0.03 mol) and acrylic acid (AA; 5 ml; 0.073 mol) in deionised water (50 ml) was 
allowed to react (room temperature, 1 h) before being mixed (with stirring) with a solution of 
low molecular weight chitosan (CS) in 0.05 M aqueous hydrochloric acid (1 % w/v; 500 ml). 
The resulting solution was adjusted to pH 5 (aq. NaOH, 0.5 M) and stirred for 24 h (10 °C) to 
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yield the crude product, which was purified by continuous dialysis (membrane cut-off 12000 
Da) against 0.5 mM hydrochloric acid (5 days) and then against water (3 days). The purity of 
the freeze-dried product was assessed by 1 H NMR spectroscopy, and its degree of 
functionalisation (DF) was determined by elemental analysis [51]: 
DF =t1c/N[3MCIN(1-DA)] xlOO 
where: t1C/N is the difference between the ratio of found C and N percentages in 
grafted CSf and the corresponding ratio in the CS sample; MCIN is the ratio of CIN molar 
masses; and DA is the degree of deacetylation of the initial chitosan. 
3.2.2. General method for the preparation of hybrid polymer networks 
To a stirred solution of AA-functionalised chitosan (CSf; DF = 67.2 %) and synthetic 
monomer (either HEMA or NIPAM; Table 3.1) in dilute aqueous acetic acid (1 % w/v; 30 
ml) was added a mixture (1:3 w/w) of ammonium persulphate and sodium bisulphite (1 % 
w/w of the acrylic functionality). After stirring (24 h, 25°C), the hydrogel products were 
separated by centrifugation, washed (methanoI2x, deionised water 3x) and freeze-dried. For 
comparison, interpolymeric complexes [ic(CSIPHEMA) and ic(CSIPNIP AM)] with similar 
composition were prepared following the same procedure but with the AA-functionalised 
chitosan being replaced by the unmodified polymer (Table 3.1). Minitablets (8 mm in 
diameter) were prepared by compression (2 tonne, 1 min). 
3.2.3. Swelling and adhesion measurements 
The swelling properties of the synthesised materials were evaluated at physiological 
pH (7.4) in PBS, by determining the volume of buffer absorbed by each sample (wafers, 0 8 
mm; 30 mg) in a micro column (QIAquick® Spin Column 50, 0 10 mm) that was attached 
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to a micro syringe. Phosphate buffer (1 ml) was injected with a micro syringe into the micro 
column. The buffer was withdrawn and measured at regular time intervals. The equilibrium 
degree of swelling, DSeq (%, weight), was calculated as follows: 
v -v DS = eq 0 X 100 
eq 
vo 
Va and Veq are, respectively, the initiaI and equilibrium sample weights; mean values given 
for each sample are the result of at least three determinations. 
The kinetic parameters of swelling were calculated from the equation used by Peppas 
[52]: 
where M t represents the amount of liquid transferred into the hydrogel at time t and M co is 
the amount transferred at equilibrium swelling; ks is the swelling constant, incorporating 
characteristics of the matrix such as porosity, and n is the diffusioI?- exponent, which is 
indicative of the mechanism of water uptake. 
The adhesion of polymer wafers (0 8 mm; 30 mg polymer; 2 tonne, 1 min) onto 
hydrated dialysis tubing membrane (cellulose, Visking DTV14000) was evaluated in PBS 
(pH=7.4) using a Stable Microsystem TAXT Plus Analyzer. The parameters used are 
described already in section 2.2.2. The maximum detachment force (MDF) and the 
corresponding work of adhesion (TWA) were determined at 20°C and at 40 °C; pure 
homopolymers (PHEMA, PNIP AM and low molecular weight chitosan) were used as 
controls. 
3.2.4. Drug release in vitro 
Drug-containing wafers (0 8 mm; 90 mg) were pressed (2 tonne, 1 min) fOllowing 
physical mixing (pestle and mortar) of each polymer (70 mg) with the appropriate active (20 
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mg): pilocarpine hydrochloride, chloramphenicol, atropine sulphate or norfloxacin (22.2 
%w/w). In vitro release profiles under sink conditions (phosphate buffer, pH 7.4; 37°C) were 
obtained spectrophotometrically using a dissolution apparatus (Copley DT -70, Erweka 
Instruments: 500 ml; U.S.P. II Apparatus - paddle method; 25 rpm) connected to a 
spectrophotometer (UV -300 Spectronic Unicam; pilocarpine - 215 nm, chloramphenicol _ 
282 nm, atropine - 219 nm, norfloxac1n - 323 nm) via an automatic flow-through sampling 
system. At the beginning of each experiment, wafers w~re introduced (dropped in) at the 
bottom of the dissolution baths, then the drug release was followed spectrophotometrically. 
Calibration was performed using standard solutions of drug (0.001 - 0.02 % w/w) in 
phosphate buffer. Blank experiments, using drug-free minitablets, confirmed that there was 
no interfering background absorption. 
3.2.5. Drug release in vivo 
Ocular wafers (11.25 mg; 0 8 mm, 0.25 mm thickness) were prepared by 
compressing (at 2 tonne, for 1 min) a mixture (obtained using pestle and mortar) of the 
powdered drug pilocarpine (1.25 mg) and polymer (10 mg) (the mixture contains 11.1 % 
w/w drug). The induced miotic effect of the ocular wafers was assessed in male, albino New 
Zealand rabbits (4.0 - 4.5 kg) until disappearance, by timed measurements of the pupillary 
diameter. As a positive control (using the other eye), corresponding amounts of drug in 
aqueous solution (i.e. 50 !J.I, containing 1.25 mg pilocarpine) were administered dropwise (2 
drops); drug-free minitablets (without loaded drug) provided the blank controls. 
Procedures were approved by the Ethical Review Committee at the University of 
Portsmouth, and all studies were performed in accordance with Home Office regulations for 
the care and use of laboratory animals. 
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3.3. Results and discussion 
3.3.1. Synthesis and characterisation of hydro gels 
Acrylic acid moieties were immobilised onto chitosan chains through amidic bonds, 
the formation of which was facilitated by water-soluble carbodiimides [53]. Various degrees 
of functionalisation were obtained, as .found by elemental analysis, but only chitosan with a 
degree of amino group functionalisation of 67.2 % was used for further experiments. The 
immobilised acrylic acid moieties provided a polymerisable anchor that allowed the modified 
chitosan to participate in radical polymerisation reactions with water-soluble co-monomers 
without the need to employ crosslinkers (Fig. 3.2). 
H 
* • 
o o 
y NH H 0=\ H x 
n 
~o 
NIPAM ~ HEMA 
OH 
Fig. 3.2. Acrylic acid-functionalised chitosan and synthetic co-monomers used. 
Hybrid polymer networks were prepared by the free radical copolymerisation of 
poly(N-isopropylacrylamide) or poly(2-hydroxyethyl methacrylate) and AA-functionalised 
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low molecular weight chitosan(CSf), as described in section 3.2.2. The final composition of 
the synthesised networks was determined by elemental analysis and is presented in Table 3.1. 
In general, lower yields were obtained as the chitosan / HEMA (NIP AM) feed ratio 
was increased (Table 3.1). At low chitosan feed ratios, interpolymeric complexes (i.e. 
ic(CSIPHEMA), ic(CSIPNIP AM) are seen to entrap more chitosan than corresponding 
hybrid polymer networks. At high feed ratios, there appears to be a limit to the amount of 
natural polymer that can be incorporated into the intermolecular complex (50~60 %, in 
ic(CSIPHEMA), ic(CSIPNIP AM). In three-dimensional hybrid networks, the presence of AA 
anchors facilitates the incorporation of up to 73 %w/w chitosan into the structure. 
Table 3.1. Feed ratio (mass of CSf per 100 g of either HEMA or NIPAM) and final 
composition (% w/w) of the synthesised hybrid polymer networks, as determined by 
elemental analysis. 
Feed ratio Final composition 
(g CSt. or CSt 
IIpn(CSf/HEMA) IIpn(CSf/NIPAM) per 100 g ic(CSIPHEMA) ic(CSIPNIPAM) 
synthetic %CSf Yield % %CSf Yield % %CS Yield % %CS Yield % 
monomer-
eitherHEMA 
orNJPAM) 
1 5 13.8 89 10.2 89 14.9 85 13.2 78 
2 10 na 84 na 90 Na 82 na 76 
3 20 20.5 74 16.5 81 42.3 72 20.4 68 
4 40 46.6 74 31.2 78 45.4 70 38.5 69 
5 60 ua 64 na 70 Na 65 na 62 
6 80 64.4 58 65.3 74 48.3 62 Na 58 
7 100 72.7 47 68.2 59 51.4 54 56.4 56 
8 140 na 34 na 51 na 50 na 43 
CS - low molecular weight chitosan; CSf - low molecular weight chitosan modified with acrylic 
acid; hpn(CSjlHEMA) - hybrid network of AA-modified chitosan with HEMA; hpn( CSjlNIPAM)-
hybrid network of AA-modified chitosan with NIPAM; ic(CSIPHEMA) - interpolymeric complex of 
low molecular weight chitosan and HEMA; ic(CSIPNIPAM) - interpolymeric complex of low 
molecular weight chitosan and NIP AM; % CSf indicates the low molecular weight chitosan 
content of the final product; na - data not available. 
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The proportion of incorporated low-molecular-weight chitosan was also influenced by 
the chemical structure of the synthetic co-monomer: yields for ic(CSIPHEMA) complexes 
were higher than for ic(CSIPNIP AM) structures. The formation of interpolymeric complexes 
(ic(CSIPHEMA), ic(CSIPNIP AM) appeared to be favoured by the hydrogen-bonded 
interactions between the OH groups of HEMA and the hydrophilic chitosan chains; in the 
case of NIP AM, such inter-chain interactions are probably suppressed by the hydrophobicity 
of the isopropyl moieties. By contrast, hpn(CSflNIP AM) hybrid polymer networks were 
obtained in better yields than corresponding hpn(CSflHEMA) structures, most probably due 
to favourable interactions between immobilised AA and NIP AM. While, at low 
concentrations of AA-functionalised low molecular weight chitosan (CSt), the modified 
biopolymer acts as a crosslinker for PNIP AM or PHEMA, at high concentrations it provides 
the skeleton of a network that is crosslinked by short chains of synthetic polymer (PNIP AM 
or HEMA); increasing the CSf to NIP AM (HEMA) ratio suppresses crosslinking, as is 
demonstrated by the observed trends in corresponding yields, Table 3.1. 
3.3.2. Swelling properties of the synthesised materials 
Under simulated physiological conditions (37.5 °e, pH 7.4), the synthesised materials 
exhibited increased equilibrium degrees of swelling with increasing amounts of incorporated 
chitosan. Hybrid networks swelled to a greater extent and, also, reached maximum swelling 
more rapidly than the corresponding interpolymeric complexes, with the NIP AM-containing 
hybrid network hpn(CSfINIPAML8 exhibiting the most pronounced increase (1150 %, Fig. 
3.3). At 37.5 °c both types of NIP AM-containing materials showed very limited swelling at 
low chitosan content, indicating the collapse of the PNIP AM chains and that hydrophobic 
interactions become dominant - PNIP AM in aqueous solution is known to exhibit a 
temperature-controlled (-31°C) conformational transition from random coil to hypercoil 
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[54]. In some cases, the wafers with high chitosan content (CS > 100, Table 3.1) - especially 
those of interpolymeric complexes containing NIP AM - disintegrated in the phosphate buffer 
solution (PBS). 
-~ 
CI 
:§ 
1 
I/) 
-o 
Q) 
e 
CI Q) 
C 
CSf or CS(g)l100 9 of synthetic 
monomer(HEMA or NIPAM) 
5 
hpn(CSf/HEMA) 
iC(CS/PNIPAM)Materlal type 
Fig. 3.3. The degree of swelling at equilibrium as a function of chit os an content (CSf = low 
molecular weight-chitosan modified with acrylic acid, HEMA = hydroxy ethyl methacrylate, 
NIP AM = N- isopropylacrylamide). 
In all cases, the rate of swelling increased with increasing chitosan content. This 
effect was more p~onounced with NIP AM-containing hybrid networks than with other 
materials (Table 3.2). 
For materials with low proportions of chitosan, the diffusion kinetic exponent of time 
n (section 3.2.3) is seen to adopt values that are close to 0.5, suggesting a Fickian transport 
process in which water diffusion into the polymeric network becomes markedly more 
significant than network relaxation, and represents the dominant mechanism controlling 
swelling. 
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3 
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Table 3.2. Kinetic parameters of swelling for selected interpolymeric complexes and hybrid 
polymeric networks (ks - swelling rate constant; n - diffusion exponent; nexp > 3 
measurements; values shown represent the mean; ± values represents standard deviation). 
Itpn(CSfmEMA) Itpn(CSfINIPAM) ic(CSIPHEMA) ic(CSIPNIPAM) 
Feed ratio 
-
CSforCS 
I - g per JOO g of 
monomer k,W"J I n ks[h-
n} N ks [h-n} n ks [h-j n 
(either HEMA 
orNIPAM) 
5 0.312± I 
0.435 ± 0.232 ± 0.474 ± 0.401 ± 0.457 ± 0.234 ± 0.408 ± 
0.005 0.003 0.017 0.044 0.008 0.011 0.016 0.006 
20 0.421± 0.524 ± 0.455 ± 0.483 ± 0.455 ± 0.433 ± 0.333 ± 0.474 ± 
0.015 0.010 0.023 0.011 0.025 0.009 0.024 0.009 
60 0.456 ± 0.555 ± 0.635 ± 0.734 ± 0.644 ± . 0.577 ± 0.558 ± 0.673 ± 
0.022 0.015 0.045 0.009 0.047 0.001 0.010 0.011 
140 0.564 ± 0.665 ± 0.834 ± 0.746 ± 0.761 ± 0.683 ± 0.495 ± 0.649 ± 
0.047 0.007 0.010 0.012 0.033 0.013 0.038 0.012 
Increased proportions of chitosan in the network are reflected by anomalous transport 
mechanisms (0.5 < n < 1.0); the swelling behaviour of NIP AM-containing hybrid polymer 
networks hpn(CSflNIP AM) appears to be more sensitive to the amount of incorporated ' 
chitosan than that of HEM A-containing materials. 
3.3.3. Adhesion characteristics 
Several methods are available for the evaluation of the adhesive strength of 
pharmaceutical formulations [55, 56]. In preliminary experiments designed to evaluate the 
adhesive potential of our materials, hydrated cellulose dialysis membrane was employed as 
the model test surface [57, 58]. Although large intersample variations were evident, tensile 
strength measurements (method: section 2.2.2) indicated that, at room temperature (20°C), 
the NIPAM-containing polymers were up to lOx more adhesive than HEMA-based 
materials. 
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Fig. 3.4. Adhesion data for hybrid polymeric networks (HPN), interpenetrating polymeric 
networks (IPN) and pure polymers: a) maximum detachment force [MDF]; b) total work of 
adhesion [TWA]; bars represent standard errors. (nexp=6; temperature 20°C) 
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There appears to be an inverse relationship between the chitosan content of the 
fonnulation and its adhesive strength (both the detachment force and the work of adhesion 
were suppressed by increasing proportions of chitosan in the fonnulation (Fig. 3.4). Of all 
materials tested, the adhesiveness of the HEMA-containing interpolymeric complex 
ic(CSIPHEMA) was least sensitive to the amount of chitosan present. This is consistent with 
the proposed weak interactions between low-molecular-weight chitosan and the cellulose 
membrane. No significant differences in the aqhesive behaviour could be identified between 
the interpolymeric complexes and the hybrid polymer networks of analogous composition. 
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Fig. 3.5. Effect of temperature on adhesive properties of selected materials (MDF; TWA; 
bars are standard errors): measurement at 20°C and 40 °C (nexp=6). 
In view of the fact that the physiologically relevant temperature of the ocular surface 
IS highly sensitive to environmental conditions, a study of adhesive potential was also 
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conducted at 40°C: NIP AM-containing materials exhibited decreased adhesion at this 
temperature (Fig. 3.5). 
3.3.4. In vitro release 
For the in vitro release studies, cholinergic agonists and antagonists (pilocarpine and 
atropine) and two broad-spectrum antibacterial agents (chloramphenicol and norfloxacin) 
were selected for investigation (Fig. 3.6). Since prolonged retention with suppressed 
discomfort and minimal disruption of vision are critical requirements for ocular inserts, 
materials for further studies were selected from polymer networks that showed adhesive 
• properties that were coupled with limited swelling. For these materials, the release of each 
drug was monitored over time; at least five experiments were performed in each case, with 
results presented as averages. 
H3~ 
N * HCI H,c~ 
o 0 
'-':::l 
.00 
CI 
NH 
OH 
a) b) 
c) d) 
Fig. 3.6. Drug structures: a) pilocarpine hydrochloride; b) chloramphenicol; c) atropine 
sulphate; and, d) norfloxacin. 
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Fig. 3.7 (a, b). Chloramphenicol release profi les from: a) HEMA-containing hybrid 
polymeric networks; and, b) HEMA-containing interpolymeric complexes; (20 mg 
chloramphenicol in 70 mg of polymer; PBS, pH=7.4; 37°C; n.:xp ~ 5; means represented, 
standard deviations were < 12 %). 
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In general, materials based on HEMA and AA-modified chitosan released their 
chloramphenicol (CHF) content at a slower rate than those based on NIP AM, with some 
materials retaining a small amount of the active even after 24 h (Fig. 3.7). 
hpn(CSflNIPAML1, which showed the slowest release of chloramphenicol, was the 
exception. 
The release rates are seen to correlate well with the equilibrium degree of swelling 
(DSeq): materials with low DSeq (200-400%), and low k values (0.30-0.56 hOn) - i.e. 
hpn(CSflHEMAL1, hpn(CSflHEMAL3, hpn(CSflNIPAML1, ic(CSIPHEMAL3 - appear 
to be most suitable for applications demanding the slow release of chloramphenicol. 
Many of the interpolymeric complex wafers that were based on NIP AM 
[ic(CSIPNIP AM)] released their chloramphenicol content in less than 3 h but, interestingly, 
only about 50 % of the loaded drug was seen to be released from NIP AM-based materials 
that contained very low proportions of chitosan [hpn(CSflNIPAML1, ic(CSIPNIPAM) 1, 
ic(CSIPNIPAML2]; probably due to strong hydrogen bonding between this drug and 
PNIPAM. 
The capability of the materials to effect the controlled release of atropine sulphate, 
norfloxacin and pilocarpine hydochloride was also considered; the data are presented in Figs. 
3.8 and 3.9. The release of atropine sulphate - a water-soluble drug - was rapid; only 
HEMA-based interpolymeric matrices appeared to exert some influence over the release 
kinetics of this active. By contrast, norfloxacin exhibited prolonged release profiles 
(extending to over 48 h) with almost all materials considered. 
The compromise between the strength of the carrier-drug interactions and the 
solubility of the active is an important issue in drug release, as is exemplified by the 
behaviour of the water-soluble ionic compounds pilocarpine hydrochloride and atropine 
sulphate, both of which are associated with rapid release rates (Fig. 3.9). 
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~ 5; means repre ented, standard deviation were < 12 %). 
Drug release from hydrophilic matrices is influenced by protean contributions from 
the processes of swelling, diffusion and erosion [59-6]], and its assessment is complicated by 
the limitations of the in vitro evaluation procedure, as is highlighted by the release profiles 
presented in Figs. 3.8 and 3.9, some of which appear to indicate that more drug is released 
than is actually present in the formulation . 
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Drugs with low water solubility (chloramphenicol, norfloxacin; aqueous solubility < 
2.5 mg/ml at 25°C) exhibited prolonged release profiles when formulated into HEMA-based 
vehicles [e.g. hpn(CSflHEMAL3, ic(CSIPHEMAL 4]. 
Drug-polymer interactions, network porosity and degree of hydrophilicity of the 
matrix are also important factors influencing controlled release. Nonetheless, in accord with 
previous findings [62], high release rates were obtained with pilocarpine (Fig. 3.9) - a water-
soluble compound that does not possesses protons capable of participating in hydrogen 
bonding (Fig. 3.6). 
3.3.5. In vivo experiments 
The rabbit is widely regarded as the ocular model of choice prior to human trials [63]. 
The readily accessible New Zealand albino rabbit model was employed for our in vivo 
studies (two animals; 48 h rest periods between experiments). 
As a positive control, an aqueous solution of pilocarpine hydrochloride was also 
administered (50 Ill, containing 1.25 mg drug); drug-free minitablets (blank controls) -
confirmed that the pure hydro gels did not contribute to the observed miotic effect. The 
variation in pupillary diameter was monitored over time using a standard pupillary diameter 
gauge. For each material, the presented values are averages from at least six experiments. 
Statistical treatment of the results (ANOV A, two-factors with replication; 6 replicates; p < 
0.05) indicated a significant difference between some of materials [hpn(CSflHEMALI, 
hpn(CSflHEMAL3, ic(CSIPHEMAL3] and control solution, and a significant interaction 
between some of materials [hpn(CSflHEMALI, hpn(CSflHEMAL3, ic(CSIPHEMAL3] 
and time. 
All inserts tested induced a relatively rapid « 30 min) decrease in pupillary diameter, 
to a minimum value. This was followed by a much slower "pupillary diameter increase" 
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stage. The end of each experiment was signalled by the pupil returning to its original size 
(Fig. 3.10). 
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Fig. 3.10. In vivo, pilocarpine-induced miotic effect (control: aqueous pilocarpine solution-
1.25 mg pilocarpine) in rabbit; nexp 2: 6, bars represent standard errors. 
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In most cases, the inserts induced a more pronounced miotic effect than the eyedrop 
control, with the period of significant activity ((112) increasing by up to 57 % (Table 3.3). The 
effect of pilocarpine, as gauged by the AVC values, was more pronounced when this active 
was released from hybrid polymer networks than from interpolymeric complexes. Overall, 
HEMA-based materials performed better than their NIP AM-containing analogues, with 
hpn(CS£'HEMAL3 representing the most promising carrier vehicle. 
Table 3.3. In vivo evaluation ofthe pilocarpine-induced miotic effect in rabbits 
(data from Fig. 3.10). 
Materials MP{mm} tmax{min} tJldmin} teJfmin} AUC {mm xmin} 
bpn(CSfIHEMALl 2.1 15 220 390 413 
Control 1.7 30 140 300 244 
hpn(CSfIHEMAL3 2.3 10 200 390 463 
Control 1.8 30 135 300 244 
hpn(CSfINIP AMLI 1.8 15 110 360 278 
Control 1.7 30 140 270 231 
ic(CSIPHEMAL3 1.9 30 170 390 346 
Control 1.8 30 125 330 230 
ic(CSIPHEMAL 4 2.1 10 140 360 303 
Control 2.0 30 110 330 238 
MP - maximum pupillary response; tmax - time to reach MP; t1l2 - MP halftime; te/-
total duration of miotic effect; A UC - area under the miosis-time profile .. hpn - hybrid 
polymeric network; ic - interpolymeric complex. 
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3.4. Conclusions 
A number of hybrid polymer networks were prepared by the free-radical induced 
copolymerisation of acrylic acid-fun~tionalised low-molecular-weight chitosan with either 2-
hydroxyethyl methacrylate or N-isopropylacrylamide, and their potential to act as 
mucoadhesive drug-release devices was compared with that of interpolymeric complexes of 
similar composition. The materials exhibited a broad range of swelling and adhesion 
properties, which could be refined by altering the relative proportion of the compositional 
units. In vitro drug release studies involving broad-spectrum antibacterials (chloramphenicol, 
norfloxacin), cholinergics (pilocarpine) and anticholinergics (atropine) demonstrated that the 
materials under consideration are promising candidate vehicles for the delivery of sparingly 
water-soluble actives, particularly norfloxacin. In vivo experiments were complem~ntary in 
that they confirmed that the degree of swelling and hydrophilicity of the matrix are key 
factors governing the ability of these materials to act as controlled release vehicles for the 
ocular delivery of therapeutic agents. HEMA-containing hybrid polymer networks appear to 
be especially promising. 
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Chapter 4 - Nanoparticulate ophthalmic vehicles 
based on chitosan-crosslinked 
poly(vinylpyrrolidone-co-[ meth] acrylic acid)s 
4.1. Introduction 
Underpinned by the principle that well-defined polymeric structures often 
degrade/disintegrate in a controlled manner to release entrapped therapeutic agents, colloidal 
drug delivery systems (microparticles, liposomes or nanoparticles) represent an attractive 
means for improved drug delivery. Such systems may be appropriate hosts for poorly soluble 
drugs or as carriers for long acting injectable depot formulations and for specific drug 
targeting. Their drug-release kinetics are influenced by several factors, including: size, 
nature of the polymeric material, hydrophilicity of the drug, drug loading capacity, method of 
preparation, and rate of biodegradation. 
Amongst the nano-sized particles, nanospheres (matrix systems in which the drug is 
physically and uniformly dispersed) and nanocapsules (vesicular systems in which the drug 
is confined to a cavity surrounded by a unique polymer membrane) represent two drug 
delivery systems of considerable promise [1]. Such systems can be prepared from preformed 
polymers or directly from monomers through the use of appropriate polymerisation 
methodology. Techniques involving the polymerization of monomers may utilise the 
dispersed phase of an emulsion, an inverse microemulsion or a liquid medium that dissolves 
the monomer but acts as a non-solvent for the polymer. The properties and release 
characteristics of nanospheres and nanocapsules are often sensitive to their adopted method 
of preparation. 
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Table 4.1. Manufacturing techniques used for preparing nanopartic1es. 
Manufacturing process Reference 
Denaturation or Burgess et al. [2] 
crosslinking of 
-
macromolecules in 
emulsion form 
Interfacial polymerisation Duc-Mauger et al. [31 
Formation in an aerosol Przyborowski et al. [4] 
phase 
Desolvation Zimmer et al. [5] 
Aggregation by pH Taplin et al. [6] 
adjustment and heat 
treatment 
Formation ofnanopartic1es Dechow et al. [7] 
via microemulsions 
Starting from preformed polymers, nanopartic1es may be prepared by the 
precipitation of synthetic polymers, or by denaturation or gelation of natural macromolecules 
(Table 4.1): Common approaches employ the emulsification of a water-immiscible organic 
solution of the polymer in a surfactant-containing aqueous phase, followed by solvent 
evaporation, or by precipitation after the addition of a non-solvent [8]. 
The next sections present a short review of the nanoparticulate systems considered so 
far for drug delivery applications, with examples of polymers and surfactants used In 
ophthalmic nano-fo~ulations; a special attention is paid to biodegradable materials. 
Synthesis and characterisation of nanopartic1es consisting of poly(vinylpyrrolidinone-
co-methacrylic acid) linear chains that are crosslinked via biodegradable short 
polysaccharidic units, and their in vitro and in vivo pilocarpine release behaviour, are 
described next. Also, preliminary studies of the potential transport of the nanopartic1es 
through rabbit cornea using 14C-radiolabelled congeners are presented. 
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4.1.1 Nanoparticles as drug delivery vehicles 
Several studies have shown that, even under conditions of rapid corneal clearance, 
nanoparticles can facilitate increased drug bioavailability and decreased systemic side effects 
[9]. The advantages of nanoparticulate drug delivery originate from two of their features. 
Firstly, because of their small size, nanoparticles penetrate small capillaries and are taken up 
by cells, allowing efficient drug accumulation at the target sites. Secondly, the use of 
biodegradable materials for nanoparticle preparation allows sustained drug release within the 
target site over a period of days or even weeks [9]. Thus, nanoparticles provide an effective 
drug delivery mechanism for drugs whose targets are cytoplasmic [10]. 
The development of nanoparticulate de1iv~ry systems for targeted drug delivery has 
been reviewed by Moghimi et al. [11]. Targeted delivery can be achieved by either active or 
passive targeting: active targeting of a therapeutic agent is achieved by conjugating the 
therapeutic agent or the carrier system to a tissue or cell-specific ligand. Passive targeting 
involves the coupling of the therapeutic agent to a macromolecule that passively reaches the 
target organ. Therapeutic agents encapsulated in nanoparticles or drugs coupled to 
macromolecules address the target tissue through an enhanced permeation and retention 
effect. An alternative approach involves the infusion of nanoparticle suspension to an 
accessible target organ or tissue using catheters. Also, localized delivery of nanoparticles in 
restenosis may prove a useful strategy. 
Nanoparticles are also useful for the delivery of pharmaceutical agents by binding to 
target cellular epitopes through a 'contact facilitated drug delivery' mechanism. Binding and 
close apposition to the targeted cell membrane permits enhanced lipid-lipid exchange with 
the lipid monolayer of the nanoparticle, which accelerates the convective flux of lipophilic 
drugs (e.g. paclitaxel), dissolved in the outer lipid membrane of the nanoparticles, into the 
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targeted cells. Such nanosystems can serve as drug reservoirs, exhibiting prolonged release 
kinetics and long persistence at the site. 
Another characteristic function of nanoparticles is their capability to transport drugs 
across several biological barriers. Delivery to the brain of a wide variety of drugs, such as 
antineoplastics and anti-HIV drugs is markedly hindered by the blood-brain barrier (the 
primary barrier to the passage of compounds from the blood to the brain, represented mainly 
by the brain capillary endothelial cells). The ap~lication of nanoparticles to brain delivery is 
a promising way of overcoming this barrier: it has been demonstrated that 
poly(butylcyanoacrylate) nanoparticles coated with polysorbate 80 are effective in 
transporting the hexapeptide dalargin and other agents into the brain [12]. 
A combination ofmucoadhesive polymers and nanoparticles may provide a means for 
prolonging residence time at the precorneal area. Endocytosis through the corneal epithelium 
depends on the particle size and size distribution of the particles: nanoparticles have been 
found in corneal cells, but the presence of micro spheres has not been reported [13]. 
. Thermo- and pH-responsive, and biodegradable nanoparticles comprised ofpolY(D,L-
lactide)-graft-poly(N-isopropylacrylamide-co-methacrylic acid) have been developed by 
grafting biodegradable poly(D,L-lactide) onto N-isopropylacrylamide and methacrylic acid. A 
core-shell type nano-structure was formed with a hydrophilic outer shell and a hydrophobic 
inner core, which exhibited a physiologically relevant phase transition temperature above 37 
°e. The drug loading level of 5-fluorouracil (5-FU) encapsulated in the POlY(D,L-lactide)-
graft_poly(N_isopropylacrylamide-co-methacrylic acid nanoparticles was as high as 20% and 
its release was strongly controlled by the pH of the medium [14]. Graziacascone et al. [15] 
published a comparative study on the encapsulation of lipophilic drugs in POlY(D,L-
lactic/glycolic acid) nanoparticles and the entrapment the particles in polyvinyl alcohol 
hydro gels. Release rates from hydro gels loaded with the particles were comparable with 
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delivery rates from poly(D,L-lactic/glycolic acid) particles, implying that particle SIze 
controls the release rates. 
Ophthalmic use of a dispersed system of nanoparticles may help overcome the 
problems of rapid elimination after instillation and low bioavailability associated with topical 
eye drops, due to the defence mechanisms of the eye (i.e. reflex blinking, lachrymation and 
an increased tear flow), and the barrier function and low pain threshold of the cornea [16,17]. 
To be effective, the particles must be retained, in the ocular cul-de-sac, and the entrapped 
drug must be released from the particles at an appropriate rate. If the drug leaks out of the 
particles too fast, then there will be little sustained drug release. If release is too slow, the 
concentration of the drug in the tears may be too low to allow adequate drug penetration into 
ocular tissues. To enhance particle retention in the ocular cul-de-sac it is desirable to 
fabricate the particles from bioadhesive materials. In all cases, one key requirement is that 
the formulation must be capable of being sterilised. 
4.1.2 Polymers and surfactants used in nanoparticulate ophthalmic 
formulations 
The use of various biodegradable polymeric particles has been investigated (Table 
4.2). Among these, poly(D,L-lactic/glycolic acid) and POlY(D,L-lactic acid) , whose 
degradation rate depends on average molecular weight and conformation, are 
pharmaceutically accepted materials [18]. Consequently, POlY(D,L-lactic/glycolic acid) / 
poly(D,L-lactic acid)-nanoparticles offer considerable promise as vehicles for specific 
targeting and sustained delivery [19,20]. 
When surfactant is used, its preferential adsorption at the surface of the particle 
allows the modification of the physico-chemical properties at the interface. While the 
surfactant concentration of emulsions is typically of the order of 0.1 %w/w, in 
microemulsions it accounts for at least 10 %w/w of the total content due to the much greater 
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interfacial area between the aqueous and oily phases. However, such high concentrations of 
surfactants can impact on ocular toxicity. Since ionic surfactants are generally too toxic for 
use in such applications, non-ionic surface active agents (poloxamers, polysorbates, 
polyethylene glycol, tyloxapol) are generally preferred [40, 41]. 
Table 4.2. Nano- and microparticulate carriers for ophthalmic use. 
Polymer Drug Reference 
Po I y(butyl )cynoacrylate amikacin Alonso et al. [21] . 
Poly( epsilon)caprolactone betaxolol Marchal-Heussler [22] 
Poly(isobutyl)cynoacrylate et al. 
Polylactic-co-glycolic acid 
Poly( epsilon)caprolactone carteolol Maincent et al. [23] 
Polylactic acid chloramphenicol Shell et al. [24] 
Albumin hydrocortisone Zimmer et al. [25] 
Poly( epsilon)caprolactone indomethacin Mason et al. [26] 
Albumin pilocarpine Zimmer et al. [5] 
Cellulose acetate hydrogen Boye et al. [27] 
phtalate Gumyetal. [28] 
Gelatine Leucuta et al. [29] 
Poly(butyl)cyanoacrylate Harmia et al. [30,34] 
Poly(hexyl)cyanoacrylate Kreuter et al. [31] 
Polylactic acid Vidmar et al. [32] 
Poly(methyl)methacrylate- Andermann et al. [33] 
acrylic acid copolymer 
Po I y( methyl )methacrylate Harmia et al. [34] 
Polyamide Evans et al. [35] 
Polyphthalamide Beal et al. [36] 
Poly(hexyl)cyanoacrylate progesterone Kreuter et al. [37] 
Poly(butyl)cyanoacrylate Li et al. . [38] 
Poly( alkyl)cyanoacrylate timolol Harmia et al. [39] 
Sorbitan fatty acid esters (Spans) and polyoxyethylene sorbitan fatty acid esters 
(Tweens) have found many pharmaceutical applications. They are often used to improve the 
stability of water-in-oiI-in-water (W/O/W) multiple emulsions, which are potentially useful 
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vehicles for encapsulating water-soluble pharmaceutical compounds or nutrients. Multiple 
emulsion systems usually require at least two surfactants: a relatively hydrophobic surfactant 
to stabilize the WIO emulsions and a relatively hydrophilic surfactant to stabilize the OIW 
emulsions. Combined Spans and Tweens work well for this purpose, even though the 
individual surfactants do not produce stable multiple emulsion systems. 
Surfactants stabilize emulsions by lowering the interfacial tension and by facilitating 
the formation of electrical or mechanical barrie!s. When a rigid interfacial complex forms at 
the primary W-O interface, emulsion stability is enhanced. Improved stability can also be 
achieved by maximizing the interfacial strength [42]. 
Due to their low toxicity, amphoteric surfactants, e.g. lecithin, are also of interest. 
However, the chemical nature of such compounds is highly variable depending on their 
origins, purity (variation of fatty acids content), composition and concentration of 
phospholipids. For example, lecithin from egg yolk contains 21 % of phosphatidy1choline, 22 
% of phosphatidylethanolamine and 19 % of phosphatidylinositol. 
Miranol MHT® (an aqueous solution containing 3.4 %w/w of NaCI and 34.5 %w/w 
of lauroamphodiacetate), is another amphoteric surfactant that is tolerated well by the eye 
[43]. 
4.1.3 Biodegradable polymers for drug delivery to the eye 
Polymer biodegradation is a process in which a deterioration in the properties of a 
material takes place due to factors such as temperature, light, radiation, presence of enzymes 
etc. Although they may arouse some immune response, biodegradable materials are 
important for many biomedical applications, including wound healing, tissue reconstruction 
and controlled drug delivery. Their main advantage is that it is often possible to control their 
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degradation rate, which, in tum, impacts upon the length of time over which the material can 
remain in contact with living tissue [44]. 
Williams, who defined biodegradation as a biological cleavage of the polymeric 
structure, proposed three types of mechanism that lead to dissolution by erosion [45]: 
1- erosion of (water-soluble) polymers that are made initially insoluble via crosslinking 
with hydrolytically unstable crosslinks (type-I); 
2- erosion of linear polymers, which are ,initially water insoluble and which become 
solubilized by hydrolysis, ionization or protonation of a pendant group, but without 
backbone cleavage ( type-2); and, 
3- erosion of polymers that are water insoluble and hydrolyse to small soluble molecules 
by backbone cleavage ( type-3); 
Erosion does not necessarily yield ,molecules of a sufficiently small size to be 
eliminated from the body, and currently there is no universal agreement as to the use of the 
terms "bioerodible" and "biodegradable". 
Erosion of polymers does not necessarily proceed by a single mechanism. Generally, 
systems in an aqueous biological environment undergo erosion through hydrolysis. The 
presence of enzymes often significantly enhances the rate of erosion [46-48]. 
polymers susceptible to type-l erosion e.g. gelatin, collagen, polyacrylamides, 
poly(vinylalcohol) and poly(vinylpyrrolidone) are normally water soluble materials that have 
been rendered insoluble by crosslinking. Such materials are considered unsuitable hosts for 
water soluble, low molecular weight species [49], but useful for the release of sparingly 
water-soluble actives (chloramphenicol, hydrocortisone acetate) [50] or water-soluble 
macromolecules such as enzymes, proteins and antigens [51-53], which can be immobilized 
in the hydrophilic matrix by physical entanglement. 
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In type-2 erosion no significant change to the molecular weight of the polymer takes 
place. Unless the erosion process produces water-soluble materials with molecular weights 
below that of the renal threshold (the concentration of a substance dissolved in the blood 
above which the kidneys begin to remove it into the urine), such materials cannot be 
employed in biomedical applications. Heller and coworkers [49] demonstrated, using rabbits, 
the usefulness of poly(vinylmethylether/maleic anhydride) disks containing hydrocortisone 
as an ophthalmic delivery system: zero-order r~lease of hydrocortisone was achieved. Trials 
with pilocarpine, a highly water soluble substance, were carried out by Urtti and coworkers 
[54, 55]: by increasing the size of the alkyl ester moiety, the hydrophobicity of the polymeric 
matrix was controlled and a constant release of pilocarpine was achieved. The erosion of 
poly(vinylmethylether/maleic anhydride) occurs via the ionisation of carboxylic acid 
functionalities, which generates hydrogen ions and causes a localised decrease in pH at the 
surface of the matrix [56]. 
Type 3 erosion leads to the formation of small, soluble molecules, resulting from the 
cleavage of the polymeric chains. As small molecules can be eliminated easily from the 
body, this mechanism conforms with the definition of biodegradability proposed by Graham 
and Wood [57]. Provided that degradation products are not toxic, polymers undergoing type 
3 erosion are particularly well suited as carriers for the systemic administration of active 
agents. Such biodegradable systems have several advantages over conventional ophthalmic 
delivery systems in that they can be applied directly to the surface of the eye or can be used 
as intraocular implants. The early use ofpoly(cyanoacrylate)s as tissue adhesives in surgical 
procedures and in the treatment of corneal perforations has now been extended to their use as 
drug-carrier nanoparticles [58]. A major advantage ofpoly(alkylcyanoacrylate) nanoparticles 
is their biodegradability [59], which occurs via surface erosion through enzymatic hydrolysis. 
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Poly(lactic acid), poly(glycolic acid) and their copolymers are biodegradable, by 
hydrolysis to release lactic and glycolic acids, which are. eliminated from the body via the 
Krebb's cycle [47, 60]. The biodegradation of these· polymers is influenced by the 
configuration of the lactic acid used, and by the proportion of lactic and glycolic acid in the 
copolymer. Moritera and coworkers [61] prepared - by solvent evaporation - poly(D,L-lactic 
acid) and POlY(D,L-lactic/glycolic acid) micro spheres (diameter = 50 /lm), which were 
loaded with 5-fluorouracil (an agent used for inhibiting cellular proliferation in 
vitreoretinopathies). When the micro spheres were injected into rabbit eyes, a release of 5-
Fluorouracil over 2-7 days was achieved, depending on the polymer used and its molecular 
weight. Kimura et al. [62] used poly(D,L-lactic acid) micro spheres loaded with adriamycin to 
prevent proliferation of fibroblasts after glaucoma-filtering surgery. After a subconjunctival 
injection, release of the antimetabolite, extending over a period of 20 days, effected a 
decrease in intraocular pressure between the 6th and the 16th day after injection, and 
maintained the filtration bleb for 15 days. Khoobehi and coworkers [63] studied the release 
of fluorescein sodium salt from poly(D,L-lactic acid) and POlY(D,L-lactic/glycolic acid). 
microspheres and examined the kinetics of the process following SUbconjunctival and 
intravitreous injections. Topical applications of poly(D,L-lactic acid) nanoparticles loaded 
with indomethacin [26] and topical application of POlY(D,L-lactic/glycolic acid) 
nanoparticles loaded with betaxolol have also been described [22]. In both cases, the 
observed increase in ocular bioavailability was explained in terms of the accumulation of 
nanoparticles in the conjunctival cul-de-sac. 
Unlike certain polY(D,L-lactic acid) and POlY(D,L-lactic/glycolic acid) polymers, 
poly(y-caprolactone) hydrolyses at very low rates. This slow hydrolysis has been utilised in 
the development of the contraceptive implant capronor [64]. Hydrolysis produces y-
hydroxycaproic acid by cleavage of the polymeric chains at the ester linkage. This random 
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cleavage of the polymeric chains leads initially to a decrease of molecular weight, without 
significant weight loss, but when M n reaches about 5000, small polymeric fragments begin 
to diffuse from the matrix. These fragment further and undergo phagocytosis [65]. Another 
study showed that poly(y-caprolactone) nanoparticles loaded with betaxolol base are more 
effective for intra ocular pressure control than nanoparticles loaded with betaxolol 
hydrochloride [22]. This enhanced effect has been explained in terms of the efficient 
agglomeration of poly(y-caprolactone) nanoparticles in the conjunctival cul-de-sac and the 
use of the active principle in its basic form. 
Heterogeneous erosion from the surface accompanied by near zero order degradation 
kinetics has been observed with polyanhydrides composed of hydrophobic backbones that 
incorporate alternating hydrophilic anhydride linkages. Polyanhydrides seem to be promising 
biocompatible materials for medical applications: neither the polymers nor their breakdown 
products provoked inflammatory responses to the cornea of rabbits over six weeks. Carriers 
of 1,3-bis(p-carboxyphenoxy) hexane copolymerised with sebacic acid are also reported to 
be useful for the controlled delivery of antimetabolites after glaucoma filtering surgery [66]. 
While polyesters such as those of lactic acid and glycolic acid are hydrophilic and 
hydrolytically biodegradable polymers, poly(ortho esters) are hydrophobic polymers, which 
under certain conditions can undergo a heterogeneous erosion process confined at the 
polymer-water interface. Because all poly(oxyethylene)s contain pH-sensitive linkages in 
their backbone, they are stable in alkaline media but susceptible to acid-catalysed hydrolysis. 
The erosion rate can be controlled by the incorporation of acidic or basic excipients into the 
polymer [67]. Because of promising biocompatibility, the semi-solid poly(oxyethylene) is 
considered to be a useful injectable bioerodible polymer for the controlled release of 5-
fluorouracil and mitomycin C in glaucoma filtering surgery [66]. 
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Polysaccharides represent a rich source ofbiocompatible gels that are widely used, in 
their natural structure or as semi-synthetic derivatives, in ophthalmic preparations. Most of 
these materials are water soluble, a property that can be controlled by the degree of 
crosslinking. Since the first use of methylcellulose in ophthalmic preparations (in the 1940s) 
its use has span eye drops, artificial tears, contact lens solutions and inserts. Higher 
concentrations of cellulose generally increase the bioavailability of a drug, but negative 
effects, such as irritation, are also increased. Nonetheless, hydroxyethyl cellulose is reported 
to show generally better tolerability than hydroxy propyl methyl cellulose or hydroxy propyl 
cellulose [66]. 
Hyaluronic acid has several uses in ophthalmology. Beside topical ocular drug 
delivery, it has been used as a tear substitute in the treatment of dry eye, for protecting the 
corneal endothelial cells during intraocular surgery and as a replacement for vitreous humour 
in humans. Owing to its mucoadhesive properties, hyaluronic acid increases the precorneal 
residence time and may also have a bioavailability enhancing effect [66]. 
Chondroitin sulfate is a polysaccharide that is comparable to hyaluronic acid in terms. 
of its viscoelasticity or its capacity to protect corneal endothelium. However, unlike 
hyaluronic acid, which is a highly viscous non-Newtonian fluid, chondroitin sulfate has low 
viscosity and displays Newtonian behaviour. Chondroitin sulphate-containing preparations 
. have been investigated for the treatment of dry eyes: isotonic saline solutions containing 1 % 
chondroitin sulfate are well tolerated. A proposed use of Chondroitin sulfate as a viscous 
agent in anterior segment surgery has proved unsatisfactory as it causes a temporary increase 
in intraocular pressure and is characterised by a high elimination rate [66]. 
Due to its mucoadhesive nature, permeability enhancing properties and 
biodegradability by lysozyme, chitosan represents another potentially useful polymer for the 
formulation of micro- and nanopartic1es, [68, 69]. Chitosan micro- or nanopartic1es are 
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reported to have a higher precorneal retention than chitosan solutions, and depending on size, 
such particles may enter the corneal epithelium by paracellular or transcellular pathways. 
Various epithelial cells show different affinity for the molecule, as is exemplified by the 
relative distribution of chitosan nanoparticles in the conjunctiva and the cornea [70]. The 
retention of chitosan micro spheres at the eye surface may be partly explained by their 
mucoadhesive properties. 
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Fig. 4.1. Structure of chitosan 
The biodegradation of the polymer is mediated by the hydrolytic actions of lysozyme 
and other enzymes and results in the fonnation of oligomers and monomers. The rate of 
degradation depends on the degree of acetylation in the chitosan molecule (Fig. 4.1),. 
suggesting that modulation of the sustained release of the drug may be possible. De Campos 
et al. [71] evaluated the potential of cyclosporin-Ioaded chitosan microspheres in rabbits and 
concluded that the system has the capability to contact intimately the corneaVconjunctival 
'epithelium. This increases delivery to external ocular tissues without compromising inner 
ocular structures and with minimum systemic drug exposure, and provides these target 
tissues with long-tenn drug levels. Similarly, Genta et al. [72] obtained a 4x increase, 
compared with an aqueous suspension in the aqueous humour concentration of acyclovir 
after a single instillation (rabbit eye) of acyclovir-loaded chitosan microspheres. No sign of 
eye inflammation or discomfort was observed in the rabbits after administration of the 
microspheres. 
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Considerable research activity has been focused on the chemical modification of 
chitin and chitosan. Graft copolymerization with various vinyl monomers may be carried out 
with several initiator systems [73]. Because of its regular structure and the strong 
intermolecular and intramolecular hydrogen bonds, the properties of grafted chitosan can be 
refined to a limited extent. It has been shown that chitosan can be bestowed with improved 
water solubility and enhanced antibacterial and antioxidant properties by primary 
derivatisation and graft modification, but ther~ are very few reports concerning the graft 
copolymerization of chitosan derivatives [73]. 
Several enzymes including chitinases, chitosanases and lysozyme can effect the 
degradation of chitosan. In vivo degradability by lysozyme - which is found ubiquitously in 
the human body (4-13 mg/l in serum and 450-1230 mg/l in tears) [74, 75] - makes chitosan 
extremely useful to pharmacy and medicine. The action of this enzyme is dependent on 
factors such as pH, the type of chitin or chitosan, and the preparation method. Davies et al. 
[76] established that chitosan is most susceptible to lysozyme hydrolysis at pH values 
ranging between pH 5.2 and 8.0, with an optimum in the acidic range [76, 77]. The natural. 
substrate for lysozyme is the p (1 ~4) glycosidic linkage, which is found in the negatively 
charged polysaccharides backbone of certain bacterial cell walls. 
Pangburn et al. [78] studied the effect of de acetylation on the susceptibilities of chitin 
and chitosan to lysozyme and concluded that pure chitin (0% deacetylation) is most 
susceptible to lysozyme, while pure chitosan (100% deacetylation) cannot be degraded by 
this enzyme. In 1990, Sashiwa et al. [79] studied the relative rates of degradation of six 
chitosans with varying degrees of deacetylation (45%,66%, 70%, 84%, 91 %, and 95%), and 
found that 70% deacetylated chitosan degraded most readily. 
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4.2. Experimental 
4.2.1. Materials and equipment 
I-Vinylpyrrolidin-2-one (VP; Sigma-Aldrich) was purified by vacuum distillation; 
methacrylic acid (MA) was passed through an inhibitor removal column (HQ, Sigma-
Aldrich). Solvents (Fischer) and other chemicals [i.e. N-hydroxysuccinimide (NBS); 1-(3-
dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDAC), chitosan oligosaccharide 
lactate, the polymerisation initiator 4,4' -azobis( 4-cyanovaleric acid) (ACV A; Sigma-Aldrich) 
and the model drug pilocarpine (Fluka)] were used as received. Phosphate buffer solutions 
(PBS, pH = 7.4, ionic strength 0.497 M) were prepared as described above (section 2.2.1). 
The size of the nanoparticles was determined using a Coulter N4 MD sub micron particle 
size analyser. 
The efficiency of the adhesion of polymer minitablets onto hydrated dialysis tubing 
membrane (cellulose, Visking DTV14000) was evaluated in phosphate buffer solution 
(pH=7.4) using a Stable Microsystem TAXT Plus Analyzer. The maximum detachment force 
(MDF) and the corresponding work of adhesion (TWA) were determined at 20°C; pure 
chitosan oligosaccharide lactate (CSo) was used as a control. 
4.2.2 Synthesis and characterisation of materials 
Synthesis of linear poly(vinylpyrro/idone-co-methacry/ic acid) copolymers 
A Parallel Synthesis Kit (Bilchi Syncor) was used for the preparation of the linear 
cp(VP/MA) copolymers. To aqueous solutions of co-monomers (20 ml; 16.6 %w/w) 
combined in different VP:MA ratios (see Table 4.3) - ACV A was added (1 %w/w) and 
solutions were stirred under N2 at SO °C, for Sh. The polymers were freeze-dried, finely 
ground, purified by Soxhlet extraction (THF, 6 h), and finally dried in vacuum (40 'C). 
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Table 4.3. Feed ratios (w/w) used for the synthesis ofpoly(vinylpyrrolidone-co-
methacrylic acid) linear copolymers, cp(VPIMA), and ofpoly(methacrylic acid), PMA. 
Material VP MA 
PMA 0 100 
cp(VPIMALI 50 50 
cp(VPIMAL2 60 40 
cp(VPIMA)_3 80 20 
cp(VPIMA) 4 95 05 
Gel permeation chromatography (GPC) was carried out using an Agilent liquid 
chromatography system (Plaquagel OH 40 8 micrometer column) operating at 40°C and 
equipped with a refractive index detector. The mobile phase (flow rate = 1 mllmin) was 10 
mmol of phosphate buffer (PH 7.4) and 100 mmol of sodium nitrate. The column was 
equilibrated for 3.5 h before starting the experiment. Calibration was achieved using a series 
of polyethylene glycol/polyethylene oxide standards (Mp 500-5,00,000) at a concentration of 
1 gil (injection volume = 100 Ill). The samples were weighed and dissolved in buffer (pH 
7.4), and then 5 III of DMSO (for end of test confirmation) was added in 20 ml of sample 
solution. The solution was then filtered and injected (100 Ill) into the column. 
Infrared spectroscopy (FTIR; KBr discs, Unicam RS 1 spectrophotometer, 4 cm-I) 
was used as a means of assessing the ratio of the co-monomers within the copolymer 
structure, by measuring the change in the intensity of the C=O stretching and N-H bending 
vibrations across the series. An accurate determination of the ratio of the co-monomers 
within the final product was performed by recording the IH_ and I3e NMR spectra of 
poly(vinylpyrrolidone-co-methacrylic acid) linear copolymers in D20, using a JEOL 
spectrometer (operating at 400.13 MHz for IH). 
As the hydrophilicitylhydrophobicity balance affects both the adhesive and drug 
release properties of a material, contact angle goniometry was used as an easily accessible 
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means of assessing the relative hydrophilicity of the linear copolymers. For copolymers 
prepared by solution polymerisation, a 3 %w/w solution was prepared and filtered through a 
0.2 Jlm poly(tetrafluoroethylene) filter in order to remove any particulate material. The films 
were deposited onto poly(methyl methacrylate) substrates by dipping (using a constant speed 
motor, operating at a dipping speed of 10 mm/sec and a raising speed of 1 mm/s), and then 
dried at 37°C for 24 h. The contact angles of the polymers and controls were determined by 
sessile drop contact angle goniometry in a thermostated cell (20°C) using a Kruss G 10 
goniometer interfaced with a video capture apparatus. The contact angles were acquired 
within 15 s of dispensing a 2 JlI volume liquid drop, using double distilled water (Aldrich, 
UK). 
General method for the synthesis of hydrogel networks based on 
poly(vinylpyrrolidone-co-methacrylic acid) copolymers crosslinked via chitosan 
oligosaccharide 
Linear poly(vinylpyrrolidone-co-methacrylic acid) copolymers [cp(VP:MA); prepared 
cf Table 4.3] were dissolved with stirring (2 h) in phosphate buffer (pH 7.4). 1-(3-
Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDAC) and N-
hydroxysuccinimide (NHS) were added in different proportions (the volume of PBS and the 
mass of reagents are given in Tables 4.8 and 4.9), and the reaction mixture was then left 
stirring for 1 h. The appropriate amount of chitosan oligosaccharide (eSo; cf Tables 4.8 and 
4.9) was dissolved in phosphate buffer (pH 7.4) and added drop wise to the reaction mixture, 
which was left overnight with stirring. The reaction mixture was then centrifuged (5000 rpm, 
10 min), the solid was washed twice with phosphate buffer (pH 7.4) and the product was 
freeze-dried. 
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Synthesis of nanoge/s based on po/y(viny/pyrrolidone-co-methacrylic acid) 
crosslinked with chitosan oligosaccharide 
Linear poly(vinylpyrrolidone-co-methacrylic acid) copolymer (cp(VPIMALI; 0.5 g) 
was dissolved in PBS (PH 7.4; 50 ml) with stirring (2 h). The solution was filtered, and the 
appropriate amounts (cf Table 4.11) of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide 
hydrochloride (EDAC) followed by N-hydroxysuccinimide (NHS) were added. The reaction 
mixture was allowed to stir for 30 min before a mixture of surfactants (Tween 80 - 15 ml, 
and Span 80 - 35 ml, dissolved in petroleum ether, boiling fraction 40-60 °C - 300 ml) was 
added with vigorous stirring. After 30 min, a solution of chitosan oligosaccharide (prepared 
according to Table 4.11 - in PBS, 2 ml; pH 7.4) was added dropwise, and the emulsion was 
stirred overnight. Petroleum ether was removed by rotary evaporation, and the surfactants 
and reaction by-products were extracted with dichloromethane (2x). The aqueous layer was 
centrifuged (20,000 rpm; 40 min) and the nanogel was freeze-dried. 
The particle size was determined at room temperature, using a Coulter N4 MD 
particle size analyser; for measurements, nanoparticles (O.lg) were dispersed in distilled· 
,water (60 ml). 
The swelling properties at pH values of 5.0, 7.4 (physiological) and 9.0 (37°C) were 
determined volumetrically (20 mg polymeric powder + 0.5ml of buffer in a micro syringe) 
with at least three measurements for each value of the equilibrium degree of swelling - DSeq 
(%). 
v -v DS = eq 0 X 100 
eq 
vo 
where Va and Veq are respectively the initial and equilibrium sample volumes. 
The efficiency of adhesion was evaluated on wafers prepared from dry, thoroughly 
ground, materials (30 mg; 2 tonne, 1 min; 0 8 mm) in phosphate buffer solution (PH = 7.4) 
using a Stable Microsystem T AXT Plus Analyzer (operating parameters as in section 2.2.2.) 
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with a test surface of hydrated dialysis tubing membrane (cellulose, Visking DTVI4000). 
Maximum detachment force (MDF) and the corresponding work of adhesion (TWA) were 
determined at room temperature; pure homopolymer (chitosan oligosaccharide lactate) was 
used as control. 
4.2.3 In vitro drug release studies 
Drug loading. The polymeric powder (100 mg) was added to a concentrated solution 
of pilocarpine hydrochloride (5 ml; 50 %w/w) , the mixture was sonicated for 30 min, and 
then stirred vigorously for 24 h. The loaded nanopartic1es were separated by centrifugation 
(20,000 rpm; 1 h) and freeze-dried. The drug loading capacity was determined by re-
suspending the dry polymeric powder (100 mg) in a closed conical flask containing 
phosphate buffer (pH 7.4; 25 ml) and applying continuous stirring: sampling of the 
supernatant at regular time intervals (up to 96 h, to ensure the complete release of the drug; 
the sample volume was replenished with fresh phosphate buffer) allowed the 
spectrophotometric (215 nm) determination of the released pilocarpine; blank experiments· 
(no drug) confirmed that the polymeric suspension did not absorb significantly in UV. 
Drug release. Each in vitro controlled-release experiment was performed on a drug-
loaded nanoparticle suspension (100 mg of drug-loaded (10 %) polymeric powder -
suspended in 5 ml oi'phosphate buffer, pH 7.4), prepared and sealed (at the start) in a dialysis 
membrane. In vitro release profiles under sink conditions (phosphate buffer, pH 7.4; 37°C) 
were performed spectrophotometrically (215 nm for pilocarpine) using a dissolution 
apparatus (Copley DT-70, Erweka Instruments; 500 ml; U.S.P. II apparatus; 25 rpm). At the 
beginning of each experiment, dialysis bags were introduced (dropped in) at the bottom of 
the dissolution baths, then the drug release was followed spectrophotometric ally, as 
described above (section 2.2.3). 
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4.2.4 Biodegradation study 
Biodegradability was studied on polymeric wafers (30 mg; 2 tonne, 1 min); each 
specimen was introduced into a flask (34°C, thermostated shaker bath) containing PBS (25 
ml; pH 7.4) and lysozyme (30 mg; Sigma-Aldrich). Samples (2 ml) were taken after 20, 24, 
48, and 120 h. Filtered aliquots (1 ml) were cooled in ice (5 min) and mixed with an alkaline 
potassium ferricyanide solution (4 ml; prepared from 0.25 g complex salt dissolved in 
sodium carbonate: 0.5 M, 500 ml). The mixture was placed in a test tube, capped with 
aluminium foil and incubated in boiling water (100 °C, 15 min). Following rapid cooling 
(within 5 min) to 25°C, its optical absorbance was recorded (420 nm, reference: deionised 
water). 
4.2.5 In vivo drug release studies 
Drug loaded nanoparticles (125 mg; 10 %w/w pilocarpine hydrochloride) were 
dispersed in PBS (pH 7.4; 0.5 ml) and administered to rabbits' eyes (male albino New 
Zealand, 4.0 - 4.5 kg) by instillation into the lower cul-de-sac (2 drops; 50 Ill; equivalent of 
1.25 mg pilocarpine hydrochloride). The induced miotic effect was monitored, until 
disappearance, by timed measurements of the pupillary diameter. Corresponding amounts of 
aqueous pilocarpine hydrochloride (1.25 mg in 50 Ill) were administered dropwise to provide 
the active control. In separate experiments, nanoparticle suspension without loaded drug 
provided the blank controls. 
Procedures were approved by the Ethical Review Committee at the University of 
Portsmouth, and all studies were performed in accordance with Home Office regulations for 
the care and use of laboratory animals. 
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4.2.6 Corneal tissue penetration by 14C-radiolabelled nanogels 
Radiolabelled nanoparticles np(CSo/cp(VPIMA))* were prepared according to the 
method described in section 4.2.3, but 14C-acrylic acid was used instead of normal 
methacrylic acid (reagents' molar ratios are presented in Table 4.11). 14C-acrylic acid was 
prepared from commercial 14C-malonic acid following a published procedure [80]: a mixture 
of 14C-malonic acid (0.47 mg, 4.51 mmol, 9.25 MBq) and anhydrous malonic acid (~.079 g, 
0.02 mmol) in dry pyridine (8 ml) was refluxed for 2 hours, and concentrated aqueous 
sulphuric acid was added dropwise to neutralize the cooled (ice bath) reaction mixture. 
Addition of water (40 ml) dissolved the precipitate that had formed, and the resulting 
solution was extracted with diethyl ether (3 x 40 ml). The combined ether extracts were dried 
over magnesium sulphate and after evaporation of the solvent gave the product (colourless 
oil, 596 mg), which was mixed with acrylic acid (80.00 g) and stored at -8°C (in separate 
batches) until use. 
The activity of the 14C-nanoparticles was verified by dissolving samples (100 mg) in 
sodium hydroxide (1 M; 1 ml), mixing with scintillation cocktail (Ultima Gold-High Flash· 
Point LSC, Perkin Elemer US) and determining their activity using a 1900 TR Packard 
Bioscience Liquid scintillation counter (LSC). 
Rabbit eyes were excised from adult albino rabbits and mounted onto Franz cells 
(Fig. 4.2). The corneal tissue was exposed to physiological saline at 37.5 °C for 5 minutes, to 
equilibrate and become wetted. A sample of nanosuspension containing 14C-radiolabelled 
nanogels was placed onto the corneal tissue of each eye, and samples (0.5 ml) from the 
receptor chamber were taken at 15 min intervals for one hour, and then every hour over a 24-
hour period. To evaluate the degree of penetration into the corneal tissue, samples were 
analysed by LSC. Aliquots (0.5 ml) of saline (0.9 %w/w NaCI) were used as blank controls 
in the LSC measurements. 
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At the end of the experiment, the corneal tissue was digested (24 h) in aqueous 
sodium hydroxide (1 M; 1 ml), mixed with scintillation cocktail (3 ml) and analysed by LSC 
to enumerate radioactivity within the corneal tissue, as a measure of nanoparticle retention. 
Fig. 4.2. Franz cell (manufactured by Permegear Inc. , Bethlehem, P A 18015 USA) 
In order to assess the probability of nanoparticles penetrating through the rabbit's 
cornea, as well as the degree of retention of nanopartcles to the ocular surface, the results 
were compared against those obtained for a crosslinked 14C-radiolabelled copolymer with a 
related composition (cp(VP/AA)M_l *), which was applied as a wafer, and acted as a 
negative control. MBA-crosslinked hydrogel cp(VP/AA)M_ l * was prepared by the same 
method as cp(VPI AA)M_ l (section 2.2 .1, Table 2.1) but using radiolabelled 14C-acrylic acid 
instead of normal acrylic acid. 
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4.3. Results and discussion 
4.3.1 Synthesis and characterisation of materials 
Linear poly(vinylpyrrolidone-co-methacrylic acid) copolymers [cp(VPIMA)] were 
synthesized by solution copolymerisation; co-monomer ratios used and yields obtained are 
presented in Table 4.4. The composition of the final product (also presented in Table 4.4, 
expressed as molar % ofMA) was determined by IH-NMR spectrosocopy. Characteristically, 
as the amount of MA in the feed decreases, the proportion of MA units in the product 
becomes lower than in the feed ratio, reflective of the reactivity ratios of the two co-
monomers. 
Table 4.4. Feed ratio (w/w), yields and composition (% molar, as determined by IH-NMR) of 
linear poly(vinylpyrrolidinone-co-methacrylic acid) copolymers. 
Material Feed ratio MA content Yield (%) 
(V PIMA) (%) 
cp(VPIMALl 50:50 53.8 75 
cp(VPIMAL2 60:40 33.8 72 
cp(VPIMAL3 80:20 8.9 65 
cp(VPIMAL4 95:05 2.2 60 
Table 4.5. GPC calibration results 
Mp Retention time (min) 
490000 5.8 
217000 6.2 
22100 8.2 
15000 8.4 
2010 9.2 
970 9.5 
Mp = peak molecular weight 
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Molecular weight distributions of the synthesised linear copolymers were detennined 
by gel penneation chromatography (GPC). The calibration curve (Fig. 4.3) was constructed 
using standard poly(ethyleneglycol)-poly(ethyleneoxide) samples (Sigma-Aldrich; Cat. No. 
02393); results of the calibration experiments are presented in Table 4.5. 
6 
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Fig. 4.3. GPC calibration curve (polynomial regression) ofpoly(ethyleneglycol)-
poly(ethyleneoxide) standards (Sigma-Aldrich; Cat. No. 02393). 
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Fig. 4.4. Typical GPC chromatogram: linear copolymer cp(VPIMALI [solvent 
phosphate buffer (PH 7.4, 10 mmol) and sodium nitrate (l00 mmol)]. 
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Values of M nand M w for each polymer were calculated from the chromatogram by 
making a series of time / height measurements across the molecular weight distribution range 
(an example is presented in Fig. 4.4), according to the equations below. 
where: 
hj = Height of the trace at time i. 
Mj = Molecular weight of the molecules at time i. 
Table 4.6. Results of GPC analysis for linear poly(vinylpyrrolidone-co-
methacrylic acid) copolymers (M n = number average molecular weight, 
M w = weight average molecular weight, PD = polydispersity index). 
Sample Mn Mw PD 
cp(VPIMALl 285645 440935 1.54 
cp(VPIMAL2 168060 384782 2.28 
cp(VPIMAL3 149560 257102 1.11 
cp(VPIMAL4 16836 48826 2.90 
The results of the GPC measurements for the poly(vinylpyrrolidone-co-methacrylic 
acid) copolymers are summarized in Table 4.6. All linear copolymers exhibited average 
molecular weights in the range 48,000 - 440,000 g·mor!, and a polydispersity index in the 
range 1.1 to 2.9. Differences in molecular weight distribution profiles may be influenced by 
the purification procedure: dependent upon solubility, solvent extraction may remove low 
molecular fractions, alongside un-reacted monomer. 
Strong IR bands in the range 800-1000 em-I, corresponding to the stretching mode of 
vinyl double bonds [81] present in the monomers, disappeared in the FTIR spectrum of the 
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copolymers, indicating that polymerisation had taken place and that there was no detectable 
residual monomer left. The water of hydration attached to the copolymers gives rise to a 
broad and intense peak at 3378 cm -1. The C-H stretching vibration of the copolymer 
backbone is manifested through a strong absorption at 2934 cm- I . Bands at 1650-1693 cm- I 
correspond to free and associated C=O stretching from monomer units. 
As the hydrophilicity/hydrophobicity balance affects both the adhesive and drug 
release properties of a material, contact angle goniometry was used as a means of assessing 
the relative hydrophilicity of the linear copolymers (there is a relationship between the 
contact angles of a liquid drop at the surface of a solid and the surface 
hydrophilicity/hydrophobicity). 
Measurements of contact angles were performed on cp(VPIMA) copolymer films 
(prepared from a 3 %w/v solution of copolymer in PBS (PH 7.4) by casting onto poly(methyl 
methacrylate) substrates, followed by drying overnight at 40°C) using water as the probe 
liquid. The contact angles were determined experimentally at 20°C using the Kruss G 10 
goniometer software. The presented contact angle data (Table 4.7) are averages from. 
between 8-12 drops on 4-6 independently prepared films. It seems that reducing the 
proportion of methacrylic acid in the structure effects a decrease in contact angle. As 
methacrylic acid is hydrophobic in nature, it affects the surface hydrophobicity of the 
polymer and hence the overall adhesiveness of the copolymer. 
Table 4.7. Contact angles, 8, oflinear poly(vinylpyrrolidone-co-methacrylic acid) films. 
Linear copolymer eo Standard deviation 0 
cp(VP/MAL1 81.6 7.2 
cp(VPIMAL2 58.2 10.2 
cp(VP/MAL3 54.1 12.8 
cp(VPIMAL4 35.1 9.5 
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'-. chitosan oligosaccharide link 
-......J synthetic polymer chain 
Fig. 4.5. Schematic structure of the crosslinked hydroge1s 
In order to create three-dimensional networks appropriate for drug loading and that 
are also biodegradable, linear poly(vinylpyrrolidone-co-methacrylic acid) copolymers were 
further crosslinked with chitosan oligosaccharidic chains (Fig. 4.5). 
RCOOH + 
/ (EDAC) 
H H CI 
I 1+ 
CH3CH2N-C=N-(CH2)3"N_CH 
I \ 3 P CH3 
R-C 
"0 reactive intermediate 
unstable 
--------- RCONHR' 
+ 
Fig. 4.6. Coupling between carboxyl and amino groups mediated by EDAC [92]. 
The crosslinking reaction employed makes use of 1-(3-dimethylaminopropyl)-3-
ethylcarbodiimide hydrochloride (EDAC), which acts as a reaction mediator; the steps of 
the crosslinking reaction mediated by carbodiimide are depicted in Fig. 4.6, 
where: 
R = linear poly(vinylpyrrolidone-co-methacrylic acid) copolymer chain 
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R ' = chitosan oligosaccharide chain 
R 
The linear copolymer cp(VPIMALI - which is the least hydrophilic (Table 4.7), and 
which was obtained with the highest yield (by using a feed ratio of VPIMA of 50/50) - was 
selected for preliminary studies that were performed in order to optimise the crosslinking 
reaction conditions. Optimisation experiments involved solvent-phase crosslinking of linear 
copolymer cp(VPIMALI with chitosan oligosaccharide lactate (CSo) in the presence of 1-
(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDAC) as a reaction mediator; 
the presence of N-hydroxysuccinimide (NHS), acting as an activator, was tested in order to 
maximize the yield of the crosslinking reaction. The general method employed for the 
synthesis of hydrogel networks was described in section 4.2.2, and the mass of reagents used, 
and yields obtained, are presented in Table 4.8. 
Table 4.8. Mass of reagents used in optimisation experiments involving crosslinking of 
cp(VPIMALI with CSo, and yields obtained for the chitosan-crosslinked hydrogels 
[CSo/cp(VPIMAL 1 ].# 
Experiment cp(VP/MALl EDAC NHS CSo Yield (%) 
(g) (g) (g) (g) 
A 0.1 0.10 0.03 0.197 21 
B 0.1 0.10 0.03 0.098 40 
C 0.1 0.05 0.03 0.197 50 
D 0.1 0.10 0.00 0.049 30 
E 0.1 0.10 0.06 0.098 47 
F 0.1 0.10 0.06 0.049 42 
G 0.1 0.05 0.06 0.098 34 
H 0.1 0.10 0.03 0.098 48 
/I 0.1 g cp(VPIMA) _1 were dissolved in 10 ml PBS, and the general method described at page 172 was 
followed (10 ml PBS were usedfor the dissolution ofCSo). 
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Optimisation experiments showed, with some exceptions, that higher yields were 
obtained when larger amounts of chitosan were used. There is an inverse correlation between 
yield and the proportion of EDAC to chitosan ratio in the mix; the presence (but not 
necessarily the amount) of N-hydroxysuccinimide appears to be important. 
Following the optimisation experiments, all cp(VPIMA) linear copolymers (Table 
4.3) were employed for further crosslinking with chitosan oligosaccharide lactate using the 
ratios given in Table 4.8, experiment C. The mass of reagents used and the code names for 
the materials thus obtained are presented in Table 4.9. 
The relative composition of the purified materials was assessed in FTIR spectra by 
estimating intensities of the C=O bands (of the corresponding VP and MA units) and the 
amide II band (1555 cm- I , N-H bending) - which was used to assess the chitosan ratio in the 
networks. 
Table 4.9. Mass of reagents used for the solution-phase preparation of hydrogel networks 
based on poly(vinylpyrrolidone-co-methacrylic acid) copolymers crosslinked via chitosan 
oligosaccharide. # 
Material cp(VP/MA) PMA EDAC NHS CSo 
(g) (g) (g) (g) (g) 
CSo/PMA - 2.0 2.200 1.300 7.890 
CSo/cp(VP/MALI 2.0 - 1.100 0.660 3.940 
CSo/cp(VPIMAL2 2.0 - 0.890 0.530 3.160 
CSo/cp(VPIMAL3 2.0 - 0.440 0.267 1.570 
CSo/cp(VP/MAL 4 2.0 - 0.110 0.066 0.390 
# 2 g cp(VPIMA} were dissolved in 200 ml PBS, and the general method described at page 172 was followed 
(200 ml PBS were usedfor the dissolution ofCSo). 
The swelling behaviour of the CSo/cp(VPIMA) hydrogel networks was examined at 
37.5 °c and at several pH values (5.0; 7.4; 9.0) - the method used was described in section 
4.2.2. The crosslinked hydro gels exhibited greater degrees of swelling and more rapid 
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swelling rates at basic pH than at acidic or physiologically relevant pH values (Fig. 4.7). This 
is consistent with literature reports on crosslinked methacrylate polymers, which confirm that 
increasing the percentage of crosslinker reduces the rate 'and degree of swelling and changes 
the water transport mechanism from Fickian diffusion to anomalous transport [91]. 
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Fig. 4.7. Effect of pH on the equilibrium swelling ofCSolPMA and 
CSo/cp(VP/MA) hydrogel networks (means represented; nexp= 3; bars 
represent standard errors). 
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he equilibrium swelling and the dynamic swelling behaviour of the synthesised materials 
were found to be highly d~pendent upon their chemical composition and upon the 
environmental conditions (especially pH). 
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Fig. 4.8 . Comparison of equilibrium swelling for materials with different 
composition, for acidic (5.0), physiological (7.4) and alkaline (9.0) pH values 
(means represented; nexp= 3; bars represent standard errors). 
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Under acidic conditions, the materials displayed a relatively low degree of swelling, 
as their carboxylic acid functionalities remained unionised. Under physiologically relevant 
conditions (pH = 7.4) the materials became more hydrophilic due to the partial ionisation of 
their carboxyl moieties. Under strongly basic conditions (PH = 9.0), ionisation was complete 
leading to maximal swelling. 
Sensitivity to pH seems to be slightly increased in materials containing a large 
proportion ofVP (Fig.4.8). 
Adhesion measurements on several polymer wafers, prepared from CSo/cp(VPIMA), 
allowed the determination of the maximum detachment force (MDF) and the corresponding 
work of adhesion (TWA) (Table 4.10). 
Table 4.10. Adhesion data for chitosan-crosslinked hydrogel neworks. 
Material MDFAv(N) SD(N) TWA (J.W) SD (J.W) 
CSolPMA 0.36 0.06 0.14 0.01 
CSo/cp(VPIMALl 0.15 0.02 0.13 0.05 
CSo/cp(VPIMAL2 0.12 0.02 0.08 0.01 
CSo/cp(VPIMAL3 0.17 0.02 0.10 0.06 
CSo/cp(VPIMAL 4 0.27 0.05 0.13 0.03 
nexp = 5; MDFAV = average maximum detachment force, TWA = total work of adhesion, SD = 
standard deviation 
The mucoadhesive strength of the polymer samples was sensitive to the relative 
proportions of MA and chitosan oligosaccharide: the higher the proportion of methacrylic 
acid the more adhesive the material, consistent with strong interactions between the 
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carboxylic groups and the test surface. The proportion of chitosan oligosaccharide also 
influences mucoadhesion, with low degrees of crosslinking promoting stronger interactions. 
Nanoparticles of chitosan-crosslinked hydrogels were prepared via an EDAC-
mediated reaction performed in emulsion (Tween and Span were used as surfactants) 
between poly(vinylpyrrolidone-co-methacrylic acid) linear copolymers cp(VPIMALI and 
chitosan oligosaccharide lactate, as described in section 4.2.2. Different ratIos of reagents 
were used for the preparation of these nanogels (see Table 4.11). Particle sizes were in the 
nanometer range, with an average of 270 nm (SD = 80). The particles were readily 
dispersible in aqueous media. 
Table 4.11. Mass of reagents used for the preparation of nanogel networks based on 
poly(vinylpyrrolidone-co-methacrylic acid) copolymers crosslinked via chitosan 
oligosaccharide, and their I4C-radiolabelled acrylic acid congener. 
Material cp(VP/MA) cp(VP/AA)* EDAC NHS Chitosan 
(g) (g) (g) (g) (g) 
np(CSo/cp(VPIMALlLl 0.50 - 0.28 0.17 1.00 
np(CSo/cp(VPIMALIL2 0.50 
- 0.28 0.17 0.50 
np(CSo/cp(VP/ AA»* - 0.50 0.33 0.20 1.20 
The real composition of the purified nanogels was examined in FTIR spectra by 
estimating intensities of the C=O bands of the corresponding VP and MA units, and the 
amide II band (1555 cm-I, broad, N-H bending) - which was used to assess the chitosan ratio 
in the network (Fig.4.9b). The partial shift of the C=O band, from -1650 cm-I in cp(VP/MA) 
linear copolymers (Fig. 4.9c) to 1693 cm-I in the final product (Fig. 4.9a) suggests strong 
interactions between the carboxyl group of methacrylic acid and the amine group of the 
chitosan oligosaccharide lactate. 
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Fig, 4.9. FTIR spectra of: (a) np(CSo/cp(VPIMALlL2 - nanogel made by crosslinking 
cp(VP/MALl linear copolymer with chitosan oligosacharide (CSo); (b) CSo - pure chitosan 
oligosaccharide lactate; and, (c) cp(VPIMALl -linear copolymer. 
Attempts to measure adhesion and swelling data on wafers prepared from dry 
nanoparticles were largely unsuccesfull because the wafers disintegrated readily in contact 
with PBS and, as a result, the nanoparticles got easily dispersed. 
14C-radiolabelled nanopartic1es [np(CSo/cp(VP/AA))* ] have a similar composition to 
np(CSo/cp(VPIMALIL2 (Table 4.11), but were prepared using 14C-acrylic acid (synthesised 
from commercially available 14C-malonic acid, as described in section 4.2.6) instead of 
methacrylic acid. The method followed for the measurement of their radioactivity is also 
presented in section 4.2.6. 
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4.3.2. In vitro results 
Nanoparticles loaded (10 %w) with the cholinergic antagonist pilocarpine were 
suspended in phosphate buffer (PH 7.4) and the release of drug was monitored 
spectrophotometrically (215 nm) over time; a minimum of five experiments were performed 
in each case, with results presented as averages (Figs. 4.11 and 4.12). The calibration curve 
obtained for pilocarpine is presented in Fig. 4.10. 
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Fig. 4.11. In vitro pilocarpine release profile from nanoparticles suspension 
[np(CSo/cp(VP/MALILI] ; control = aqueous solution containing 10 mg 
pilocarpine; nexp = 5; standard error bars presented. 
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Blank experiments showed that neither the buffer nor the pure nanoparticulate 
suspension display any significant absorbance in the UV region of interest (215 nm). 
Statistical treatment of the results (ANOV A, two-factors with replication; 5 replicates; 
p < 0.05) indicated that there is no significant difference between the nanoparticulate 
formulation [np(CSo/cp(VPIMALlLl] and the control (Fig. 4.11). 
Materials with lower crosslinking densities [np(CSo/cp(VPIMAL lL2] were found to 
release the drug at slower rates (Fig. 4.12). Statistical treatment of the results (ANOV A, two-
factors with replication; 5 replicates; p < 0.05;) indicated a significant difference between the 
nanoparticulate formulation [np(CSo/cp(VPIMALlL2] and control solution, and a significant 
interaction between the type of formulation and time. These results suggest that the more 
hydrophilic the delivery vehicle the less suitable it is for applications that demand the 
immobilisation of water-soluble, low molecular weight drugs. Nonetheless, such highly 
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hydrophilic gels may be useful for the release of active agents that are sparingly soluble in 
water (e.g. hydrocortisone-acetate), or for that of water-soluble macromolecules (enzymes, 
proteins, antigens). 
4.3.3 Biodegradation study 
The biodegradation study was performed on polymeric wafers - prepared from 
np(CSo/cp(VPIMALlLl and np(CSo/cp(VPIMALlL2 - using commercially. available 
lysozyme [82, 83]. The adopted method involves the reduction of ferricyanide solution 
(yellow) in N-acetyl-D-glucosamine (NacGlc) and hot alkali to a colourless product: 
The greater the concentration of NAcGlc, the lower the recorded optical absorption 
(Fig. 4.13). Calibration plots were constructed from absorbance (420 nm) measurements of a 
series of standard solutions. 
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Fig. 4.13. The calibration plot obtained for N-acetyl-D-glucosamine. 
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The concentration of lysozyme employed in the biodegradation study was chosen to 
correspond to the concentration in human serum (lysozyme: substrate = 0.6 : 1) [78]. Results 
(Fig. 4.14) show that the proportion of chitosan in the structure influences biodegradability 
greatly: higher proportions of chitosan (higher crosslinking densities) may prevent the 
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enzyme from accessmg its site of action. The data are consistent with a continuous 
biodegradation process, which becomes faster with decreasing crosslinking density. For a 
higher proportion of chitosan (i.e. in np(CSo/cp(YPIMALlLl), the increase in the rate of 
biodegradation is very rapid over time, suggesting that the diffusion of the enzyme into the 
network could represent the rate-limiting step. 
4.3.4 In vivo experiments 
Readily accessible New Zealand albino rabbits, the ocular model of choice [84], were 
employed for in vivo studies (two animals; 48 hours rest period between experiments; more 
details in section 4.2.5). As a positive control, an aqueous solution of pilocarpine 
hydrochloride was administered (50 Ill, containing 1.25 mg active; 2 drops - the same 
amount as in the nanoparticulate suspension freshly prepared usmg 
np(CSo/cp(YPIMALlL2). The application of drug-free polymeric suspenSIOn (blank 
controls) confirmed that the nanopartic1es did not contribute to the observed miotic effect. 
The variation in pupillary diameter ~as monitored over time using a standard 
pupillary diameter gauge. The presented values (Fig. 4.15) are averages from six 
experiments. The polymeric suspension containing pilocarpine hydrochloride induced a 
relatively rapid decrease in pupillary diameter, which was followed by a much slower 
"pupillary diameter increase" stage. The end of each experiment was signalled by the 
pupillary diameter returning to its original size. 
In all observations (6 experiments) the polymeric suspension containing pilocarpine 
hydrochloride induced a more pronounced miotic effect than the free drug in a conventional 
solution. Statistical treatment of the results (ANOYA, two-factors with replication; 6 
replicates; p < 0.05;) indicated a significant difference between the nanoparticulate 
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formulation [np(CSo/cp(VPIMAL1L2] and control solution, and a significant interaction 
between type of formulation [np(CSo/cp(VPIMAL1L2] and time. 
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Fig. 4.15. Miotic response in rabbits to instillation of pilocarpine hydrochloride: in 
solution (-+-), and loaded in a nanoparticle np(CSo/cp(VPIMAL1L2 suspension (-.-), 
control - aqueous solution containing 1.25 mg pilocarpine; nexp = 6, means and standard 
error bars represented. 
The results revealed that materials with reduced hydrophilicity, which have a limited 
swelling capacity, yield more prolonged release profiles. The concentration of methacrylic 
acid (more hydrophobic than acrylic acid) and the degree of crosslinking are probably the 
key factors that control pilocarpine release from this type of nanoparticulate system. 
In accord with previous studies involving non-ionic surfactants [85], the suspension 
was found to be very well tolerated by animals. 
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4.3.5 Corneal tissue penetration by 14C-radiolabelled nanogels 
It has been reported that poly(alkylcyanoacrylate) nanoparticies damage the corneal 
epithelium by disrupting the cell membrane [86], and previous microscopy studies indicated 
possible corneal penetration by chitosan nanoparticies [71]. 
In this work, an in vitro experiment was designed to examine the likeliness of the 
transport of the chitosan-crosslinked poly(vinylpyrrolidone-co-methacrylic acid) 
nanoparticies through the rabbit's corneal membrane. 
The l4C-radiolabelled nanoparticles (np(CSo/cp(VP/AA»* - prepared as described in 
section 4.2.6) - were dispersed in 0.9 %w/w NaCI aqueous solution. The size of the nanogels 
and the radioactivity of the nanosuspension were highly reproducible (at around 1786 DPM). 
The radioactivity detected in the ~amples taken from the receptor chamber of the Franz cell 
following treatment with the nanosuspension np(CSo/cp(VP/AA»* is summarized in Table 
4.12. 
Table 4.12. Results of in vitro experiments on diffusion of radio labelled polymers through 
the rabbit cornea 
% activity % activity Time(br) % activity % activity 
Time detected detected detected detected 
(b) (DPM» (DPM) (DPM) (DPM) 
np(CSo/cp(VP/ AA»* Control np(CSo/cp(VP/ AA»* Control 
0 0 0 11 2.51 0.038 
0.15 1.06 0.010 12 2.68 0.039 
0.30 1.11 0.015 13 3.02 0.040 
0.45 1.45 0.018 14 3.35 0.042 
1 1.56 0.019 15 3.52 0.043 
2 1.62 0.020 16 3.75 0.045 
3 1.67 0.022 17 3.97 0.046 
4 1.79 0.025 18 4.00 0.048 
5 1.84 0.026 19 4.25 0.049 
6 1.90 0.028 20 4.70 0.050 
7 1.95 0.029 21 4.75 0.052 
8 2.01 0.030 22 4.81 0.054 
9 2.12 0.032 23 4.81 0.055 
10 2.35 0.035 24 4.81 0.055 
DPM = decaying per minute; control = UC-radiolabelled cp(VPIAA)Mj *. I1exp=4, SD < 15%. 
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The cp(VP/AA)M_l * control appears to have released through the corneal membrane 
the least amount of radio label, irrespective of the length of the treatment period. Statistical 
treatment of the data (ANOV A, two-factor, without replication) indicated that there is a 
significant difference between the nanoparticulate formulation [np(CSo/cp(VP/AA))*] and 
the cp(VP/AA)M_l * control, suggesting that nano articles are permeating through the 
corneal membrane. No significant interaction between time and type of formulation has been 
found. 
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Fig. 4.16. Percentage of 14C-activity (LSC) detected in corneal tissue following 
digestion (sodium hydroxide, 1 M) of the rabbit cornea treated with nanoparticulate 
formulation [np(CSo/cp(VP/AA))*], and rabbit cornea treated with polymer wafer 
[cp(VP/AA)M_ l *] as control. (nexp =4; means and standard error bars represented) 
In order to determine the retention of polymers into the ocular tissue, the corneal 
membrane was analyzed at the end of the experiment, and Fig. 4.16 summarizes the results 
of this tissue absorption study. The LSC data showed that there is a significant difference 
202 
between the nanosuspension-induced levels of radiolabel absorption into the ocular tissues 
and that associated with the control; the activity ratio found inside the corneal tissue was 27 
% of the initially administered dose, much higher than that in the control (only 5 %). This 
indicates a much higher degree of retention at the ocular surface level in the case of the 
nanoparticles, and could potentially translate into a significant increase in the bioavailability 
of any active that is delivered using this type of formulation. 
4.4 Conclusions 
Aimed towards ophthalmic applications, nanoparticles (100-300 nm) of 
poly(vinylpyrrolidinone-co-methacrylic acid) incorporating short polysaccharidic chains as 
cross links have been synthesised and have been formulated with pilocarpine hydrochloride 
for delivery through an aqueous medium. The materials possess good bioadhesive properties, 
which facilitate their retention on the ocular surface. Release experiments have demonstrated 
that some of these nanoparticles are capable of effecting the controlled release of pilocarpine 
hydrochloride. In vivo experiments have shown that the nanoparticles are tolerated well by 
the eye. 
To study the in vitro transport of the nanoparticles through the rabbit cornea, 14C_ 
radiolabelled congeners, [np(CSo/cp(VP/AA»*], have been synthesised using 14C-Iabelled 
acrylic acid. Results have indicated partial diffusion of the radiolabel through the corneal 
membrane, suggesting possible corneal penetration by the nanoparticles. 
Also, the activity ratio found inside the corneal tissue is 5 x higher for nanoparticles 
than for the control wafer. This indicates a higher degree of retention at the ocular surface 
level, which could potentially translate into a significant increase in the bioavailability of any 
active delivered using this type of nanoparticulate formulation. 
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Chapter 5 - General discussion and conclusions 
Conventional topical ocular treatments have major drawbacks including poor ocular 
bioavailability (i.e. less than 5 % of the administered active is absorbed or becomes available 
at the site of physiological activity), pulsed drug entry, systemic exposure, and, generally, a 
low effectiveness for intraocular drug deiivery. Therapeutic advances in this field are 
hindered by the difficulties of increasing bioavailability and of delivering actives to the site 
of action, especially in the treatment of the posterior of the eye; current research on 
polymeric delivery may address those issues. Certain polymers are already used as carriers or 
sustained release vehicles, while 'smart' hydrogels - that react to disease-specific 
environmental triggers and/or chemical signals to effect drug release - are emerging as 
components of a new generation of therapeutics (Sections 1.1 and 1.5). 
An ideal polymeric drug carrier should have a loading capacity that can ensure 
therapeutic doses will be able to penetrate to - and/or reside at - the desired site of action, 
and release the active in a controlled manner. The carrier should also be non-toxic , 
biocompatible and biodegradable - the latter especially for intraocular administration. For 
most ophthalmic applications the carrier should not impede vision, since tolerability and 
acceptance by the patient are critical. The carrier's mucoadhesive properties are very 
imp~rtant when surface eye diseases are targeted, while for the treatment of intraocular 
ailments it must be able to enhance corneal drug penetration. 
Efficient drug delivery to the eye still represents a major challenge, despite the 
considerable research effort dedicated to it in the last decade. Previous studies attempted 
either to increase the bioavailability of ophthalmic drugs by making use of methods that aim 
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to improve the corneal penetration of the active and to delay its elimination from the eye, or 
to to achieve controlled release of the drug by using various types of ophthalmic inserts. 
This project is directed towards the preparation and evaluation of novel polymeric 
vehicles that can effect the controlled release of ocular drugs, and it aims to combine recent 
advances in mucoadhesion and polymer-based drug delivery. Previous work at the University 
of Portsmouth has established the great promise of polycarbophil and chitosan as 
mucoadhesives and it is envisaged that, based on these types of polymeric materials, ocular 
wafers or a nanoparticulate formulation could be developed. 
In this work, a number of hydrogel-type polymeric materials - based mainly on 
polymers with regulatory approval, such as polysaccharides (chitosan), polyacrylates (acrylic 
acid, methacrylic acid) and poly(vinylpyrrolidone)s - have been synthesised and 
characterised in terms of their chemical and physical structure, using a range of spectroscopic 
methods, and by swelling and adhesion measurements. The synthesized materials have been 
formulated as either ophthalmic inserts or nanosuspensions, both of which have been 
investigated, both in vitro and in vivo, for their ability to act as ophthalmic drug carriers that 
effect a sustained release and increase the bioavailability of the active. A number of 
ophthalmic drugs, with either antibiotic or antiglaucoma action (viz. chloramphenicol, 
norfloxacin, pilocarpine hydrochloride and atropine sulphate), have been employed for this 
purpose. The degree to which every objective of this project (Section 1.8) has been fulfilled 
is summarised below, according to each type of material. 
Copolymeric hydrogels [cp(VP/MA)M; cp(VP/AA)M] constituted of 
vinylpyrrolidone and methacrylic or acrylic acid repeat units have been synthesised by 
radical-induced polymerisation reactions in the presence of N,N'-methylenebisacrylamide 
crosslinker (Section 2.3.1). 
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The effects of network composition and drug solubility upon the swelling properties, 
adhesion behaviour and drug release characteristics have been studied: it has been found that, 
dependent on composition, cp(VP/AA)M and cp(VPIMA)M crosslinked hydrogels exhibit a 
broad range of swelling and adhesion properties, which can be fine-tuned by altering the 
relative proportion of each constitutional repeat unit (Section 2.3.2). 
In vitro drug release studies involving pilocarpine hydrochloride or chloramphenicol 
have demonstrated that the materials .under consideration [i.e. cp(VP/AA)M and 
cp(VPIMA)M] are most appropriate for the delivery of sparingly water-soluble actives (i.e. 
chloramphenicol or norfloxacin) (Section 2.3.3). 
In vivo experiments have revealed that the degree of swelling and hydrophobicity of 
the matrix are key factors in effecting controlled drug release, and have confirmed the 
potential of cp(VPIMA)M-based inserts for the ocular delivery of pilocarpine hydrochloride 
(Section 2.3.4). 
A series of hybrid polymeric hydrogels [hpn(CSflNIP AM); hpn(CSflHEMA)], 
prepared by the reaction of acrylic acid-functionalised chitosan with either N-
isopropylacrylamide or 2-hydroxyethyl methacrylate monomers, have also been synthesised, 
pressed into minitablets and investigated for their capacity to act as controlled release 
vehicles for ophthalmic drug delivery (Sections 3.3.1 to 3.3.3). 
For comparison, inter-polymeric complex analogues [ic(CSIPHEMA); 
ic(CSIPNIP AM)] synthesised using the same monomers and pure, un-functionalised chitosan 
- have been examined by means of an identical characterisation protocol: the effects of 
network structure and composition upon the swelling properties, adhesion behaviour and 
drug release characteristics have been investigated (Sections 3.3.1 to 3.3.3). 
Comparative in vitro studies employing chloramphenicol, atropine sulphate, 
norfloxacin or pilocarpine hydrochloride have informed the selection of drug-specific carrier 
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compositions [hybrid polymeric hydrogels hpn(CSflNIP AM); hpn(CSfIHEMA)] for the 
controlled delivery of these compounds (Section 3.3.4). 
In vivo (rabbit model) experiments involving the delivery of pilocarpine have 
indicated that chitosan-based hybrid polymer networks containing 2-hydroxyethyl 
methacrylate [hpn(CS£'HEMA)] have a high potential for the delivery of this therapeutic 
agent (Section 3.3.5). 
Hydrogel nanoparticles [np(CSo/cp(VPIMA»] have been prepared from linear 
poly(vinylpyrrolidinone-co-methacrylic acid) [cp(VP/MA)] that was crosslinked via short 
polysaccharidic chains (CSo). The materials are biodegradable (Section 4.3.3), and possess 
good bioadhesive properties, which facilitate their retention on the ocular surface (Section 
4.3.1). 
Pilocarpine hydrochloride-loaded nanoparticIes (100-300 nm) ofnp(CSo/cp(VPIMA» 
have been formulated for delivery through an aqueous medium, and drug release experiments 
have indicated that some of these nanoparticles are capable of sustaining the miotic effect of 
the active (Sections 4.3.2 and 4.3.4). 
14C-Radiolabelled nanoparticles [np(CSo/cp(VP/AA»*] have been synthesised and 
used to study in vitro the transport of the nanoparticulate formulation through the rabbit 
cornea. Results have indicated partial diffusion of the radiolabel through the corneal 
membrane, suggesting possible corneal penetration by the nanoparticles. In addition, the 
activity ratio found inside the corneal tissue was 5 x higher for the nanoparticles than that for 
the control wafer. This indicates a much higher degree of retention at the ocular surface level 
in the case of the nanoparticles, and could translate into a significant increase in the 
bioavailability of any active that is delivered using this type of formulation (Section 4.3.5). 
All the synthesised polymeric hydrogels (both inserts and nanospuspensions) that 
have been tested in vivo (rabbit model) show a very good tolerance by the eye. 
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The fonnulation of biodegradable polymers as colloidal systems holds significant 
promise for ophthalmic drug delivery, and further work should mainly focus onto the 
improvement of biodegradability and drug loading capacity ofnp(CSo/cp(VPIMA)). For this 
purpose, chitosan chains with different molecular weight and different degrees of 
deacetylation should be investigated. Such colloidal systems would be suitable for poorly 
water-soluble drugs, and would allow drop-wise administration while maintaining the drug 
activity at the site of action. 
Additionally, surface-modified nanoparticulate carriers could be used to investigate 
the release of a wider variety of actives. Although several synthetic methods and drug 
loading techniques are reported to be safe and reproducible, no procedure for the fonnulation 
of drug-loaded nanoparticles has yet been standardised. The major developmental issues in 
the case of nanoparticles include at present fonnulation stability, particle size uniformity, 
control of drug release rate, and large-scale manufacture of sterile preparations. 
Surface modification of the colloidal drug carrier might facilitate the modulation of 
carrier / ocular tissue interaction, leading to materials with selective affinity for the corneal 
tissue. Natural limiting factors, however, are the low concentration of mucins on the ocular 
tissue and the high mucin turnover rate. 
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